<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Quetiapine versus other atypical antipsychotics for schizophrenia - Asmal, L - 2013 | Cochrane Library</title> <meta content="Quetiapine versus other atypical antipsychotics for schizophrenia - Asmal, L - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006625.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Quetiapine versus other atypical antipsychotics for schizophrenia - Asmal, L - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006625.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006625.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Quetiapine versus other atypical antipsychotics for schizophrenia" name="citation_title"/> <meta content="Laila Asmal" name="citation_author"/> <meta content="University of Stellenbosch" name="citation_author_institution"/> <meta content="laila@sun.ac.za" name="citation_author_email"/> <meta content="Srnka J Flegar" name="citation_author"/> <meta content="University of Stellenbosch" name="citation_author_institution"/> <meta content="Jikun Wang" name="citation_author"/> <meta content="East China Normal University" name="citation_author_institution"/> <meta content="Christine Rummel‐Kluge" name="citation_author"/> <meta content="University of Leipzig" name="citation_author_institution"/> <meta content="Katja Komossa" name="citation_author"/> <meta content="University Hospital of Zurich" name="citation_author_institution"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD006625.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/11/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006625.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006625.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006625.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Benzodiazepines [adverse effects, therapeutic use]; Clozapine [adverse effects, therapeutic use]; Dibenzothiazepines [adverse effects, *therapeutic use]; Medication Adherence [statistics &amp; numerical data]; Olanzapine; Piperazines [adverse effects, therapeutic use]; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone [adverse effects, therapeutic use]; Schizophrenia [*drug therapy]; Thiazoles [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006625.pub3&amp;doi=10.1002/14651858.CD006625.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006625\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006625\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006625.pub3",title:"Quetiapine versus other atypical antipsychotics for schizophrenia",firstPublishedDate:"Nov 18, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006625.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006625.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006625.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006625.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006625.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006625.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006625.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006625.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006625.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006625.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5071 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006625.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/appendices#CD006625-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/table_n/CD006625StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/table_n/CD006625StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Quetiapine versus other atypical antipsychotics for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#CD006625-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Laila Asmal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#CD006625-cr-0003">Srnka J Flegar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#CD006625-cr-0004">Jikun Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#CD006625-cr-0005">Christine Rummel‐Kluge</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#CD006625-cr-0006">Katja Komossa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information#CD006625-cr-0007">Stefan Leucht</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information/en#CD006625-sec1-0016">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 November 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006625.pub3">https://doi.org/10.1002/14651858.CD006625.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006625-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006625-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006625-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006625-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006625-abs-0001" lang="en"> <section id="CD006625-abs1-0001"> <h3 class="title" id="CD006625-abs1-0001">Background</h3> <p>In many countries, second‐generation ('atypical') antipsychotic drugs have become the first‐line drug treatment for people with schizophrenia. It is not clear how the effects of the various second‐generation antipsychotic drugs differ. </p> </section> <section id="CD006625-abs1-0002"> <h3 class="title" id="CD006625-abs1-0002">Objectives</h3> <p>To evaluate the effects of quetiapine compared with other second‐generation (atypical) antipsychotic drugs in the treatment of people with schizophrenia and schizophrenia‐like psychoses. </p> </section> <section id="CD006625-abs1-0003"> <h3 class="title" id="CD006625-abs1-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group Trials Register (May 2010), inspected references of all identified studies, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. </p> </section> <section id="CD006625-abs1-0004"> <h3 class="title" id="CD006625-abs1-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) comparing oral quetiapine with other oral forms of atypical antipsychotic medication in people with schizophrenia or schizophrenia‐like psychoses. </p> </section> <section id="CD006625-abs1-0005"> <h3 class="title" id="CD006625-abs1-0005">Data collection and analysis</h3> <p>We extracted data independently. For dichotomous data, we calculated risk ratios (RRs) and their 95% confidence intervals (CIs) on an intention‐to‐treat basis based on a random‐effects model. We calculated number needed to treat for an additional beneficial outcome (NNTB) where appropriate. For continuous data, we calculated mean differences (MDs), again based on a random‐effects model. </p> </section> <section id="CD006625-abs1-0006"> <h3 class="title" id="CD006625-abs1-0006">Main results</h3> <p>Efficacy data tended to favour the control drugs over quetiapine (Positive and Negative Syndrome Scale (PANSS) total score vs olanzapine: 11 RCTs, n = 1486, mean quetiapine endpoint score 3.67 higher, CI 1.95 to 5.39, <i>low quality</i> ; vs risperidone: 13 RCTs, n = 2155, mean quetiapine endpoint score 1.74 higher, CI 0.19 to 3.29, <i>moderate quality</i> ; vs paliperidone: 1 RCT, n = 319, mean quetiapine endpoint score 6.30 higher, CI 2.77 to 9.83, <i>moderate quality</i> ), but the clinical meaning of these data is unclear. No clear mental state differences were noted when quetiapine was compared with clozapine, aripiprazole or ziprasidone. Compared with olanzapine, quetiapine produced slightly fewer movement disorders (7 RCTs, n = 1127, RR use of antiparkinson medication 0.51, CI 0.32 to 0.81, <i>moderate quality</i> ) and less weight gain (8 RCTs, n = 1667, RR 0.68, CI 0.51 to 0.92, <i>moderate quality</i> ) and glucose elevation, but increased QTc prolongation (3 RCTs, n = 643, MD 4.81, CI 0.34 to 9.28). Compared with risperidone, quetiapine induced slightly fewer movement disorders (8 RCTs, n = 2163, RR use of antiparkinson medication 0.5, CI 0.36 to 0.69, <i>moderate quality</i> ), less prolactin increase (7 RCTs, n = 1733, MD ‐35.25, CI ‐43.59 to ‐26.91) and some related adverse effects but greater cholesterol increase (6 RCTs, n = 1473, MD 8.57, CI 4.85 to 12.29). On the basis of limited data, compared with paliperidone, quetiapine induced fewer parkinsonian side effects (1 RCT, n = 319, RR use of antiparkinson medication 0.64, CI 0.45 to 0.91, <i>moderate quality</i> ) and less prolactin increase (1 RCT, n = 319, MD ‐49.30, CI ‐57.80 to ‐40.80) and weight gain (1 RCT, n = 319, RR weight gain of 7% or more of total body weight 2.52, CI 0.5 to 12.78, <i>moderate quality</i> ). Compared with ziprasidone, quetiapine induced slightly fewer extrapyramidal adverse effects (1 RCT, n = 522, RR use of antiparkinson medication 0.43, CI 0.2 to 0.93, <i>moderate quality</i> ) and less prolactin increase. On the other hand, quetiapine was more sedating and led to greater weight gain (2 RCTs, n = 754, RR 2.22, CI 1.35 to 3.63, <i>moderate quality</i>) and cholesterol increase when compared with ziprasidone. </p> </section> <section id="CD006625-abs1-0007"> <h3 class="title" id="CD006625-abs1-0007">Authors' conclusions</h3> <p>Available evidence from trials suggests that most people who start quetiapine stop taking it within a few weeks (around 60%). Comparisons with amisulpride, sertindole and zotepine do not exist. Although efficacy data favour olanzapine and risperidone compared with quetiapine, the clinical meaning of these data remains unclear. Quetiapine may produce fewer parkinsonian effects than paliperidone, aripiprazole, ziprasidone, risperidone and olanzapine. Quetiapine appears to have a similar weight gain profile to risperidone, as well as clozapine and aripiprazole (although data are very limited for the latter two comparators). Quetiapine may produce greater weight gain than ziprasidone and less weight gain than olanzapine and paliperidone. Most data that have been reported within existing comparisons are of very limited value because of assumptions and biases within them. Much scope is available for further research into the effects of this widely used drug. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006625-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006625-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006625-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006625-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006625-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006625-abs-0004" lang="en"> <h3>Quetiapine versus other atypical antipsychotic drugs for schizophrenia</h3> <p>Quetiapine is a second‐generation antipsychotic. Second‐generation or atypical antipsychotic drugs have become the mainstay of treatment in many countries for people with schizophrenia. They are called <i>second‐generation drugs</i> because they are newer than the older drugs, known as <i>typical antipsychotics</i>. Second‐generation drugs are thought to be better than the older drugs in reducing the symptoms of schizophrenia, such as hearing voices and seeing things, and are suggested to produce fewer side effects, such as sleepiness, weight gain, tremors and shaking. However, it is not clear how the various second‐ generation antipsychotic drugs differ from one other. The aim of this review therefore was to evaluate the effects of quetiapine compared with other second‐generation antipsychotic drugs for people with schizophrenia. The review included a total of 35 studies with 5971 people, which provided information on six comparisons (quetiapine vs the following: clozapine, olanzapine, risperidone, ziprasidone, paliperidone and aripiprazole). Comparisons with amisulpride, sertindole and zotepine do not exist, so more research is needed. A major limitation of all findings was the large number of people leaving studies and stopping quetiapine treatment (50.2% of people). The most important finding to note is that if a group is started on quetiapine, most will be off this drug within a few weeks (although the reasons for stopping quetiapine treatment are not covered by the review and so remain uncertain). Quetiapine may be slightly less effective than risperidone and olanzapine in reducing symptoms, and it may cause less weight gain and fewer side effects and associated problems (such as heart problems and diabetes) than olanzapine and paliperidone, but more than are seen with risperidone and ziprasidone. The limited information tends to suggest that people taking quetiapine may need to be hospitalised more frequently than those taking risperidone or olanzapine. This may lead to higher costs in some settings, but the information is not robust enough to guide managers. </p> <p>This summary has been written by a consumer, Ben Gray (Benjamin Gray, Service User and Service User Expert, Rethink Mental Illness). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006625-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006625-sec1-0007"></div> <h3 class="title" id="CD006625-sec1-0008">Implications for practice</h3> <section id="CD006625-sec1-0008"> <section id="CD006625-sec2-0016"> <h5 class="title">1. For people with schizophrenia</h5> <p>For people with schizophrenia, it may be important to know that most people who start the drug within short trials choose to stop taking it within a few weeks. Quetiapine may be slightly less effective than risperidone and olanzapine. However, quetiapine may have low risk for extrapyramidal adverse effects and prolactin increase, and its use may lead to less weight gain and fewer associated problems than are seen with olanzapine and paliperidone but more than with risperidone and ziprasidone. </p> </section> <section id="CD006625-sec2-0017"> <h5 class="title">2. For clinicians</h5> <p>Clinicians should know that for only six of nine possible comparisons of quetiapine with other second‐generation antipsychotic drugs, relevant studies were identified, and that the evidence is limited because very high numbers of participants leave the studies early. Our most robust finding is that most people who are started on quetiapine will be off this drug within a few weeks. Certainly, more studies comparing quetiapine with other second‐generation antipsychotic drugs are needed. </p> </section> <section id="CD006625-sec2-0018"> <h5 class="title">3. For managers/policy makers</h5> <p>Little information on service use (such as time in hospital) or functioning is available, but the limited data suggest that people taking quetiapine may need to be hospitalised more frequently than those receiving risperidone or olanzapine. This may be accompanied by higher overall costs in some settings. Furthermore, a single study suggested better general functioning of participants treated with olanzapine. We believe that these findings are not sufficiently robust to guide managers. </p> </section> </section> <h3 class="title" id="CD006625-sec1-0009">Implications for research</h3> <section id="CD006625-sec1-0009"> <section id="CD006625-sec2-0019"> <h5 class="title">1. General</h5> <p>Adherence to the <a href="http://www.consortstatement.org" target="_blank">CONSORT</a> statement (<a href="./references#CD006625-bbs2-0278" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA2001;285:1987‐1. ">Moher 2001</a>) probably would have resulted in a more conclusive review. Clear descriptions of randomisation would have reassured users of these trials that selection bias had been minimised, and well‐described and tested blinding could have encouraged greater confidence in the control of performance and detection bias. The use of binary outcomes should take preference over continuous results because they are easier to interpret, and the use of validated rating scales would have provided more usable data. Reporting of outcomes with their means and standard deviations again would have provided more usable data and would have facilitated synthesis of findings. When data are presented in a graph, the exact numbers and standard deviations should be reported. We were able to use only published reports, and even these many trials report at least some of their data in a way as to make them unusable for those wishing to undertake reviews (<a href="./references#CD006625-bbs2-0001" title="Astrazeneca1998 . A multicentre, double‐blind randomised comparison of seroquel (TM) and risperidone in the treatment of schizophrenic patients with acute exacerbation. Astrazeneca trial data. ">Astrazeneca 1998</a>; <a href="./references#CD006625-bbs2-0005" title="ConleyRR , KellyDL , NelsonMW , RichardsonCM , FeldmanS , BenhamR , et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy‐refractory schizophrenia. Clinical Neuropharmacology2005;28(4):163‐8. KellyDL , ConleyRR . A randomized double‐blind 12‐week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology2006;31(3):340‐6. KellyDL , ConleyRR . Thyroid function in treatment‐resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry2005;66:80‐4. RichardsonCM , KellyDL , GoldJM , McMahonR , YuY , ConleyRR . Risperidone vs quetiapine vs fluphenazine in treatment‐resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin2005;31:501‐2. ">Conley 2005</a>; <a href="./references#CD006625-bbs2-0006" title="DeberdtW , LipkovichI , HeinlothAN , LiuL , Kollack‐WalkerS , EdwardsSE , et al. Double‐blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Therapeutics and Clinical Risk Management2008;4(4):713–20. ">Deberdt 2008</a>; <a href="./references#CD006625-bbs2-0009" title="HuGH , WuYJ , LiQX . A comparative study between quetiapine and risperidone in the treatment of first‐episode schizophrenia. Chinese Medical Journal of Metallurgical Industry2008;25(1):16‐7. ">Hu 2008</a>; <a href="./references#CD006625-bbs2-0010" title="KinonBJ , Liu‐SiefertH , HillAL , RoychowdhuryS , EdwardsSB . Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20‐24, 2003. KinonBJ , NoordsyDL , Liu‐SeifertH , GulliverAH , Ascher‐SvanumH , Kollack‐WalkerS . Randomized, double‐blind 6‐month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology2006;26(5):453‐61. ">Kinon 2006b</a>; <a href="./references#CD006625-bbs2-0013" title="LiY , FengYG . A double blind comparing study between the effects of quetiapine and clozapine on the life quality of the patients with schizophrenia. Medical Journal of Chinese Peoples Health2005;17:262‐4. ">Li 2005</a>; <a href="./references#CD006625-bbs2-0011" title="LiY , WangCH , ZhangDH , WangLH , ZhaoZ . A study of quetiapine and clozapine in treatment of first‐episode schizophrenia. Chinese Journal of Nervous and Mental Diseases2002;28:219‐20. ">Li 2002</a>; <a href="./references#CD006625-bbs2-0012" title="LiCH . A study of quetiapine and clozapine in treatment of schizophrenia. Chinese Journal of Nervous and Mental Diseases2003;29:306‐7. ">Li 2003</a>; <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>; <a href="./references#CD006625-bbs2-0015" title="LiuY , XuM , ChenX . A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry2004;17(1):6‐8. ">Liu 2004</a>; <a href="./references#CD006625-bbs2-0016" title="LuX , ChengH , SongS , SunL , ZhangY , FanY . A study of quetiapine and risperidone and clozapine in the treatment of schizophrenia. China and Foreign Medical Journal2006;4(6):62‐4. ">Lu 2006</a>; <a href="./references#CD006625-bbs2-0017" title="LuoX , AnBF . Comperison of quetiapine and aripiprazole in the treatment of first episode schizophrenia. Journal of Clinical Psychological Medicine2008;18(3):191‐2. ">Luo Xin 2008</a>; <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a>; <a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a>; <a href="./references#CD006625-bbs2-0022" title="PengX , HuangY , LiuXY . A clinical analysis of aripiprazole and quetiapine in treatment of first episode schizophrenia. Journal of Clinical Psychological Medicine2007;17(5):329‐30. ">Peng 2007</a>; <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a>; <a href="./references#CD006625-bbs2-0024" title="RiedelM , MullerN , StrassnigM , SpellmannI , EngelRR , MusilR , et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2005;255(6):432‐7. RiedelM , SpellmannI , MullerN , StrassnigM , Muller‐ArendsA , DehningS , MollerHJ . Cognitive benefits of quetiapine versus risperidone in schizophrenia. Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21‐26, 2005. RiedelM , SpellmannI , StrassnigM , DouhetA , DehningS , Opgen‐RheinM , et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2007;257:360‐70. ">Riedel 2005</a>; <a href="./references#CD006625-bbs2-0025" title="RiedelM , MüllerN , SpellmannI , EngelRR , MusilR , ValdevitR , et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia. European Archieves of Psychiatry and Clinical Neuroscience2007;257(7):402‐12. ">Riedel 2007</a>; <a href="./references#CD006625-bbs2-0026" title='SacchettiE , ValsecchiP , ReginiC , Galluzoa , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Schizophrenia Research2004;67(1):150. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP . Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update", Florence, Italy, November 10‐13, 2004. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Journal of the European College of Neuropsychopharmacology2003;13(4):S350. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine, and risperidone in schizophrenia. Journal of the European College of Neuropsychopharmacology2004;14(Suppl 3):S286. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , et al. Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Proceedings of the 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, September 20‐24, 2003. '>Sacchetti 2004</a>; <a href="./references#CD006625-bbs2-0027" title="SirotaP , PannetI , KorenA , TchernichovskyE . Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Human Psychopharmacology2006;21(4):227‐34. SirotaP , TchernichowskyE , PanetI , KorenA . The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia. Schizophrenia Research2004;67(1):170. ">Sirota 2006</a>; <a href="./references#CD006625-bbs2-0028" title="SongGM , LiJH , ZhongH , LuSL . Control study of risperidone oral solution and quetiapine on schizophrenia. Modern Journal of Integrated Traditional Chinese and Western Medicine2008;17(32):4961‐3. ">Song 2008</a>; <a href="./references#CD006625-bbs2-0030" title="SvestkaJ , SynekO , ZourkovaA . A double‐blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders. Journal of the European College of Neuropsychopharmacology2003;13(4):S291. ">Svestka 2003b</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>; <a href="./references#CD006625-bbs2-0034" title="WeiSZ , TangQS , XuZN , RangXJ , LuB . Dummy parallel controlled study in the female first‐episode schizophrenia treated with aripiprazole and quetiapine. Chinese Journal of Nervous and Mental Disorders2006;32(6):511‐7. ">Wei 2006b</a>). More data may have never reached publication. Several trials had to be excluded solely because all numerical data were impossible to use (<a href="./references#CD006625-bbs2-0039" title="AntonovaE , KumariV , HalariR , ZachariahE , MehrotraR , KumarA , et al. Superior cognitive efficacy of atypical antipsychotics olanzapine, risperidone, and quetiapine, as a group, relative to low doses of conventional antipsychotics. Schizophrenia Bulletin2005;31:474. ">Antonova 2005</a>; <a href="./references#CD006625-bbs2-0047" title="ByerlyM , WeberM . Clozapine versus quetiapine for schizophrenia. Stanley Foundation Research Programs1999. ">Byerly 1999</a>; <a href="./references#CD006625-bbs2-0048" title="ByerlyMJ , NakoneznyP , BugnoR , BolesJ . A randomized, double‐blind pilot trial of switching to quetiapine vs. risperidone continuation in outpatients with risperidone‐associated sexual dysfunction. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. ">Byerly 2006</a>; <a href="./references#CD006625-bbs2-0148" title="SarmaK . Lurasidone HCl ‐ A Long Term Phase 3 Study ofPatients With Chronic Schizophrenia (PEARL 3Ext). Clinical Trial Registration Data2008. ">Sarma 2008a</a>; <a href="./references#CD006625-bbs2-0069" title="DaviesLM , LewisS , JonesPB , BarnesTRE , GaughranF , HayhurstD , et al. Cost‐effectiveness of first‐ v. second‐generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Value in Health2008;11(4):549‐62. ">Davies 2007</a>). When trials do not make all data available, this must give cause for concern (<a href="http://alltrials.net" target="_blank">ALLTRIALS</a>). </p> </section> <section id="CD006625-sec2-0020"> <h5 class="title">2. Specific</h5> <section id="CD006625-sec3-0039"> <h6 class="title">2.1 Reviews</h6> <p>This review should be updated both with a relevant search and with data from more open studies. However, this will have to wait until we gather energy after the marathon of producing this review (<a href="#CD006625-tbl-0017">Table 1</a>) </p> <div class="table" id="CD006625-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies possible to include but not fully blinded</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study tag</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0036" title="AnBF , LiuXQ , ChenJX . A comparative study between quetiapine and clozapine in the treatment of schizophrenia and the relation with the plasman levels of IL‐2, SIL‐2R. Schuan Mental Health2003;16(3):152‐4. ">An 2003</a>;<a href="./references#CD006625-bbs2-0037" title="AnBF , ZhangML , QiSG . Comparitive study between the effect olanzapine and quetiapine in first‐episode schizophrenia. Journal of Clinical Psychological Medicine2006;16(2):84‐5. ">An 2006</a>;<a href="./references#CD006625-bbs2-0040" title="ArangoC , RoblesO , ParelladaM , FraguasD , Sancho‐RuizA , MedinaO , et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry2009;18:418‐28. ">Arango 2009</a>; <a href="./references#CD006625-bbs2-0043" title="BanN , CuiJB . Analysis of the efficacy of aripiprazole and quetiapine in the treatment of schizophrenia. Occupation and Health2008;24(3):292‐3. ">Ban 2008</a>; <a href="./references#CD006625-bbs2-0044" title="BeuzenJ‐N , PansM , ModellS , HagensP , McQuadeR , IwamotoT , et al. Naturalistic study of aripiprazole treatment. Proceedings of the XIII World Congress of Psychiatry, Cairo, Egypt, September 10‐15, 2005. ">Beuzen 2005</a>; <a href="./references#CD006625-bbs2-0045" title="BoterH , PeuskensJ , LibigerJ , FleischhackerWW , DavidsonM , GalderisiS , KahnRS . Effectiveness of antipsychotics in first‐episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research2009;115:97‐103. GalderisiS , DavidsonM , KahnRS , MucciA , BoterH , GheorgheMD , et al. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophrenia Research2009;115:104‐14. KahnRS , FleischhackerWW , BoterH , DavidsonM , VergouweY , KeetIPM , et al. Effectiveness of antipsychotic drugs in first‐episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet2008;371:1085–97. ">Boter 2005</a>; <a href="./references#CD006625-bbs2-0046" title="BrecherM , NewcomerJW , RatnerRE , ErikssonJW , EmsleyR , MeulienD , et al. Differential effects of quetiapine, olanzapine and risperidone on glucose metabolism: a 24‐week study in schizophrenia. International Congress on Schizophrenia Research. 2007. ">Brecher 2007</a>; <a href="./references#CD006625-bbs2-0049" title="CaiQQ , WangZW , LinYC , WangXY . A control study of quetiapine and clozapine in the treatment of schizophrenia. The Medicine Magazine of China2005;3(8):465‐6. ">Cai 2005</a>; <a href="./references#CD006625-bbs2-0051" title="CaoD , XieS‐P , ChenQ‐B , YuanY‐G , FangQ . Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation2005;9(36):63‐8. ">Cao 2005</a>; <a href="./references#CD006625-bbs2-0051" title="CaoD , XieS‐P , ChenQ‐B , YuanY‐G , FangQ . Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation2005;9(36):63‐8. ">Cao 2005</a>a; <a href="./references#CD006625-bbs2-0053" title="CaoD , XieSP , ChenQB , YuanYG , FangQ . Effects of antipsychotic on pituitary‐gonadal axis in male patients with schizophrenia. Journal of Clinical Psychological Medicine2006;16(4):209‐11. ">Cao 2006a</a>;<a href="./references#CD006625-bbs2-0055" title="ChangGS , LiJ . A control study of quetiapine and risperidone in the treatment of schizophrenia. China Practice Medicine2007;2(34):52‐3. ">Chang 2007</a>; <a href="./references#CD006625-bbs2-0056" title="ChangYS , GuYS . A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health2008;20(17):2010‐1. ">Chang 2008</a>; <a href="./references#CD006625-bbs2-0057" title="ChaudhryHR , NiazS , ArshadN , PerachaF , AyubA , MuftiKA . Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels. Journal of the European College of Neuropsychopharmacology2006;16(Suppl 4):S241. ">Chaudhry 2006</a>; <a href="./references#CD006625-bbs2-0058" title="ChenZE , LiuHR , WuSQ . A control study of quetiapine and risperidone in the treatment of female schizophrenia. Herald of Medicine2006;25(6):548‐50. ">Chen 2006a</a>; <a href="./references#CD006625-bbs2-0060" title="ChenJG . Control study on management of first‐episode schizophrenia with risperidone and quetiapine. China Pharmaceuticals2007;16(9):43‐4. ">Chen 2007a</a>; <a href="./references#CD006625-bbs2-0061" title="ChenFX . A control study of quetiapine vs risperidone in first‐episode schizophrenia. Jiangxi Medicine2007;42(10):917‐8. ">Chen 2007b</a>; <a href="./references#CD006625-bbs2-0062" title="ChenF , WangHY , LiDY , ZhouBW , ChenFY . A control study of quetiapine and aripiprazole in the treatment of female first‐episode schizophrenia. Journal of Psychiatry2007;20(6):381‐3. ">Chen 2007c</a>; <a href="./references#CD006625-bbs2-0063" title="ChenHB , FuF , YangQJ . A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Information2008;21(3):389‐90. ">Chen 2008</a>; <a href="./references#CD006625-bbs2-0065" title="CorteseL , CaligiuriMP , WilliamsR , SchieldropP , ManchandaR , MallaA , HarricharanR . Reduction in neuroleptic‐induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol2008;28:69‐73. ">Cortese 2008</a>; <a href="./references#CD006625-bbs2-0066" title="DaiJ‐P , ZhaoZ‐H , MaiG‐Y . Comparative study on the effect of olanzapine and seroquel of schizophrenia. Chinese Journal of Behavioral Medical Science2004;13(3):291‐3. ">Dai 2004</a>; <a href="./references#CD006625-bbs2-0067" title="DaiJ‐P , ZhaoZ‐H , LiuG‐X . Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Sience2005;14(8):712‐14. ">Dai 2005</a>; <a href="./references#CD006625-bbs2-0070" title="DingY , AnB , LiG , LiY . A comparative study of risperidone and quetiapine in the treatment of schizophrenia and relationship between efficacy and the serum levels of il‐2?sil‐2r. Shandong Archives of Psychiatry2004;17(2):76‐8. ">Ding 2004</a>; <a href="./references#CD006625-bbs2-0073" title="FengD‐J , ZhouT , XiongL‐H , ThianD‐F . A study of quetiapine and clozapine in treatment of chronic schizophrenia. Journal of Luzhou Medical College2003;26(6):511‐12. ">Du 2003</a>; <a href="./references#CD006625-bbs2-0075" title="FanJ‐H , LiW‐J . A study of quetiapine in treatment of negative symptoms dominant schizophrenia. Sichuan Mental Health2005;18:178. ">Fan 2005</a>; <a href="./references#CD006625-bbs2-0077" title="FleischhackerWW , KeetIPM , KahnRS . The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophrenia Research2005;78(2‐3):147‐56. ">Fleischhacker 2005</a>; <a href="./references#CD006625-bbs2-0078" title="FuH , YuH , HuoJ . A comparative study of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2005;11(4):313‐4. ">Fu 2005</a>; <a href="./references#CD006625-bbs2-0079" title="FuH , YuH , HuoJ . A comparative study of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2005;11(4):313‐4. ">Fu 2005a</a>; <a href="./references#CD006625-bbs2-0080" title="GaoCZ , GaoZ . A study of quetiapine in the treatment of first‐onset schizophrenia. Journal of Clinical Psychological Medicine2003;13(4):221‐2. ">Gao 2003</a>; <a href="./references#CD006625-bbs2-0084" title="HarriganEP , MiceliJJ , AnzianoR , WatskyE , ReevesKR , CutlerNR , et al. A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology2004;24(1):62‐9. ">Harrigan 2004</a>; <a href="./references#CD006625-bbs2-0085" title="HeJ , ChenYX . A controlled study on quetiapine and clozapine in the treatment of schizophrenic patients. Medical Journal of Chinese Civil Administration2003;15(6):335‐6. ">He 2003</a>; <a href="./references#CD006625-bbs2-0086" title="HoracekJ , SeifertovaD , JanuL , PetranovaT . The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia. Proceedings of the Biennial Winter Workshop on Schizophrenia, February 7‐13, 2004. ">Horacek 2004</a>; <a href="./references#CD006625-bbs2-0087" title="HuangS‐P , MaZ‐W , GuoB‐Y . Effectiveness of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2003;9(4):206‐7. ">Huang 2003</a>; <a href="./references#CD006625-bbs2-0090" title="JiangZX , HeXY , HeXC , LiLW , PengZE . A control study of quetiapine and aripiprozole in the treatment of schizophrenia. Journal of Clinical Research2006;23(8):1327‐8. ">Jiang 2006</a>; <a href="./references#CD006625-bbs2-0092" title="KeksNA , TonsoM , TaboneK , McHughM , ThomasR , TuneP , GelmanM . Clinical experience with atypical antipsychotics in acute inpatient unit: focus on quetiapine. International Journal of Psychiatry in Clinical Practice2006;10(2):1‐4. ">Keks 2006</a>; <a href="./references#CD006625-bbs2-0095" title="KnegteringR , CasteleinS , BousH , Van DerLindeJ , BruggemanR , KluiterH , et al. A randomized open‐label study of the impact of quetiapine versus risperidone on sexual functioning. Journal of Clinical Psychopharmacology2004;24(1):56‐61. ">Knegtering 2004</a>; <a href="./references#CD006625-bbs2-0096" title="KolotkinRL , Corey‐LislePK , CrosbyRD , KanHJ , McQuadeRD . Changes in weight and weight‐related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. European Psychiatry2008;23:561‐6. ">Kolotkin 2008</a>; <a href="./references#CD006625-bbs2-0097" title="Koponen . Study in Schizophrenic In‐Patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose. Clinical Trial Registration Data2008. ">Koponen 2008</a>; <a href="./references#CD006625-bbs2-0101" title="LiHF , GuNF , XieB , LiM , ZhangL , ChengY , WangMJ . Quetiapine in treatment of schizophrenia: a randomized, controlled, multicentre study. Chinese Journal of New Drugs and Clinical Remedies2001;20(4):260‐3. ">Li 2001</a>; <a href="./references#CD006625-bbs2-0103" title="LiCM . A comparison of cognitive function in the first‐onset schizophrenia treated with quetiapine and clozapine. Medical Journal of Chinese People Health2003;15(12):718‐21. ">Li 2003a</a>; <a href="./references#CD006625-bbs2-0104" title="LiX , LaoG , CaoL . Comparison of efficacy and safety of seroquel and resperidone in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science2003;12(1):45‐6. ">Li 2003b</a>; <a href="./references#CD006625-bbs2-0105" title="LiH . A controlled study of schizophrenia treated with quetiapine and clozapine. Chinese Modern Medical and Clinical2005;3(7):33‐4. ">Li 2005a</a>; <a href="./references#CD006625-bbs2-0106" title="LiG , ChenQ‐G , ZhangQ‐H . A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia. Chinese Journal of Behavioral Medical Science2005;14(11):1007‐8, 1036. ">Li 2005b</a>; <a href="./references#CD006625-bbs2-0107" title="LiM , LvW , XingX . A control study of quetiapine and aripiprazole in the treatment of schizophrenia. Chinese Journal of Postgraduate Medicine2007;30(11):49‐50. ">Li 2007a</a>; <a href="./references#CD006625-bbs2-0108" title="LiQ , WangW , ChenC , LiYM . Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia. Huaxi Pharmacy2007;22(3):354‐5. ">Li 2007h</a>; <a href="./references#CD006625-bbs2-0109" title="LiG , ZuoJ , ChenQ , ZhouH . A comparison analysis on the efficacy of quetiapine and risperidone in the treatment of schizophrenia. Tianjin Pharmacy2008;20(1):42‐4. ">Li 2008a</a>; <a href="./references#CD006625-bbs2-0111" title="LiW . Influence on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine. Medical Information2008;21(12):2253‐5. ">Li 2008c</a>; <a href="./references#CD006625-bbs2-0112" title="LiDM . The cross‐check analysis of risperdal and quetiapine alleviating negative symptoms of schizophrenia. Laboratory Medicine and Clinic2008;5(19):1162‐3. ">Li 2008d</a>; <a href="./references#CD006625-bbs2-0114" title="LinZ . Analysis of therapeutic effect of quetiapine on schizophrenia patient. China Tropical Medicine2005;5(6):1299. ">Lin 2005</a>; <a href="./references#CD006625-bbs2-0115" title="LinH , WangJ . A study of quetiapine in the treatment of elderly schizophrenia. Qinghai Pharmacy2007;37(4):67‐8. ">Lin 2007</a>; <a href="./references#CD006625-bbs2-0099" title="L’ItalienG , HanssensL , KanHJ , BakerRA , MarcusRN , McQuadeRD , et al. Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the Star trial). Proceedings of the 11th International Congress on Schizophrenia Research, Colorado Springs, Colorado, USA, March 28‐April 1, 2007. ">L'Italien 2007</a>; <a href="./references#CD006625-bbs2-0116" title="LiuX , LinL , FanY , DongX . A comparative study of new anti‐psychopathic drugs lead to gain weight. Medical Journal of Chinese People's Health2003;15(4):230‐1. ">Liu 2003</a>; <a href="./references#CD006625-bbs2-0117" title="LiuK , WangX , JiangL , GengH , CngX , ShiL , ZhaoH . A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Hebei Mental Health2003;16(1):37‐9. ">Liu 2003a</a>; <a href="./references#CD006625-bbs2-0118" title="LiuY , XuM , ChenX . A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry2004;17(1):6‐8. ">Liu 2004a</a>; <a href="./references#CD006625-bbs2-0119" title="LiuY , XuM , ChenX . A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry2004;17(1):6‐8. ">Liu 2004b</a>; <a href="./references#CD006625-bbs2-0120" title="LiuCX , LiuSH , TuZM , LiuB . A study of quetiapine with small doze of clozapine in treatment of resistant schizophrenia. Medical Journal of Chinese People´s Health2005;17:748‐9. ">Liu 2005</a>; <a href="./references#CD006625-bbs2-0121" title="LiuH , ShiY , LiuZ . A comparative study between quetiapine and risperidone in the treatment of schizophrenia. Journal of Heze Medical College2005;17(1):15‐6. ">Liu 2005a</a>; <a href="./references#CD006625-bbs2-0122" title="LiuZ , HanJ , ChengY , YanM , ZhouH . Study on quetiapine fumarate and risperidone in the treatment of schizophrenia. Journal of Hebei Medical College for Continuing Education2006;23(2):14‐6. ">Liu 2006</a>; <a href="./references#CD006625-bbs2-0125" title="LuS , ZhangS‐A , RenY . Comparative study on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine. Journal of Nursing Science2005;20(3):57‐9. ">Lu 2005</a>; <a href="./references#CD006625-bbs2-0126" title="LuoY , ZhangS‐W , WangA‐Q . The comparative study of quetiapine and clozapine in the treatment of female schizophrene. Medical Journal of Chinese People Health2005;17(6):269‐70. ">Luo 2005</a>; <a href="./references#CD006625-bbs2-0127" title="LvB , WangJ , LinY . A control study of quetiapine and risperidone in the treatment of eldly schizophrenia. Shandong Pharmacy2008;48(16):91‐2. ">Lv 2008</a>; <a href="./references#CD006625-bbs2-0129" title="MintzerJE , MullenJA , SweitzerDE . A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Current Medical Research and Opinion2004;20(9):1483‐91. ">Mintzer 2004</a>; <a href="./references#CD006625-bbs2-0130" title="MullenJ , JibsonMD , SweitzerD . A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clinical Therapeutics2001;23(11):1839‐54. ">Mullen 2001</a>; <a href="./references#CD006625-bbs2-0133" title="PanM , WangH , ZhangS . A controlled study of domestic quetiapine and risperidone in the treatment of first‐episode schizophrenia. Journal of Clinical Psychosomatic Diseases2004;10(4):244‐6. ">Pan 2004</a>; <a href="./references#CD006625-bbs2-0134" title="PanM , ZhangS‐Q , ZhaoZ . A comparative study of domestic quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese Peoples Health2004;16(10):597‐8, 637. ">Pan 2004a</a>; <a href="./references#CD006625-bbs2-0135" title="PanM , ZhangS , ZhaoZ . Influence of three antipsychotic drugs on electrocardiogram in patients with schizophrenia. Journal of XinXiang Medical College2004;21:403‐4. ">Pan 2004b</a>; <a href="./references#CD006625-bbs2-0137" title="PangD , WangC , CuiA . Effect of quetiapine fumarate and clozapine on clinical rehabilitation of schizophrenia:a controlled study. Chinese Journal of Clinical Rehabilitation2002;6(7):1007. ">Pang 2002</a>; <a href="./references#CD006625-bbs2-0139" title="PettyF . Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia. Clinical Trial Registration Data2006. ">Petty 2005</a>; <a href="./references#CD006625-bbs2-0140" title="Pfizer . Effect and Safety of Ziprasidone Compared to Other Atypical Antipsychotic Drug in Schizophrenic Patients. Clinical Trial Registration Data2005. ">Pfizer 2005</a>; <a href="./references#CD006625-bbs2-0141" title="QiF , WangL , ZhenY . Comparison of efficacy and safety of quetiapine and risperidone in the treatment of schizophrenia. Shanghai Archives of Psychiatry2004;16(2):78‐9, 119. ">Qi 2004</a>; <a href="./references#CD006625-bbs2-0142" title="QianD , PanB , YangG . Cost‐effectiveness analysis of 3 kinds of therapeutic schemes for schizophrenia. Evaluation and Analysis of Drug Use in Hospital of China2004;4(2):110‐1. ">Qian 2004</a>; <a href="./references#CD006625-bbs2-0143" title='ReznikI , SlavkinL , ShabashE , ShakedG , KertzmanS , SpivakB , et al. Quetiapine ("Seroquel") and olanzapine for acute treatment of patients with schizophrenia: an open‐label, comparative study. Proceedings of the XXIV Collegium Internationale Neuro‐Psychopharmacologicum; Paris, France, June 20‐24, 2004. 1‐4. '>Reznik 2004</a>; <a href="./references#CD006625-bbs2-0144" title="RieraL , TandonR , StockEG , KujawaMJ , TorbeynsAF , BorianFE . Broad effectiveness trial with aripiprazole. Proceedings of the Twelfth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February 7‐13, 2004. ">Riera 2004</a>; <a href="./references#CD006625-bbs2-0145" title="RuanJ , HuangG . A control study of quetiapine and clozapine in the treatment of difficult‐to‐treat schizophrenia. Medical Journal of Chinese People's Health2005;17(12):747‐8. ">Ruan 2005</a>; <a href="./references#CD006625-bbs2-0147" title="SajatovicM , MullenJA , SweitzerD . Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychotic disorders. Proceedings of the 155th Annual Meeting of the American Psychiatric Association, Philadelphia, Pennsylvania, USA, May 18‐23, 2002. ">Sajatovic 2002</a>; <a href="./references#CD006625-bbs2-0150" title="SongF . A control study of quetiapine and clozapine in the treatment of schizophrenia. Health Horizon·Medical Science Fascicule2006;(7):91. ">Song 2006</a>; <a href="./references#CD006625-bbs2-0160" title="SwansonJW , SwartzMS , VanDornRA . Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. ">Swanson 2006</a>; <a href="./references#CD006625-bbs2-0161" title="TangY . A controlled study of schizophrenia treated with quetiapine and clozapine. Shanghai Archives of Psychiatry2003;15(1):27‐9. ">Tang 2003</a>; <a href="./references#CD006625-bbs2-0162" title="TangZ‐K , XuC‐M , ChenD . A comparative study of quetiapine and clozapine in the treatment of recurrent schizophrenia. Shandong Archives of Psychiatry2005;18(3):167‐8. ">Tang 2005</a>; <a href="./references#CD006625-bbs2-0164" title="TianB , LiJ , JingH , ZhangW , LiuY . A comparative study between seroquel and risperidone in the treatment of schizophrenia. Shandong Archives of Psychiatry2006;19(1):25‐6. ">Tian 2006</a>; <a href="./references#CD006625-bbs2-0167" title="WangM , LiuM , LuL . A controlled study on seroquel and risperidone in the treatment of schizophrenic patients. Journal of Clinical Psychological Medicine2000;10(4):200‐1. ">Wang 2000</a>; <a href="./references#CD006625-bbs2-0168" title="WangX . Comparative study of effects of quetiapine and clozapine on quality of life of schizophrenics. Journal of Clinical Psychosomatic Diseases2004;10(3):167‐8. ">Wang 2004</a>; <a href="./references#CD006625-bbs2-0170" title="WangC‐H , LiY , LiuX . Cognitive function and p300 potentials in first‐episode schizophrenia treated with quetiapine and risperidone. Chinese Mental Health Journal2005;19(5):333‐6. ">Wang 2005</a>; <a href="./references#CD006625-bbs2-0171" title="WangC‐H , LiY , WangL‐H , PanM , ZHaoZ , MuJ‐L . Comparison of cognitive function and event related potentials in first episode schizophrenic treated with antipsychotic drugs. Journal of Clinical Psychological Medicine2005;15(3):168‐70. ">Wang 2005a</a>; <a href="./references#CD006625-bbs2-0172" title="WangX , YangJ , GuoH . Clinical study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2005;11(2):118‐9. ">Wang 2005b</a>; <a href="./references#CD006625-bbs2-0173" title="WangX‐F , WangW‐H , WangJ‐C . Analysis of quetiapine in treatment of first‐episode schizophrenia. Sichuan Mental Health2005;18:235‐6. ">Wang 2005c</a>; <a href="./references#CD006625-bbs2-0174" title="WangY , SunM , ShaoX . A comparative study between quetiapine and clozapine in the treatment of schizophrenia. Heath Psychology Journal2005;13(4):271‐2. ">Wang 2005d</a>; <a href="./references#CD006625-bbs2-0176" title="WangJ , RanR . Effects of quetiapine vs clozapine on the quality of life in first‐episode schizophrenics. Journal of Clinical Psychosomatic Disorders2006;12(6):416‐7. ">Wang 2006b</a>; <a href="./references#CD006625-bbs2-0184" title="WeiS . A randomized, double blind double dummy parallel controlled study in the female first‐onset schizophrenia treated with aripiprazole and quetiapine. Nervous Diseases and Mental Health2006;6(3):194‐7. ">Wei 2006</a>; <a href="./references#CD006625-bbs2-0187" title="WenS , ChenF . A control study of quetiapine and risperidone in the treatment of schizophrenia. Modern Medicine Health2005;21(22):3089‐90. ">Wen 2005</a>; <a href="./references#CD006625-bbs2-0188" title="WuY , WangX . A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychological Medicine2005;15(2):106‐7. ">Wu 2005</a>; <a href="./references#CD006625-bbs2-0189" title="XiangDF , LiuXL . Treatment of 31 cases of schizophrenia with quetiapine. Herald of Medicine2005;24(1):40‐2. ">Xiang 2005</a>; <a href="./references#CD006625-bbs2-0190" title="XuMQ , PengMY . A study of Quetiapine in treatment of schizophrenia. Journal of Clinical Psychology Medicine2002;12:227‐8. ">Xu 2002</a>; <a href="./references#CD006625-bbs2-0191" title="XuLZ , OuyangJL , GaoSZ . Effects of domestic quetiapine vs clozapine in treatment of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2003;7477(9):542‐5. ">Xu 2003</a>; <a href="./references#CD006625-bbs2-0192" title="XuXF , ZhangXB , ZhouCY , DaiXG . Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia. Journal of Jiangsu Clinical Medicine2005;9(1):20‐2. ">Xu 2005</a>; <a href="./references#CD006625-bbs2-0195" title="YangFS , YangYL , ZhangZH . Control study on quetiapine and clozapine in treatment of refractory schizophrenia. Medical Journal of Chinese People Health2004;16(1):12‐3. ">Yang 2004</a>; <a href="./references#CD006625-bbs2-0196" title="YangQ‐P , HuangY‐P , YangB‐X . The effect of quetiapine and risperidone on the EEG of first‐episode schizophrenic patients. Shandong Archives of Psychiatry2005;18(3):159‐60. ">Yang 2005</a>; <a href="./references#CD006625-bbs2-0197" title="YangQ‐P , HuangY‐P , YangB‐X . The effect of quetiapine and risperidone on the EEG of first‐episode schizophrenic patients. Shandong Archives of Psychiatry2005;18(3):159‐60. ">Yang 2005a</a>; <a href="./references#CD006625-bbs2-0198" title="YangY . Control study of quetiapine and clozapine in the treatment of refractory schizophrenia. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2006;14(4):276‐7. ">Yang 2006</a>; <a href="./references#CD006625-bbs2-0203" title="YuG , LiangS , HeZ‐G . Comparison of quetiapine and clozapine in treatment of schizophrenia. Journal of Clinical Psychiatry Medicine2003;25:4‐5. ">Yu 2003</a>; <a href="./references#CD006625-bbs2-0204" title="YuH , KongH . A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychological Medicine2005;15(6):362. ">Yu 2005</a>; <a href="./references#CD006625-bbs2-0205" title="YuW , LiuH , PanS . A control study of quetiapine and loxapine in the treatment of schizophrenia. Journal of Clinical Psychological Medicine2006;16(5):298. ">Yu 2006</a>; <a href="./references#CD006625-bbs2-0206" title="YuanF‐J , GaoM‐Z , LiuX . A contrast observation of quetiapine and clozapine in affecting electroencephalogram. Journal of Practical Medical Techniques2005;12(2B):482‐4. ">Yuan 2005</a>; <a href="./references#CD006625-bbs2-0208" title="ZhangL , WuY , GuoC . A comparative study between quetiapine and risperidone in the treatment of schizophrenia. Health Psychology Journal2003;11(4):262‐3. ">Zhang 2003</a>; <a href="./references#CD006625-bbs2-0209" title="ZhangM , ZhangH‐F , GuW . A comparative study of quetiapine and clozapine in the treatment of schizophrenia. Shandong Archives of Psychiatry2005;18(2):86‐8. ">Zhang 2005</a>; <a href="./references#CD006625-bbs2-0210" title="ZhangH , ZhangM , GuW . A comparative study of social function in schizophrenia patients treated with seroquel (quetiapine) or clozapine. Sichuan Mental Health2005;18(2):91‐3. ">Zhang 2005a</a>; <a href="./references#CD006625-bbs2-0211" title="ZhangR‐X , CaoY‐F . A comparative study of EKG changed by quetiapine and clozapine in the treatment of schizophrenia. Medical Journal of Chinese People Health2005;17(6):290‐1. ">Zhang 2005b</a>; <a href="./references#CD006625-bbs2-0212" title="ZhangY , JiangY , ZhaoS . A comparative study of quetiapine combined with clomipramine in treatment of schizophrenia with obsessive‐compulsive symptoms. Chinese Journal of Health Psychology2005;13(4):260‐2. ">Zhang 2005c</a>; <a href="./references#CD006625-bbs2-0213" title="ZhangW , MaJ , MaL . A control study of quetiapine and risperidone in the treatment of first‐episode schizophrenia. Chinese Journal of Current Traditional and Western Medicine2005;3(12):1088‐9. ">Zhang 2005d</a>; <a href="./references#CD006625-bbs2-0215" title="ZhangY , ZhouB . A control study of quetiapine and clozapine in the treatment of schizophrenia. Journal of Clinical Psychological Medicine2006;16(5):300. ">Zhang 2006a</a>; <a href="./references#CD006625-bbs2-0219" title="ZhaoF , ZhangZ , LiH . Control studies of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2004;10(1):25‐6. ">Zhao 2004</a>; <a href="./references#CD006625-bbs2-0220" title="ZhaoL , LiY , QiF . Control study of quetiapine and risperidone in treatment of schizophrenics. Heath Psychology Journal2005;13(1):56, 79‐80. ">Zhao 2005</a>; <a href="./references#CD006625-bbs2-0221" title="ZhaoYH , FangJH , WangSH , AnCG , MaX , LiHX . A study of quetiapine and clozapine in treatment of schizophrenia. Journal of Clinical Psychology Medicine2005;15:231‐2. ">Zhao 2005a</a>; <a href="./references#CD006625-bbs2-0224" title="ZhongZ‐Y , TaoJ , WangX‐L , WuX‐L , ZhangJ‐B . Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia. Zhongguo Linchuang Kangfu2006;10(2):30‐2. ">Zhong 2006a</a>; <a href="./references#CD006625-bbs2-0225" title="ZhouP , GongF , FanC . A control of treating chronic schizophrenia with seroquel or clozapine. Jiangxi Medical Journal2003;38(6):395‐6. ">Zhou 2003</a>; <a href="./references#CD006625-bbs2-0226" title="ZhouR , DaiX . A comparative study of quetiapine and clozapine in the treatment of patients with schizophrenia. Shanghai Archives of Psychiatry2003;15(4):215‐7. ">Zhou 2003a</a> </p> </td> </tr> </tbody> </table> </div> <p>Excluded studies, as is common, suggest that other reviews that should be added to the quetiapine suite (<a href="#CD006625-tbl-0018">Table 2</a>). </p> <div class="table" id="CD006625-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies relevant to other quetiapine comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0223" title="ZhengJ , WangB , FuA , LiP . A control study of quetiapine and clozapine in the treatment of schizophrenia. Medical Recapitulate2007;13(23):1878‐9. ">Zheng 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus quetiapine + clozapine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0054" title="CaoCA , GuoJH , GaoH . Comparison of curative effect and safety of quetiapine and risperidone in the treatment of female schizophrenia. Medical Journal of Chinese People's Health2006;18(6):433‐4. ">Cao 2006d</a>; <a href="./references#CD006625-bbs2-0082" title="GuoZY , LiuJM , YangJZ , GuoH , WangAQ . Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life. China Journal of Health Psychology2008;16(5):544‐6. ">Guo 2008</a>; <a href="./references#CD006625-bbs2-0132" title="NaiX , HuX , QiuW , LiuN , WeiH . Effect of quetiapine on cognitive function of patients with first episode schizophrenia. Journal of Medical Forum2007;28(2):38‐9. ">Nai 2007</a>; <a href="./references#CD006625-bbs2-0214" title="Zhangw , MaJ , XuF . Comparison study on treatment of primary schizophrenia with quetiapine and chlorpromazine. Heilongjiang Medical Journal2006;30(2):81‐2. ">Zhang 2006</a>; <a href="./references#CD006625-bbs2-0154" title="SunX , ZouS , LiZ , HanZ . Effect of cognitive function in first‐episode schizophrenia treated with quetiapine. Journal of Clinical Psychological Medicine2006;16(2):94‐5. ">Sun 2006e</a>; <a href="./references#CD006625-bbs2-0193" title="XuB . Comparative observation on the efect of quetiapine fumarate on chronic schizoprenia patients. China Tropical Medicine2006;6(6):1032. ">Xu 2006</a>; <a href="./references#CD006625-bbs2-0217" title="ZhangL . A comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Modern Medicine Journal of China2007;9(2):97‐8. ">Zhang 2007a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus chlorpramazine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0199" title="YangM , MuX , ZhaoA . A clinical study of quetiapine associated with clonazepam in the treatment of schizophrenia. Journal of Qiqihar Medical College2006;27(9):1034‐5. ">Yang 2006a</a>; <a href="./references#CD006625-bbs2-0200" title="YangC , GuoP , GuoH . Control study on using quetiapine to treat schizophrenic patients. China Practical Medicine2006;1(1):24‐6. ">Yang 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus haloperidol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0059" title="ChenRY , LuoRQ , WangAQ , MeiHB . A study of quetiapine on the quality of life of elderly schizophrenia. Medical Journal of Chinese People's Health2006;18(6):447‐8. ">Chen 2006k</a>; <a href="./references#CD006625-bbs2-0156" title="SunM , LiangF , MengY . A control study on quetiapine in gerontic first‐episode schizophrenia. Journal of Chinese Psychosomatic Disorders2007;13(5):407‐8. ">Sun 2007b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus perphenazine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0222" title="ZhaoL , GongGQ . A study of low‐dos equetiapine with sulpiride in the treatment of schizophrenia. Journal of Clinical Research2007;24(7):1181‐2. ">Zhao 2007</a>; <a href="./references#CD006625-bbs2-0227" title="ZhouM . A study of quetiapine with sulpiride in the treatment of chronic schizophrenia. Journal of Clinical Psychological Medicine2006;16(6):368. ">Zhou 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus sulpiride</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0083" title="HaoH . A control study of quetiapine and seroquel in the treatment of schizophrenia. Journal of Medical Forum2007;28(15):60‐1. ">Hao 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine from non‐domestic source vs domestic quetiapine</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD006625-sec3-0040"> <h6 class="title">2.2 Trials</h6> <p>Comparisons with amisulpride, sertindole and zotepine do not exist. Studies comparing quetiapine with aripiprazole and with paliperidone are few and comprise small sample sizes. Most data that have been reported within existing comparisons are almost without value because of the assumptions and biases contained within them. Therefore, there is plenty of room for further research into the effects of this widely used drug. We realize that planning for such studies needs meticulous attention to detail, but we suggest some pointers that have come from our reading and understanding of the existing trials (<a href="#CD006625-tbl-0019">Table 3</a>). </p> <div class="table" id="CD006625-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blindness: double ‐ described and tested.<br/> Duration: 6 months minimum. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia (operational criteria).<br/> N = 3000*.<br/> Age: any.<br/> Gender: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Quetiapine: dose ˜300‐800 mg/day. N=300.</p> <p>2. Amisulpride: dose ˜ 400‐800 mg/day. N=300.</p> <p>3. Aripiprazole: dose ˜ 10‐30 mg/day. N=300.</p> <p>4. Clozapine: dose ˜ 300‐800 mg/day. N=300.</p> <p>5. Olanzapine: dose ˜ 10‐20 mg/day. N=300.</p> <p>6. Ziprasidone: dose ˜ 120‐160 mg/day. N=300.</p> <p>7. Risperidone: dose ˜ 4‐8 mg/day. N=300.</p> <p>8. Sertindole: dose ˜ 12‐24 mg/day. N=300.</p> <p>9. Zotepine: dose ˜ 100‐300 mg/day. N=300.</p> <p>10. Paliperidone: dose˜ 6‐12 mg/day. N=300.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global state: CGI**, relapse.</p> <p>Leaving study early (any reason, adverse events, inefficacy).<br/> Mental state: PANSS.<br/> Service outcomes: hospitalised, time in hospital, attending out patient clinics.<br/> Adverse events: UKU.<br/> Employment, family satisfaction, patient satisfaction. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<br/> <br/> **Primary outcome. </p> </div> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006625-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006625-sec1-0001"></div> <div class="table" id="CD006625-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">QUETIAPINE versus ARIPIPRAZOLE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus ARIPIPRAZOLE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus ARIPIPRAZOLE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus ARIPIPRAZOLE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score</b> <br/> PANSS total </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 1. General ‐ average endpoint score in the intervention groups was<br/> <b>1.62 higher</b> <br/> (0.89 lower to 4.14 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 2. Positive symptoms ‐ average endpoint score in the intervention groups was<br/> <b>0.62 higher</b> <br/> (1.13 lower to 2.38 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high = poor)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high = poor) in the intervention groups was<br/> <b>1 higher</b> <br/> (0.25 lower to 2.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: substantial improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.67</b> <br/> (0.12 to 3.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> <br/> (6 to 178) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b> <br/> (18 to 535) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> <br/> (30 to 892) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic ‐ weight gain</b> ≥<b>7% of total body weight</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.52</b> <br/> (0.1 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>155<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (1 to 27) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (5 to 137) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> <br/> (10 to 274) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated serious ‐ only one study adequately described appropriate allocation concealment methods (but not sequence generation). All other studies did not adequately describe sequence generation and allocation concealment.<br/> <sup>2</sup> Inconsistency: rated 'no' the P value for heterogeneity not statistically significant and I<sup>2</sup> &lt; 50%.<br/> <sup>3</sup> Imprecise data: rated serious ‐ only a few studies contributed to this outcome and confidence interval was wide.<br/> <sup>4</sup> Moderate risk equates to that found within study.<br/> <sup>5</sup> Risk of bias: rated serious ‐ the one study that contributed to this outcome adequately described appropriate allocation concealment methods but not sequence generation.<br/> <sup>6</sup> Imprecise data: rated serious ‐ only one study with a wide confidence interval reported this outcome.<br/> <sup>7</sup> Publication bias: rated no ‐ only one study reported this outcome making publication bias difficult to assess<br/> <sup>8</sup> Risk of bias: rated serious ‐ neither of the two studies reporting this outcome adequately described appropriate allocation concealment and sequence generation methods.<br/> <sup>9</sup> Imprecise data: rated serious ‐ only two studies reported this outcome, both with wide confidence intervals crossing the line of no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006625-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">QUETIAPINE versus CLOZAPINE ‐ all data short term for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus CLOZAPINE all data short term for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus CLOZAPINE all data short term </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus CLOZAPINE all data short term</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score short term (PANSS total, high = poor)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score short term (PANSS total, high = poor) in the intervention groups was<br/> <b>0.5 lower</b> <br/> (2.85 lower to 1.86 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 2. Positive symptoms ‐ average endpoint score in the intervention groups was<br/> <b>0.7 lower</b> <br/> (2.07 lower to 0.68 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score short term</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 3. Negative symptoms ‐ average endpoint score short term in the intervention groups was<br/> <b>2.23 lower</b> <br/> (3.48 to 0.99 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: substantial improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>5</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.22</b> <br/> (0.11 to 0.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>135<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/> (22 to 94) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>5</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (55 to 235) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>5</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> <br/> (88 to 376) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risks were calculated from pooled risk differences. No events in either group (RD 0.0 CI ‐0.13 to 0.13) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic ‐ weight gain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>5</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.53</b> <br/> (0.25 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>135<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> <br/> (25 to 111) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>5</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (62 to 278) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>5</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> <br/> (100 to 444) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated serious none of the studies adequately described sequence generation and allocation concealment.<br/> <sup>2</sup>Inconsistency: rated 'no' the P value for heterogeneity not statistically significant and I<sup>2</sup> &lt; 50%.<br/> <sup>3</sup>Imprecise data: rated serious wide confidence intervals for all individual studies, all crossing the line of no effect.<br/> <sup>4</sup>Imprecise data: rated serious only two studies, both with wide confidence intervals.<br/> <sup>5</sup>Moderate risk equates to that within trials.<br/> <sup>6</sup>Imprecise data: rated serious one small study. No events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006625-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">QUETIAPINE versus OLANZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus OLANZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus OLANZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus OLANZAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score (PANSS total, high = poor)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score (PANSS total, high = poor) in the intervention groups was<br/> <b>3.67 higher</b> <br/> (1.95 to 5.39 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1486<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 2. Positive symptoms ‐ average endpoint score in the intervention groups was<br/> <b>1.02 higher</b> <br/> (0.81 lower to 2.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ endpoint score</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 3. Negative symptoms ‐ average endpoint score in the intervention groups was<br/> <b>0.86 higher</b> <br/> (0.32 lower to 2.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: general ‐ average change in endpoint score medium term</b> <br/> QLS total score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life: general ‐ average change in endpoint score medium term in the intervention groups was<br/> <b>1.8 higher</b> <br/> (2.42 lower to 6.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>7</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.98</b> <br/> (0.84 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1615<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b> <br/> (84 to 113) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b> <br/> (252 to 339) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> <br/> (420 to 565) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>7</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1127<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Risks were calculated from pooled risk differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (10 to 44) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> <br/> (21 to 89) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b> <br/> (31 to 133) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic ‐ weight significant gain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>7</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.69</b> <br/> (0.51 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1321<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> <br/> (102 to 190) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b> <br/> (204 to 380) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> <br/> (306 to 570) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated serious no studies adequately described sequence generation and allocation concealment.<br/> <sup>2</sup>Imprecision: rated ’very serious’ only few studies contribute data to this event and the CI was quite wide.<br/> <sup>3</sup>Risk of bias: rated serious one study adequately described appropriate allocation concealment methods but not sequence generation, and another study adequately described sequence generation but not allocation concealment. All other studies did not adequately describe sequence generation and allocation concealment.<br/> <sup>4</sup>Inconsistency: rated ’no’ although the P value for heterogeneity was statistically significant and the I<sup>2</sup> &gt; 50%, the direction of the effect of almost all studies was the same. Exclusion of one outlier (<a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>) rendered the heterogeneity not statistically significant and I<sup>2</sup> &lt; 50%. Therefore, this inconsistency does not challenge the overall results.<br/> <sup>5</sup>Imprecision: rated 'no' exclusion of potentially skewed data (<a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>) revealed an overall significant difference in favour of olanzapine.<br/> <sup>6</sup>Risk of bias: rated serious no studies adequately described sequence generation and allocation concealment.<br/> <sup>7</sup>Moderate risk equates to that of studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006625-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">QUETIAPINE versus PALIPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus PALIPERIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus PALIPERIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus PALIPERIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score</b> <br/> PANSS total </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score in the intervention groups was<br/> <b>6.3 higher</b> <br/> (2.77 to 9.83 higher)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 2. Positive symptoms average endpoint score in the intervention groups was<br/> <b>1.60 higher</b> <br/> (0.42 to 2.78 higher)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 3. Negative symptoms ‐ average endpoint score in the intervention groups was<br/> <b>1.3 higher</b> <br/> (0.52 to 2.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: substantial improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.64</b> <br/> (0.45 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>128 per 1000</b> <br/> (90 to 182) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> <br/> (180 to 364) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>384 per 1000</b> <br/> (270 to 546) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 3. Metabolic weight gain</b> ≥<b>7% of total body weight</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.52</b> <br/> (0.5 to 12.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (5 to 128) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>252 per 1000</b> <br/> (50 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Calculated using generic inverse variance.<br/> <sup>2</sup>Imprecision: rated ’serious’ only one study contributes data to outcome and the CI was quite wide.<br/> <sup>3</sup>Moderate risk equates to that within the trial. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006625-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">QUETIAPINE versus RISPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus RISPERIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus RISPERIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus RISPERIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score</b> <br/> PANSS total score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score in the intervention groups was<br/> <b>1.74 higher</b> <br/> (0.19 to 3.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2155<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 2. Positive symptoms ‐ average endpoint score in the intervention groups was<br/> <b>1.38 higher</b> <br/> (0.51 to 2.24 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1492<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 3. Negative symptoms ‐ average endpoint score in the intervention groups was<br/> <b>0.69 higher</b> <br/> (0.02 lower to 1.41 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1367<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: general average endpoint score</b> <br/> QLS total score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life: general average endpoint score in the intervention groups was<br/> <b>3.44 lower</b> <br/> (4.46 to 2.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.21</b> <br/> (1.06 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2226<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>298 per 1000</b> <br/> (261 to 340) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>289 per 1000</b> <br/> (253 to 330) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>6</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.5</b> <br/> (0.36 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2163<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (18 to 34) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> <br/> (54 to 103) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> <br/> (90 to 172) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic weight gain</b> ≥<b>7% of total body weight</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>6</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.96</b> <br/> (0.82 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2070<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> <br/> (82 to 114) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> <br/> (164 to 228) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> <br/> (246 to 342) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. Only two studies adequately described sequence generation.<br/> <sup>2</sup>Inconsistency: rated ’no’ although the P value for heterogeneity was statistically significant and the I<sup>2</sup> &gt; 50%, the direction of the effect of almost all studies was the same. Therefore, this inconsistency does not challenge the overall results.<br/> <sup>3</sup>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. One study adequately described sequence generation and one study sequence generation.<br/> <sup>4</sup>Imprecision: rated serious most studies comprised small samples sizes with wide confidence intervals.<br/> <sup>5</sup>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. One study adequately described sequence generation and two studies sequence generation.<br/> <sup>6</sup>Moderate risk equates to that within trials. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006625-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">QUETIAPINE versus ZIPRASIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus ZIPRASIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus ZIPRASIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus ZIPRASIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score</b> <br/> PANSS total score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score in the intervention groups was<br/> <b>3.7 higher</b> <br/> (2.97 lower to 10.37 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score medium term</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 2. Positive symptoms ‐ average endpoint score medium term in the intervention groups was<br/> <b>0 higher</b> <br/> (2.18 lower to 2.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score medium term</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 3. Negative symptoms ‐ average endpoint score medium term in the intervention groups was<br/> <b>1.6 higher</b> <br/> (0.34 lower to 3.54 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: substantial improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.36</b> <br/> (1.03 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>754<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> <br/> (103 to 181) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b> <br/> (206 to 362) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>408 per 1000</b> <br/> (309 to 543) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.43</b> <br/> (0.2 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>522<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (10 to 47) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> <br/> (20 to 93) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b> <br/> (30 to 140) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic weight gain</b> ≥<b>7% of total body weight</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 2.22</b> <br/> (1.35 to 3.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>754<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (14 to 36) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> <br/> (68 to 182) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> <br/> (135 to 363) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated serious ‐ inadequately described sequence generation and allocation concealment.<br/> <sup>2</sup>Imprecision: rated serious ‐ only one study contributed to this important outcome and the confidence interval was large.<br/> <sup>3</sup>Moderate risk equates to that within trials. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006625-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006625-sec1-0002"></div> <p> </p> <section id="CD006625-sec2-0001"> <h3 class="title" id="CD006625-sec2-0001">Description of the condition</h3> <p>Schizophrenia is a serious psychiatric disorder that affects almost 1% of the population at some point in their lives (<a href="./references#CD006625-bbs2-0240" title="AndreasenNC . Assessment issues and the cost of schizophrenia. Schizophrenia Bulletin1991;17:408‐10. ">Andreasen 1991</a>). Its typical manifestations are positive symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), negative symptoms such as apathy and lack of drive and disorganisation of behaviour and thought and catatonic symptoms such as mannerisms and bizarre posturing, as well as cognitive impairment (<a href="./references#CD006625-bbs2-0247" title="CarpenterWTJr , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>; <a href="./references#CD006625-bbs2-0280" title="MueserKT , McGurkSR . Schizophrenia. Lancet2004;363(9426):2063‐72. ">Mueser and McGurk 2004</a>). The degree of suffering and disability is considerable, with 80% to 90% not working (<a href="./references#CD006625-bbs2-0276" title="MarvahaS , JohnsonS . Schizophrenia and employment ‐ a review. Social Psychiatry and Psychiatric Epidemiology2004;39:337‐49. ">Marvaha 2004</a>) and a two‐fold increase in mortality (<a href="./references#CD006625-bbs2-0236" title="AllebeckP , VarlaA , WistedtB . Suicide and violent death among patients with schizophrenia. Acta Psychiatrica Scandinavia1986;74(1):43‐9. ">Allebeck 1986</a>). Conventional antipsychotic drugs, such as chlorpromazine and haloperidol, have traditionally been used as first‐line antipsychotic drugs for people with schizophrenia (<a href="./references#CD006625-bbs2-0270" title="KaneJM . Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica1993;46:585‐93. ">Kane 1993</a>). The re‐introduction of clozapine in the United States and findings indicating that clozapine seemed more effective than other drugs, as well as its association with fewer movement disorders than chlorpromazine (<a href="./references#CD006625-bbs2-0269" title="KaneJM , HonigfeldG , SingerJ , MeltzerH , Clozaril Collaborative Study Group. Clozapine for the treatment of treatment‐resistant schizophrenia: a double‐blind comparison with chlorpromazine. Archives of General Psychiatry1988;45:789‐96. ">Kane 1988</a>), have boosted the development of new/second‐generation/atypical antipsychotic drugs (SGAs). </p> </section> <section id="CD006625-sec2-0002"> <h3 class="title" id="CD006625-sec2-0002">Description of the intervention</h3> <p>No good definition has been put forth for what an 'atypical' antipsychotic is, but these agents were initially said to differ from typical antipsychotic drugs in that they do not cause movement disorders (catalepsy) in rats at clinically effective doses (<a href="./references#CD006625-bbs2-0242" title="ArntJ , SkarsfeldtT . Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology1998;18:63‐101. ">Arnt 1998</a>). The terms 'new' and 'second‐generation' antipsychotic drugs are not much better because clozapine is now a very old drug. According to treatment guidelines (<a href="./references#CD006625-bbs2-0241" title="American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2nd Edition. American Journal of Psychiatry, 2004:1‐114. ">APA 2004</a>; <a href="./references#CD006625-bbs2-0258" title="GaebelW , FalkaiP , WeinmannS , WobrockT . Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf2006. ">Gaebel 2006</a>), second‐generation antipsychotic drugs include agents such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine and paliperidone. It remains unclear whether some older compounds such as sulpiride or perazine have atypical properties (<a href="./references#CD006625-bbs2-0279" title="MollerHJ . New assessment of atypical antipsychotics [Aktuelle Bewertung neuer/atypischer Neuroleptika]. Nervenarzt2000;71:329‐44. ">Moller 2000</a>); therefore, they have been excluded from this review. The second‐generation antipsychotic drugs have raised hopes for superior effects in several areas, such as compliance, cognitive functioning, negative symptoms, movement disorders, quality of life and the treatment of people whose illness had formerly been resistant to treatment. </p> </section> <section id="CD006625-sec2-0003"> <h3 class="title" id="CD006625-sec2-0003">How the intervention might work</h3> <p>Experimental laboratory studies have suggested that quetiapine is a clozapine‐like atypical antipsychotic (<a href="#CD006625-fig-0001">Figure 1</a>; <a href="./references#CD006625-bbs2-0259" title="GoldsteinJM , LitwinLC , SuttonEM , MalickJB . Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology1993;112:293‐8. ">Goldstein 1993</a>; <a href="./references#CD006625-bbs2-0277" title="MiglerBM , WarawaEJ , MalickJB . Seroquel: behavioral profile of a potential atypical antipsychotic. Psychopharmacology1993;112:299‐307. ">Migler 1993</a>; <a href="./references#CD006625-bbs2-0283" title="SallerCF , SalamaAI . Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology1993;112:285‐92. ">Saller 1993</a>). In contrast to olanzapine, risperidone, sertindole and ziprasidone, which have high affinities (&lt;50 nM) for both dopamine‐2 (D2) and serotonin‐2A (5‐HT2A) receptors, quetiapine is similar to clozapine in having only moderate affinities (&lt;500 nM) for these sites (<a href="./references#CD006625-bbs2-0260" title="GoldsteinJM . Preclinical tests that predict clozapine‐like atypical antipsychotic actions. Critical issues in the treatment of schizophrenia. International Academy of biochemical Drug Research1995;10:95‐101. ">Goldstein 1995</a>). Quetiapine has a high affinity for histamine receptors (&lt;50 nM) (<a href="./references#CD006625-bbs2-0242" title="ArntJ , SkarsfeldtT . Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology1998;18:63‐101. ">Arnt 1998</a>). </p> <div class="figure" id="CD006625-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Quetiapine." data-id="CD006625-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Quetiapine.</p> </div> </div> </div> </section> <section id="CD006625-sec2-0004"> <h3 class="title" id="CD006625-sec2-0004">Why it is important to do this review</h3> <p>The debate continues as to how much the second‐generation antipsychotic drugs improve these outcomes compared with conventional antipsychotic drugs (<a href="./references#CD006625-bbs2-0253" title="DugganL , FentonM , RathboneJ , DardennesR , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2005</a>; <a href="./references#CD006625-bbs2-0255" title="El‐SayehHG , MorgantiC . Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3] ">El‐Sayeh 2006</a>), and the results of recent studies are sobering (<a href="./references#CD006625-bbs2-0268" title="JonesPB , BarnesTRE , DaviesL , DunnG , LloydH , HayhurstKP , et al. Randomized controlled trial of the effect on quality of life. Archives of General Psychiatry2006;63:1079‐6. ">Jones 2006</a>; <a href="./references#CD006625-bbs2-0274" title="LiebermannJA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , KeefeRSE , DavisSM . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353:1209‐23. ">Liebermann 2005</a>). Nevertheless, in some parts of the world, especially in the highly industrialised countries, second‐generation antipsychotic drugs have become the mainstay of treatment. They also differ in terms of their costs: although amisulpride and risperidone are already available in generic formulations in many countries, quetiapine for example still is not. Therefore, the question as to whether these agents differ from each other in terms of their clinical effects becomes increasingly important. In this review, we aim to summarise evidence from randomised controlled trials (RCTs) that compared quetiapine with other second‐generation antipsychotic drugs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006625-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006625-sec1-0003"></div> <p>To evaluate the effects of quetiapine compared with other second‐generation (atypical) antipsychotic drugs in the treatment of people with schizophrenia and schizophrenia‐like psychoses. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006625-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006625-sec1-0004"></div> <section id="CD006625-sec2-0005"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006625-sec3-0001"> <h4 class="title">Types of studies</h4> <p>We included relevant RCTs that were at least single‐blind (blind raters). When a trial was described as double‐blind but it was only implied that the study was randomised, we included it in a sensitivity analysis. If no substantive difference within primary outcomes was noted (see <a href="#CD006625-sec3-0004">Types of outcome measures</a>) when these implied randomisation studies were added, we included them in the final analysis. If a substantive difference within primary outcomes was described, we used only clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi‐randomised studies, such as those that allocated by using alternate days of the week. We included randomised cross‐over studies but only data up to the point of first cross‐over because of the instability of the problem behaviours and the likely carry‐over effects of all treatments. </p> <p><i>Please note:</i> This update adopted the same criteria for considering the types of studies for inclusion as were applied in the previous version of this review, wherein only RCTs that were at least single‐blind (blind raters) were included. We therefore did not include open‐label studies in this update. However, open‐label trials provide valuable information, particularly for objective outcomes, and will be included in the next update. </p> </section> <section id="CD006625-sec3-0002"> <h4 class="title">Types of participants</h4> <p>We included people with schizophrenia and other types of schizophrenia‐like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. No clear evidence suggests that the schizophrenia‐like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<a href="./references#CD006625-bbs2-0247" title="CarpenterWTJr , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). </p> </section> <section id="CD006625-sec3-0003"> <h4 class="title">Types of interventions</h4> <section id="CD006625-sec4-0001"> <h5 class="title">1. Quetiapine</h5> <p>Any oral form of application, any dose.</p> </section> <section id="CD006625-sec4-0002"> <h5 class="title">2. Other 'atypical' antipsychotic drugs</h5> <p>Amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole, ziprasidone, zotepine: any oral form of application, any dose. </p> </section> </section> <section id="CD006625-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <p>We grouped outcomes into short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks). </p> <section id="CD006625-sec4-0003"> <h5 class="title">Primary outcomes</h5> <section id="CD006625-sec5-0001"> <h6 class="title">1. Global state</h6> <p>No clinically important response as defined by the individual studies (e.g. clinical global impression (CGI) less than much improved or less than 50% reduction on a rating scale) </p> </section> </section> <section id="CD006625-sec4-0004"> <h5 class="title">Secondary outcomes</h5> <section id="CD006625-sec5-0002"> <h6 class="title">1. Leaving the study early (any reason, adverse events, inefficacy of treatment)</h6> </section> <section id="CD006625-sec5-0003"> <h6 class="title">2. Global state</h6> <p>2.1 No clinically important change in global state (as defined by individual studies)<br/> 2.2 Relapse (as defined by the individual studies) </p> </section> <section id="CD006625-sec5-0004"> <h6 class="title">3. Mental state (with particular reference to the positive and negative symptoms of schizophrenia) </h6> <p>3.1 No clinically important change in general mental state score<br/> 3.2 Average endpoint general mental state score<br/> 3.3 Average change in general mental state score<br/> 3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<br/> 3.5 Average endpoint specific symptom score<br/> 3.6 Average change in specific symptom score </p> </section> <section id="CD006625-sec5-0005"> <h6 class="title">4. General functioning</h6> <p>4.1 No clinically important change in general functioning<br/> 4.2 Average endpoint general functioning score<br/> 4.3 Average change in general functioning score </p> </section> <section id="CD006625-sec5-0006"> <h6 class="title">5. Quality of life/satisfaction with treatment</h6> <p>5.1 No clinically important change in general quality of life<br/> 5.2 Average endpoint general quality of life score<br/> 5.3 Average change in general quality of life score </p> </section> <section id="CD006625-sec5-0007"> <h6 class="title">6. Cognitive functioning</h6> <p>6.1 No clinically important change in overall cognitive functioning<br/> 6.2 Average endpoint overall cognitive functioning score<br/> 6.3 Average change in overall cognitive functioning score </p> </section> <section id="CD006625-sec5-0008"> <h6 class="title">7. Service use</h6> <p>7.1 Admitted</p> </section> <section id="CD006625-sec5-0009"> <h6 class="title">8. Adverse effects</h6> <p>8.1 Number of people with at least one adverse effect<br/> 8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, sedation, seizures, weight gain, effects on white blood cell count)<br/> 8.3 Average endpoint specific adverse effects<br/> 8.4 Average change in specific adverse effects </p> </section> <section id="CD006625-sec5-0010"> <h6 class="title">9. Summary of findings table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD006625-bbs2-0284" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used the <a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADEPRO</a> profiler to import data from Review Manager 5 (<a href="http://www.ims.cochrane.org/revman" target="_blank">RevMan</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on all outcomes that we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p>1. Mental state: general average endpoint score (Positive and Negative Syndrome Scale (PANSS) total, high = poor). </p> <p>2. Mental state: positive symptoms average endpoint score (PANSS positive subscore, high = poor). </p> <p>3. Mental state: negative symptoms average endpoint score (PANSS negative subscore, high = poor) </p> <p>4. Quality of life: general average endpoint score (quality of life total score (QLS), low = poor). </p> <p>5. Adverse effects: central nervous system sedation.</p> <p>6. Adverse effects: extrapyramidal effects use of antiparkinson medication.</p> <p>7. Adverse effects: metabolic weight gain of 7% or more of total body weight.</p> </section> </section> </section> </section> <section id="CD006625-sec2-0006"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied within the limitations of the search tools.</p> <section id="CD006625-sec3-0005"> <h4 class="title">Electronic searches</h4> <section id="CD006625-sec4-0005"> <h5 class="title">1. Cochrane Schizophrenia Group Trials Register (update May 2010)</h5> <p>We searched the Specialised Register of the Cochrane Schizophrenia Group (May 2010) using the phrase: </p> <p>[(quetiapine* or seroquel* or ICI‐204636* or (ICI and 204636) or ICI204636* in title or *quetiapine* or *seroquel* or *ICI‐204636* or (ICI and 204636) or *ICI204636* in title, abstract or index terms of REFERENCE) or (quetiapine in interventions of STUDY) </p> <p>This register is compiled by systematic searches of major databases, handsearches and searches of conference proceedings (see <a href="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html" target="_blank">Group Module</a>). The Cochrane Schizophrenia Group Trials Register is maintained on Meerkat 1.5. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references that have been identified as the same study are also selected. </p> </section> <section id="CD006625-sec4-0006"> <h5 class="title">2. Previous searches from earlier versions of this review</h5> <p>Please see <a href="./appendices#CD006625-sec2-0021">Appendix 1</a>. </p> </section> </section> <section id="CD006625-sec3-0006"> <h4 class="title">Searching other resources</h4> <section id="CD006625-sec4-0007"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all identified studies for more trials.</p> </section> <section id="CD006625-sec4-0008"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study to request missing information.</p> </section> <section id="CD006625-sec4-0009"> <h5 class="title">3. Drug companies</h5> <p>We contacted the manufacturers of all included atypical antipsychotic drugs to ask for additional data. </p> </section> </section> </section> <section id="CD006625-sec2-0007"> <h3 class="title" id="CD006625-sec2-0007">Data collection and analysis</h3> <p> For previous data collection methods, see <a href="./appendices#CD006625-sec2-0022">Appendix 2</a>. </p> <section id="CD006625-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LA and SJF for the 2010 update, KK and CRK for the 2007 review, JW in discussion with LA for Chinese language studies) independently inspected all reports. We resolved any disagreement by discussion, and when there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought further information and added these trials to the list of those awaiting assessment. </p> </section> <section id="CD006625-sec3-0008"> <h4 class="title">Data extraction and management</h4> <section id="CD006625-sec4-0010"> <h5 class="title">1. Extraction</h5> <p>Review authors LA, SJF and JW extracted data from included studies for the 2010 update; review authors KK and CRK extracted data for the 2007 review. We extracted only data presented in graphs and figures whenever possible. When further information was necessary, we contacted authors of studies to obtain missing data or to ask for clarification. If studies were multi‐centre, where possible, we separately extracted data relevant to each component centre. </p> </section> <section id="CD006625-sec4-0011"> <h5 class="title">2. Management</h5> <section id="CD006625-sec5-0011"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD006625-sec5-0012"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p>a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD006625-bbs2-0275" title="MarshallM , LockwoodA , AdamsC , BradleyC , JoyC , FentonM . Unpublished rating scales ‐ a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and </p> <p>b. the measuring instrument has not been written or modified by one of the trialists for that particular trial. </p> <p>Ideally the measuring instrument should be a self‐report or should be completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <a href="#CD006625-sec2-0008">Description of studies</a>. </p> </section> <section id="CD006625-sec5-0013"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>Both endpoint and change data provide advantages. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be challenging to perform in unstable and difficult to measure conditions such as schizophrenia. We decided to primarily use endpoint data and to use change data only if the former were not available. We combined endpoint and change data in the analysis by using mean differences (MDs) rather than standardised mean differences throughout (<a href="./references#CD006625-bbs2-0266" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD006625-sec5-0014"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes often are not normally distributed. To avoid the pitfalls of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: (1) standard deviations (SDs) and means are reported in the paper or are obtainable from the authors; (2) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<a href="./references#CD006625-bbs2-0237" title="AltmanDG , BlandJM . Detecing skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>)); and (3) if a scale started from a positive value (such as PANSS, which can have values ranging from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases, skew is present if 2 SDs &gt; (S S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have finite starting and ending points, and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants into other tables within the data analyses section rather than into a statistical analysis. Skewed data pose less of a problem when the mean is examined if the sample size is large; we entered such endpoint data into syntheses. When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether or not data are skewed. If we found skewed change data according to the above rules, we entered these into statistical analyses. </p> </section> <section id="CD006625-sec5-0015"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month), to a common metric (e.g. mean days per month). </p> </section> <section id="CD006625-sec5-0016"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' and 'not clinically improved' subgroups. It is generally assumed that if a 50% reduction is noted in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS; <a href="./references#CD006625-bbs2-0281" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD006625-bbs2-0271" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered a clinically significant response (<a href="./references#CD006625-bbs2-0272" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79:231‐8. ">Leucht 2005</a>; <a href="./references#CD006625-bbs2-0273" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale Scores (BPRSS). British Journal of Psychiatry2005;187:366‐71. ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD006625-sec5-0017"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for quetiapine. </p> </section> </section> </section> <section id="CD006625-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors worked independently by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006625-bbs2-0266" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies to request additional information. </p> <p>We have noted the level of risk of bias both in the text of the review and in the 'Summary of findings' tables. </p> </section> <section id="CD006625-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <section id="CD006625-sec4-0012"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that the RR is more intuitive (<a href="./references#CD006625-bbs2-0245" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405‐11. ">Boissel 1999</a>) than the odds ratio and that odds ratios tend to be interpreted by clinicians as RRs (<a href="./references#CD006625-bbs2-0249" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium, Cape Town, South Africa, October 25‐28, 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial outcome (NNTB)/number needed to treat for an additional harmful outcome (NNTH) statistic with its CIs is intuitively attractive to clinicians but is problematic in its inaccuracy of calculations in meta‐analyses and in interpretation (<a href="./references#CD006625-bbs2-0267" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table/s, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD006625-sec4-0013"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we used estimated mean differences (MDs) between groups. We prefer not to calculate effect size measures (standardised mean differences (SMDs)). However, if scales of considerable similarity were used, we presumed that a small difference in measurement would be noted, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD006625-sec3-0011"> <h4 class="title">Unit of analysis issues</h4> <section id="CD006625-sec4-0014"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data pose problems. Authors often fail to account for intraclass correlation in clustered studies, leading toward a 'unit of analysis' error (<a href="./references#CD006625-bbs2-0250" title="DivineGW , BrownJT , FrazerLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7:623‐9. ">Divine 1992</a>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD006625-bbs2-0244" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD006625-bbs2-0261" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If we had found studies in which clustering was not accounted for in primary studies, we would have presented data in a table, with an (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies to obtain intraclass correlation coefficients for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD006625-bbs2-0261" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). If we had found studies for which clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non cluster randomised study but would have adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect = 1 + (m 1) * ICC] (<a href="./references#CD006625-bbs2-0251" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported, it was assumed to be 0.1 (<a href="./references#CD006625-bbs2-0288" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999;3(5):3‐92. ">Ukoumunne 1999</a>). </p> <p>If cluster studies had been appropriately analysed by taking ICCs into account, and if relevant data had been documented in the report, synthesis with other studies using the generic inverse variance technique would have been possible. </p> </section> <section id="CD006625-sec4-0015"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern associated with cross‐over trials is the carry‐over effect. This occurs if an effect (e.g. pharmacological, physiological, psychological) of treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase, participants can differ systematically from their initial state despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD006625-bbs2-0256" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). Both effects are very likely in severe mental illness; therefore we used data only from the first phase of cross‐over studies. </p> </section> <section id="CD006625-sec4-0016"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>When a study involves more than two treatment arms, we presented the additional treatment arms in comparisons if they were relevant. If data were binary, we simply added these and combined them within the two‐by‐two table. If data were continuous, we combined them in accordance with the formula in Section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006625-bbs2-0266" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.. ">Higgins 2011</a>). When the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD006625-sec3-0012"> <h4 class="title">Dealing with missing data</h4> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD006625-bbs2-0289" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH . The Leeds Outcomes Stakeholders Survey (LOSS) study. Proceedings of the 15th Cochrane Colloquium, Sao Paulo, October 23‐27, 2007. ">Xia 2007</a>). Although high rates of premature discontinuation are a major problem in this field, we believe that it is unclear which degree of attrition leads to a high degree of bias. Therefore, we did not exclude trials on the basis of the percentage of participants completing them. However, we addressed the attrition problem in all parts of the review, including the abstract. For this purpose, we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early among all studies and comparators pooled). </p> </section> <section id="CD006625-sec3-0013"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD006625-sec4-0017"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially to judge clinical heterogeneity without seeing comparison data. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise. When such situations or participant groups arose, we fully discussed these. </p> </section> <section id="CD006625-sec4-0018"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially to judge methodological heterogeneity without seeing comparison data. We simply inspected all studies for clearly outlying methods that we had not predicted would arise. When such methodological outliers arose, we fully discussed these. </p> </section> <section id="CD006625-sec4-0019"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD006625-sec5-0018"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD006625-sec5-0019"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD006625-bbs2-0264" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on magnitude and direction of effects and strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic was interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD006625-bbs2-0266" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<a href="#CD006625-sec3-0016">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD006625-sec3-0014"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD006625-bbs2-0254" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006625-bbs2-0266" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases, but they have limited power to detect small‐study effects. We did not use funnel plots for outcomes when 10 or fewer studies were included, or when all studies were of similar size. In other cases, for which funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD006625-sec3-0015"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument regarding preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us, and the random‐effects model takes into account differences between studies even if no statistically significant heterogeneity is noted. However, use of the random‐effects model creates a disadvantage: It puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can inflate or deflate the effect size. We chose the random‐effects model for all analyses. However, the reader is able to choose to inspect the data using the fixed‐effect model, if preferred. </p> </section> <section id="CD006625-sec3-0016"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If data were clearly heterogeneous, we checked that data were correctly extracted and entered and that we had made no unit of analysis errors. If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data. </p> </section> <section id="CD006625-sec3-0017"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses to examine the change in robustness of sensitivity to include studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotic drugs may have been biased by the use of inappropriate comparator doses (<a href="./references#CD006625-bbs2-0263" title="HeresS , DavisJ , MainoK , JetzingerE , KisslingW , LeuchtS . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry2006;163:185‐94. ">Heres 2006</a>). Therefore, we also analysed whether exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006625-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006625-sec1-0005"></div> <section id="CD006625-sec2-0008"> <h3 class="title">Description of studies</h3> <p>For substantive descriptions of studies, please see <a href="./references#CD006625-sec2-0025" title="">Characteristics of included studies</a> and <a href="./references#CD006625-sec2-0026" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD006625-sec3-0018"> <h4 class="title">Results of the search</h4> <p>Results of the search are presented in <a href="#CD006625-fig-0002">Figure 2</a> (study flow diagram). We found 537 references, of which 134 were closely inspected during the May 2010 search. The original April 2007 search strategy yielded 3620 references, of which 104 were closely inspected. </p> <div class="figure" id="CD006625-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006625-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006625-sec3-0019"> <h4 class="title">Included studies</h4> <p>We were able to include 35 studies in total; this includes 14 added in the 2010‐2011 update. Seven studies were sponsored by pharmaceutical companies producing quetiapine, six were sponsored by the manufacturer of the comparator antipsychotic and ten had a neutral sponsor. For the remaining twelve studies, the sponsor was unclear. </p> <section id="CD006625-sec4-0020"> <h5 class="title">1. Length of trials</h5> <p>Twenty‐six studies were short term with a duration of 2 to 12 weeks. Six studies were medium term, and two trials fell into the long‐term category. </p> </section> <section id="CD006625-sec4-0021"> <h5 class="title">2. Setting</h5> <p>Seven trials were conducted in an inpatient or outpatient setting, sixteen studies were conducted exclusively in an inpatient setting and two studies were conducted exclusively in an outpatient setting. Ten studies did not report the setting. </p> </section> <section id="CD006625-sec4-0022"> <h5 class="title">3. Participants</h5> <p>Twenty‐three studies included participants with diagnoses derived from the <i>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV)</i>. <a href="./references#CD006625-bbs2-0024" title="RiedelM , MullerN , StrassnigM , SpellmannI , EngelRR , MusilR , et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2005;255(6):432‐7. RiedelM , SpellmannI , MullerN , StrassnigM , Muller‐ArendsA , DehningS , MollerHJ . Cognitive benefits of quetiapine versus risperidone in schizophrenia. Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21‐26, 2005. RiedelM , SpellmannI , StrassnigM , DouhetA , DehningS , Opgen‐RheinM , et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2007;257:360‐70. ">Riedel 2005</a> and <a href="./references#CD006625-bbs2-0008" title="HattaK , SatoK , HamakawaH , TakebayashiH , KimuraN , OchiS , et al. Effectiveness of second‐generation antipsychotics with acute‐phase schizophrenia. Schizophrenia Research2009;113:49‐55. ">Hatta 2009</a> additionally used the <i>International Classification of Diseases, Tenth Revision (ICD‐10).</i> Ten studies diagnosed participants according to the <i>Chinese Classification of Mental Disorders Version 3 (CCMD‐3).</i><a href="./references#CD006625-bbs2-0104" title="LiX , LaoG , CaoL . Comparison of efficacy and safety of seroquel and resperidone in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science2003;12(1):45‐6. ">Li 2003b</a> used <i>CCMD‐2.</i> Five studies included only acutely ill people (<a href="./references#CD006625-bbs2-0004" title="CanusoC , CarothersJ , DirksB , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3‐6, 2008. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia. Schizophrenia Research2008;98:158‐9. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3‐7, 2007. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress, Orlando, FL, October 11‐14, 2007. CanusoCM , DirksB , CarothersScD , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Randomized, double‐blind, placebo‐controlled study of paliperidone extended‐release and quetiapine in inpatients with recently exacerbated schizophrenia. American Journal of Psychiatry2009;AiA:1‐11. ">Canuso 2008</a>; <a href="./references#CD006625-bbs2-0025" title="RiedelM , MüllerN , SpellmannI , EngelRR , MusilR , ValdevitR , et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia. European Archieves of Psychiatry and Clinical Neuroscience2007;257(7):402‐12. ">Riedel 2007</a>; <a href="./references#CD006625-bbs2-0030" title="SvestkaJ , SynekO , ZourkovaA . A double‐blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders. Journal of the European College of Neuropsychopharmacology2003;13(4):S291. ">Svestka 2003b</a>; <a href="./references#CD006625-bbs2-0032" title="WangDF , WangXR . A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health2006;35(18):1697‐8. ">Wang 2006</a>; <a href="./references#CD006625-bbs2-0034" title="WeiSZ , TangQS , XuZN , RangXJ , LuB . Dummy parallel controlled study in the female first‐episode schizophrenia treated with aripiprazole and quetiapine. Chinese Journal of Nervous and Mental Disorders2006;32(6):511‐7. ">Wei 2006b</a>), and four included only people with a first episode of schizophrenia (<a href="./references#CD006625-bbs2-0009" title="HuGH , WuYJ , LiQX . A comparative study between quetiapine and risperidone in the treatment of first‐episode schizophrenia. Chinese Medical Journal of Metallurgical Industry2008;25(1):16‐7. ">Hu 2008</a>; <a href="./references#CD006625-bbs2-0017" title="LuoX , AnBF . Comperison of quetiapine and aripiprazole in the treatment of first episode schizophrenia. Journal of Clinical Psychological Medicine2008;18(3):191‐2. ">Luo Xin 2008</a>; <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a>; <a href="./references#CD006625-bbs2-0033" title="WeiQW , FangYR , ShenXL , TianT , LiaoJG , FangXG . A comparative study of social function in first‐episode schizophrenic patients treated with quetiapine and risperidone. Shandong Archives of Psychiatry2006;19(1):34‐6. ">Wei 2006a</a>). Two studies included people with chronic schizophrenia or people with more than one schizophrenic episode (<a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>, <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a>). Only one study focused on treatment‐resistant participants (<a href="./references#CD006625-bbs2-0005" title="ConleyRR , KellyDL , NelsonMW , RichardsonCM , FeldmanS , BenhamR , et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy‐refractory schizophrenia. Clinical Neuropharmacology2005;28(4):163‐8. KellyDL , ConleyRR . A randomized double‐blind 12‐week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology2006;31(3):340‐6. KellyDL , ConleyRR . Thyroid function in treatment‐resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry2005;66:80‐4. RichardsonCM , KellyDL , GoldJM , McMahonR , YuY , ConleyRR . Risperidone vs quetiapine vs fluphenazine in treatment‐resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin2005;31:501‐2. ">Conley 2005</a>). </p> </section> <section id="CD006625-sec4-0023"> <h5 class="title">4. Study size</h5> <p><a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a> was the largest study, with 1453 participants; <a href="./references#CD006625-bbs2-0021" title="OzguvenHd , OnerO , BaskakB , OnerP , AtbasogluEC . The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single‐blind trial in patients with schizophrenia. Schizophrenia Research2004;67(1):190‐1. ">Ozguven 2004</a> was the smallest, randomly assigning only 22 people. Six studies had fewer than 50 participants, and three randomly assigned more than 400 people. </p> </section> <section id="CD006625-sec4-0024"> <h5 class="title">5. Interventions</h5> <section id="CD006625-sec5-0020"> <h6 class="title">5.1 Quetiapine: All included studies used flexible dosing</h6> <p>Overall, quetiapine was given in a dose range from 50 mg/d to 800 mg/d. <a href="./references#CD006625-bbs2-0005" title="ConleyRR , KellyDL , NelsonMW , RichardsonCM , FeldmanS , BenhamR , et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy‐refractory schizophrenia. Clinical Neuropharmacology2005;28(4):163‐8. KellyDL , ConleyRR . A randomized double‐blind 12‐week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology2006;31(3):340‐6. KellyDL , ConleyRR . Thyroid function in treatment‐resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry2005;66:80‐4. RichardsonCM , KellyDL , GoldJM , McMahonR , YuY , ConleyRR . Risperidone vs quetiapine vs fluphenazine in treatment‐resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin2005;31:501‐2. ">Conley 2005</a> limited the upper dose range to 500 mg/d, <a href="./references#CD006625-bbs2-0034" title="WeiSZ , TangQS , XuZN , RangXJ , LuB . Dummy parallel controlled study in the female first‐episode schizophrenia treated with aripiprazole and quetiapine. Chinese Journal of Nervous and Mental Disorders2006;32(6):511‐7. ">Wei 2006b</a> used a dose range of 100 mg/d to 400 mg/d and <a href="./references#CD006625-bbs2-0021" title="OzguvenHd , OnerO , BaskakB , OnerP , AtbasogluEC . The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single‐blind trial in patients with schizophrenia. Schizophrenia Research2004;67(1):190‐1. ">Ozguven 2004</a> had a mean dose that was higher than the upper dose range of 800 mg/d (827 mg/d). </p> </section> <section id="CD006625-sec5-0021"> <h6 class="title">5.2 Comparators</h6> <p>The comparator drugs were aripiprazole, clozapine, olanzapine, paliperidone, risperidone and ziprasidone, again given in flexible doses. Some studies also included treatment arms with fluphenazine, perphenazine and perospirone, but because these are not second‐generation antipsychotic drugs, we did not report these results. </p> </section> </section> <section id="CD006625-sec4-0025"> <h5 class="title">6. Outcomes</h5> <section id="CD006625-sec5-0022"> <h6 class="title">6.1 Leaving the study early</h6> <p>The number of participants leaving the studies early was reported for the categories ‘any reason’, ‘adverse events’ and ‘lack of efficacy’. </p> </section> <section id="CD006625-sec5-0023"> <h6 class="title">6.2 No clinically significant response</h6> <p>We pre‐specified at least 50% PANSS/BPRS reduction from baseline as a clinical relevant cut‐off to define, but only <a href="./references#CD006625-bbs2-0030" title="SvestkaJ , SynekO , ZourkovaA . A double‐blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders. Journal of the European College of Neuropsychopharmacology2003;13(4):S291. ">Svestka 2003b</a> reported this outcome. Instead, <a href="./references#CD006625-bbs2-0015" title="LiuY , XuM , ChenX . A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry2004;17(1):6‐8. ">Liu 2004</a> indicated at least 50% SANS reduction from baseline, <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a> and <a href="./references#CD006625-bbs2-0224" title="ZhongZ‐Y , TaoJ , WangX‐L , WuX‐L , ZhangJ‐B . Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia. Zhongguo Linchuang Kangfu2006;10(2):30‐2. ">Zhong 2006a</a> at least 30 % PANSS total score reduction from baseline, <a href="./references#CD006625-bbs2-0021" title="OzguvenHd , OnerO , BaskakB , OnerP , AtbasogluEC . The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single‐blind trial in patients with schizophrenia. Schizophrenia Research2004;67(1):190‐1. ">Ozguven 2004</a> at least 20% SANS total score reduction from baseline, <a href="./references#CD006625-bbs2-0005" title="ConleyRR , KellyDL , NelsonMW , RichardsonCM , FeldmanS , BenhamR , et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy‐refractory schizophrenia. Clinical Neuropharmacology2005;28(4):163‐8. KellyDL , ConleyRR . A randomized double‐blind 12‐week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology2006;31(3):340‐6. KellyDL , ConleyRR . Thyroid function in treatment‐resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry2005;66:80‐4. RichardsonCM , KellyDL , GoldJM , McMahonR , YuY , ConleyRR . Risperidone vs quetiapine vs fluphenazine in treatment‐resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin2005;31:501‐2. ">Conley 2005</a> a CGI (<a href="./references#CD006625-bbs2-0262" title="GuyU . ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, 1976. ">Guy 1976</a>) of mild or better combined with at least 20% BPRS total reduction from baseline and <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a> all PANSS items mild or better plus a CGI of mild or better. </p> </section> <section id="CD006625-sec5-0024"> <h6 class="title">6.3 Outcome scales</h6> <p>Details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are given under 'Outcomes' in the '<a href="#CD006625-sec3-0019">Included studies</a>' section. </p> <section id="CD006625-sec6-0001"> <p><b>6.3.1 Global state scales</b></p> <p>6.3.1.1 Clinical Global Impression Scale ‐ CGI (<a href="./references#CD006625-bbs2-0262" title="GuyU . ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This is used to assess both severity of illness and clinical improvement by comparing the conditions of the standardised person against other people with the same diagnosis. A seven‐point scoring system is usually used, and low scores show decreased severity and/or overall improvement. </p> </section> <section id="CD006625-sec6-0002"> <p><b>6.3.2 Mental state scales</b></p> <p>6.3.2.1 Positive and Negative Syndrome Scale ‐ PANSS (<a href="./references#CD006625-bbs2-0271" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>)<br/> This schizophrenia scale consists of 30 items, each of which can be defined on a seven‐point scoring system ranging from 1 (absent) to 7 (extreme). It can be divided into three subscales that can be used to measure the severity of general psychopathology, positive symptoms (PANSS‐P) and negative symptoms (PANSS‐N). A low score indicates lesser severity. </p> <p>6.3.2.2 Brief Psychiatric Rating Scale ‐ BPRS (<a href="./references#CD006625-bbs2-0281" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>)<br/> This scale is used to assess the severity of the abnormal mental state. The original scale consists of 16 items, but a revised 18‐item scale is commonly used. Each item is defined on a seven‐point scale ranging from 'not present' to 'extremely severe', and scoring ranges from 0 to 6 or from 1 to 7. Scores can range from 0 to 126, and high scores indicate more severe symptoms. </p> <p>6.3.2.3 Scale for the Assessment of Negative Symptoms ‐ SANS (<a href="./references#CD006625-bbs2-0239" title="AndreasenNC . Scale for the assessment of negative symptoms (SANS). British Journal of Psychiatry1989;7:53‐8. ">Andreasen 1989</a>)<br/> This six‐point scale gives a global rating of the following negative symptoms: alogia, affective blunting, avolition‐apathy, anhedonia‐associality and attention impairment. Higher scores indicate more severe symptoms. </p> <p>6.3.2.4 Scale for the Assessment of Positive Symptoms ‐ SAPS (<a href="./references#CD006625-bbs2-0238" title="AndreasenNC . Scale for the assessment of positive symptoms (SAPS). The University of Iowa1984. ">Andreasen 1984</a>)<br/> This four‐point scale gives a global rating for the following positive symptoms: hallucination, delusion, bizarre attitudes and positive formal thought disorder. </p> </section> <section id="CD006625-sec6-0003"> <p><b><i>6.3.3 Global Assessment of Functioning</i> ‐ <i>GAF (DSM IV, 1994)</i> </b></p> <p>A rating scale for patients´ overall capacity of psychosocial functioning, with scores ranging from 1 to 100. Higher scores indicate a higher level of functioning. </p> </section> <section id="CD006625-sec6-0004"> <p><b>6.3.4. Quality of Life Scales</b></p> <p>6.3.4.1 Quality of Life Scale ‐ QLS (<a href="./references#CD006625-bbs2-0246" title="HeinrichsDW , HanlonET , CarpenterWTJr . The quality of life scale: an instrument for rating the schizophrenic deficit syndrom. Schizophrenia Bulletin1984;10:388‐96. ">Carpenter 1984</a>)<br/> This semi‐structured interview is administered and rated by trained clinicians. It contains 21 items, rated on a seven‐point scale on the basis of interviewers' judgement of patient functioning. A total QLS and four subscale scores are calculated, with higher scores indicating less impairment. </p> </section> <section id="CD006625-sec6-0005"> <p><b>6.3.5 Adverse effects scales</b></p> <p>6.3.5.1 Abnormal Involuntary Movement Scale ‐ AIMS (<a href="./references#CD006625-bbs2-0262" title="GuyU . ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This scale has been used to assess tardive dyskinesia, a long‐term, drug‐induced movement disorder, and short‐term movement disorders such as tremor. </p> <p>6.3.5.2 Barnes Akathisia Scale ‐ BAS (<a href="./references#CD006625-bbs2-0243" title="BarnesTR . A rating scale for drug induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>)<br/> This scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness and any distress associated with the condition. These items are rated from 0 (normal) to 3 (severe). In addition, an item for rating global severity is included (ranging from 0 (absent) to 5 (severe)). A low score indicates low levels of akathisia. </p> <p>6.3.5.3 Extrapyramidal Symptom Rating Scale ‐ ESRS (<a href="./references#CD006625-bbs2-0248" title="ChouinardG , Ross‐ChouinardA , AnnableL , JonesBD . The extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences1980;7:233. ">Chouinard 1980</a>)<br/> This is a questionnaire that pertains to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items) and a CGI of tardive dyskinesia. High scores indicate severe levels of movement disorder. </p> <p>6.3.5.4 Simpson Angus Scale ‐ SAS (<a href="./references#CD006625-bbs2-0285" title="SimpsonEN , AngusJWF . A rating scale for extrapyramidal side‐effects. Acta Psychiatrica Scandinavica Supplementum1970;212:11‐9. ">Simpson 1970</a>)<br/> This ten‐item scale, which includes a scoring system of 0 to 4 for each item, measures drug‐induced parkinsonism, a short‐term drug‐induced movement disorder. A low score indicates low levels of parkinsonism. </p> </section> </section> <section id="CD006625-sec5-0025"> <h6 class="title">6.4 Other adverse effects</h6> <p>Other adverse effects were reported as continuous variables for QTc prolongation (ms), cholesterol level (mg/dL), glucose level (mg/dL), prolactin level (ng/mL) and weight (kg). Still other adverse events were reported in a dichotomous manner in terms of the number of people with a given effect. </p> </section> <section id="CD006625-sec5-0026"> <h6 class="title">6.5 Service use</h6> <p>Service use was described as the number of participants re‐hospitalised during the trial. </p> </section> </section> </section> <section id="CD006625-sec3-0020"> <h4 class="title">Excluded studies</h4> <p>We excluded 196 studies for the following reasons: 51 (26%) were not randomised, 113 (58%) were open label, 22 (11%) employed inappropriate interventions, 9 (5%) reported no usable data, 1 included participants with mood disorders and 1 was a pooled analysis rather than a trial. </p> <section id="CD006625-sec4-0026"> <h5 class="title">Awaiting assessment</h5> <p>One trial (<a href="./references#CD006625-bbs2-0231" title="GafoorR , LandauS , CraigTKH , ElanjitharaT , PowerP , McGuireP . Efficacy and adverse effects of quetiapine versus risperidone in first‐episode schizophrenia. Journal of Clinical Psychopharmacology2010;30:600‐6. GafoorR , PowerP , CraigT , KerwinR , McGuireP . A comparative study of quetiapine and risperidone in patients with first‐episode psychosis. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S509. ">Gafoor 2005</a>) is awaiting assessment until further information can be obtained. </p> </section> <section id="CD006625-sec4-0027"> <h5 class="title">Ongoing studies</h5> <p>Four randomised trials comparing quetiapine with other antipsychotic drugs seem to be ongoing (<a href="./references#CD006625-bbs2-0232" title="EliLilly , Company . Comparison of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder. Eli Lilly and Company Clinical Trial Registry2004. [8894] ">Eli Lilly 2004b</a>; <a href="./references#CD006625-bbs2-0233" title="LiHF . A 6‐Week, Multicenter, Rater‐Blind, Randomized,Risperidone‐Controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia. WHO registration2009; Vol. 1. ">Li 2009b</a>; <a href="./references#CD006625-bbs2-0234" title="RatnaL . A multi‐centre, double‐blind, randomised study to compare the safety tolerability and efficacy of quetiapine and risperidone in the treatment of schizophrenia in subjects with inadequate symptom control improved Response In Schizophrenia ‐ IRIS. National Research Register2003; Vol. 1. ">Ratna 2003</a>; <a href="./references#CD006625-bbs2-0235" title="ReynoldsC . A six month, rater blind comparison of quetiapine and risperidone in the treatment of tardive dyskinesia in patients with schizophrenia. National Research Register2001; Vol. 3. ">Reynolds 2001</a>). For further details, see '<a href="./references#CD006625-sec2-0028" title="">Characteristics of ongoing studies</a>'. </p> </section> </section> </section> <section id="CD006625-sec2-0009"> <h3 class="title">Risk of bias in included studies</h3> <p>For details, please refer to the risk of bias tables (<a href="#CD006625-fig-0003">Figure 3</a>, <a href="#CD006625-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD006625-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006625-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD006625-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD006625-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD006625-sec3-0021"> <h4 class="title">Allocation</h4> <p>All of the included studies were described as randomised; however, only five studies from the total of 37 described the method of randomisation (<a href="./references#CD006625-bbs2-0004" title="CanusoC , CarothersJ , DirksB , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3‐6, 2008. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia. Schizophrenia Research2008;98:158‐9. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3‐7, 2007. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress, Orlando, FL, October 11‐14, 2007. CanusoCM , DirksB , CarothersScD , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Randomized, double‐blind, placebo‐controlled study of paliperidone extended‐release and quetiapine in inpatients with recently exacerbated schizophrenia. American Journal of Psychiatry2009;AiA:1‐11. ">Canuso 2008</a>; <a href="./references#CD006625-bbs2-0007" title="EerdekensM , KramerM , CletonA , VanderboschA , NatarajanJ , EarnestJ , et al. Proceedings of the 20th European College of Neuropsychopharmacology, Vienna, Austria, October 13‐17, 2007. HoughDW , NatarajanJ , VandeboschA , RossenuS , KramerM , EerdekensM . Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;0(0):1‐10. . ">Eerdekens 2007</a>; <a href="./references#CD006625-bbs2-0010" title="KinonBJ , Liu‐SiefertH , HillAL , RoychowdhuryS , EdwardsSB . Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20‐24, 2003. KinonBJ , NoordsyDL , Liu‐SeifertH , GulliverAH , Ascher‐SvanumH , Kollack‐WalkerS . Randomized, double‐blind 6‐month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology2006;26(5):453‐61. ">Kinon 2006b</a>; <a href="./references#CD006625-bbs2-0016" title="LuX , ChengH , SongS , SunL , ZhangY , FanY . A study of quetiapine and risperidone and clozapine in the treatment of schizophrenia. China and Foreign Medical Journal2006;4(6):62‐4. ">Lu 2006</a>; <a href="./references#CD006625-bbs2-0032" title="WangDF , WangXR . A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health2006;35(18):1697‐8. ">Wang 2006</a>). Only four were explicit about the method of allocation concealment used (<a href="./references#CD006625-bbs2-0004" title="CanusoC , CarothersJ , DirksB , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3‐6, 2008. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia. Schizophrenia Research2008;98:158‐9. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3‐7, 2007. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress, Orlando, FL, October 11‐14, 2007. CanusoCM , DirksB , CarothersScD , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Randomized, double‐blind, placebo‐controlled study of paliperidone extended‐release and quetiapine in inpatients with recently exacerbated schizophrenia. American Journal of Psychiatry2009;AiA:1‐11. ">Canuso 2008</a>; <a href="./references#CD006625-bbs2-0007" title="EerdekensM , KramerM , CletonA , VanderboschA , NatarajanJ , EarnestJ , et al. Proceedings of the 20th European College of Neuropsychopharmacology, Vienna, Austria, October 13‐17, 2007. HoughDW , NatarajanJ , VandeboschA , RossenuS , KramerM , EerdekensM . Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;0(0):1‐10. . ">Eerdekens 2007</a>; <a href="./references#CD006625-bbs2-0008" title="HattaK , SatoK , HamakawaH , TakebayashiH , KimuraN , OchiS , et al. Effectiveness of second‐generation antipsychotics with acute‐phase schizophrenia. Schizophrenia Research2009;113:49‐55. ">Hatta 2009</a>; <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a>). For all other studies, it was unclear whether the allocation strategies were appropriate. </p> </section> <section id="CD006625-sec3-0022"> <h4 class="title">Blinding</h4> <p>Thirteen of the included studies were 'single‐blind' (blind raters); all other included studies were 'double‐blind'. Nine studies used identical capsules for blinding (<a href="./references#CD006625-bbs2-0004" title="CanusoC , CarothersJ , DirksB , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3‐6, 2008. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia. Schizophrenia Research2008;98:158‐9. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3‐7, 2007. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress, Orlando, FL, October 11‐14, 2007. CanusoCM , DirksB , CarothersScD , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Randomized, double‐blind, placebo‐controlled study of paliperidone extended‐release and quetiapine in inpatients with recently exacerbated schizophrenia. American Journal of Psychiatry2009;AiA:1‐11. ">Canuso 2008</a>; <a href="./references#CD006625-bbs2-0007" title="EerdekensM , KramerM , CletonA , VanderboschA , NatarajanJ , EarnestJ , et al. Proceedings of the 20th European College of Neuropsychopharmacology, Vienna, Austria, October 13‐17, 2007. HoughDW , NatarajanJ , VandeboschA , RossenuS , KramerM , EerdekensM . Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;0(0):1‐10. . ">Eerdekens 2007</a>; <a href="./references#CD006625-bbs2-0010" title="KinonBJ , Liu‐SiefertH , HillAL , RoychowdhuryS , EdwardsSB . Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20‐24, 2003. KinonBJ , NoordsyDL , Liu‐SeifertH , GulliverAH , Ascher‐SvanumH , Kollack‐WalkerS . Randomized, double‐blind 6‐month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology2006;26(5):453‐61. ">Kinon 2006b</a>; <a href="./references#CD006625-bbs2-0011" title="LiY , WangCH , ZhangDH , WangLH , ZhaoZ . A study of quetiapine and clozapine in treatment of first‐episode schizophrenia. Chinese Journal of Nervous and Mental Diseases2002;28:219‐20. ">Li 2002</a>; <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>; <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a>; <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a>; <a href="./references#CD006625-bbs2-0024" title="RiedelM , MullerN , StrassnigM , SpellmannI , EngelRR , MusilR , et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2005;255(6):432‐7. RiedelM , SpellmannI , MullerN , StrassnigM , Muller‐ArendsA , DehningS , MollerHJ . Cognitive benefits of quetiapine versus risperidone in schizophrenia. Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21‐26, 2005. RiedelM , SpellmannI , StrassnigM , DouhetA , DehningS , Opgen‐RheinM , et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2007;257:360‐70. ">Riedel 2005</a>; <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a>). The other trials did not provide any information on the blinding procedure. No study examined whether blinding was effective. We found that the adverse effect profiles of some of the compounds are quite different, and we believe that this may have made blinding difficult. We therefore conclude that the risk of bias for objective outcomes (e.g. death, laboratory values) was less than that for subjective outcomes, and for the latter, risk was considerable as a result of poor blinding. </p> </section> <section id="CD006625-sec3-0023"> <h4 class="title">Incomplete outcome data</h4> <p>Nineteen studies displayed attrition bias. Other than poorly described reasons for premature study discontinuation, a major problem was the very high attrition, which in thirteen studies was higher than 30% (50.2% overall, <a href="./references#CD006625-bbs2-0001" title="Astrazeneca1998 . A multicentre, double‐blind randomised comparison of seroquel (TM) and risperidone in the treatment of schizophrenic patients with acute exacerbation. Astrazeneca trial data. ">Astrazeneca 1998</a>; <a href="./references#CD006625-bbs2-0004" title="CanusoC , CarothersJ , DirksB , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3‐6, 2008. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia. Schizophrenia Research2008;98:158‐9. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3‐7, 2007. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress, Orlando, FL, October 11‐14, 2007. CanusoCM , DirksB , CarothersScD , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Randomized, double‐blind, placebo‐controlled study of paliperidone extended‐release and quetiapine in inpatients with recently exacerbated schizophrenia. American Journal of Psychiatry2009;AiA:1‐11. ">Canuso 2008</a>; <a href="./references#CD006625-bbs2-0005" title="ConleyRR , KellyDL , NelsonMW , RichardsonCM , FeldmanS , BenhamR , et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy‐refractory schizophrenia. Clinical Neuropharmacology2005;28(4):163‐8. KellyDL , ConleyRR . A randomized double‐blind 12‐week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology2006;31(3):340‐6. KellyDL , ConleyRR . Thyroid function in treatment‐resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry2005;66:80‐4. RichardsonCM , KellyDL , GoldJM , McMahonR , YuY , ConleyRR . Risperidone vs quetiapine vs fluphenazine in treatment‐resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin2005;31:501‐2. ">Conley 2005</a>; <a href="./references#CD006625-bbs2-0006" title="DeberdtW , LipkovichI , HeinlothAN , LiuL , Kollack‐WalkerS , EdwardsSE , et al. Double‐blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Therapeutics and Clinical Risk Management2008;4(4):713–20. ">Deberdt 2008</a>; <a href="./references#CD006625-bbs2-0008" title="HattaK , SatoK , HamakawaH , TakebayashiH , KimuraN , OchiS , et al. Effectiveness of second‐generation antipsychotics with acute‐phase schizophrenia. Schizophrenia Research2009;113:49‐55. ">Hatta 2009</a>; <a href="./references#CD006625-bbs2-0010" title="KinonBJ , Liu‐SiefertH , HillAL , RoychowdhuryS , EdwardsSB . Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20‐24, 2003. KinonBJ , NoordsyDL , Liu‐SeifertH , GulliverAH , Ascher‐SvanumH , Kollack‐WalkerS . Randomized, double‐blind 6‐month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology2006;26(5):453‐61. ">Kinon 2006b</a>; <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>; <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a>; <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a>; <a href="./references#CD006625-bbs2-0024" title="RiedelM , MullerN , StrassnigM , SpellmannI , EngelRR , MusilR , et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2005;255(6):432‐7. RiedelM , SpellmannI , MullerN , StrassnigM , Muller‐ArendsA , DehningS , MollerHJ . Cognitive benefits of quetiapine versus risperidone in schizophrenia. Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21‐26, 2005. RiedelM , SpellmannI , StrassnigM , DouhetA , DehningS , Opgen‐RheinM , et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2007;257:360‐70. ">Riedel 2005</a>; <a href="./references#CD006625-bbs2-0025" title="RiedelM , MüllerN , SpellmannI , EngelRR , MusilR , ValdevitR , et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia. European Archieves of Psychiatry and Clinical Neuroscience2007;257(7):402‐12. ">Riedel 2007</a>; <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a>; <a href="./references#CD006625-bbs2-0035" title="HarveyPD , PattersonTL , PotterLS , ZhongK , BrecherM . Improvement in social competence with short‐term atypical antipsychotic treatment: a randomized, double‐blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. American Journal of Psychiatry2006;163(11):1918‐25. ZhongKX , SweitzerDE , HamerRM , LiebermanJA . Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double‐blind, flexible‐dose, 8‐week study. Journal of Clinical Psychiatry2006;67(7):1093‐103. ">Zhong 2006</a>). In most studies, the last‐observation‐carried‐forward method was used to account for attrition. This is an imperfect method, which assumes that a participant's outcome would not have changed if he/she had remained in the study; this is often wrong. However, it is questionable whether other methods (e.g. imputation strategies, mixed‐effects models) could have coped better with such dramatically high rates of attrition. The high loss to follow‐up is a clear threat to the validity of findings. </p> </section> <section id="CD006625-sec3-0024"> <h4 class="title">Selective reporting</h4> <p>Only five studies were judged to be free of selective reporting (<a href="./references#CD006625-bbs2-0002" title="AtmacaM , KulogluM , TezcanE , UstundagB . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry2003;64(5):598‐604. ">Atmaca 2003</a>; <a href="./references#CD006625-bbs2-0003" title="ByerlyMJ , NakoneznyPA , RushAJ . Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double‐blind pilot trial. Psychiatry Research2008;159:115‐20. ">Byerly 2008</a>; <a href="./references#CD006625-bbs2-0011" title="LiY , WangCH , ZhangDH , WangLH , ZhaoZ . A study of quetiapine and clozapine in treatment of first‐episode schizophrenia. Chinese Journal of Nervous and Mental Diseases2002;28:219‐20. ">Li 2002</a>; <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>; <a href="./references#CD006625-bbs2-0008" title="HattaK , SatoK , HamakawaH , TakebayashiH , KimuraN , OchiS , et al. Effectiveness of second‐generation antipsychotics with acute‐phase schizophrenia. Schizophrenia Research2009;113:49‐55. ">Hatta 2009</a>). For most of the other trials, risk of bias was high, mainly because of incomplete reporting of pre‐defined outcomes (<a href="./references#CD006625-bbs2-0005" title="ConleyRR , KellyDL , NelsonMW , RichardsonCM , FeldmanS , BenhamR , et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy‐refractory schizophrenia. Clinical Neuropharmacology2005;28(4):163‐8. KellyDL , ConleyRR . A randomized double‐blind 12‐week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology2006;31(3):340‐6. KellyDL , ConleyRR . Thyroid function in treatment‐resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry2005;66:80‐4. RichardsonCM , KellyDL , GoldJM , McMahonR , YuY , ConleyRR . Risperidone vs quetiapine vs fluphenazine in treatment‐resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin2005;31:501‐2. ">Conley 2005</a>; <a href="./references#CD006625-bbs2-0010" title="KinonBJ , Liu‐SiefertH , HillAL , RoychowdhuryS , EdwardsSB . Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20‐24, 2003. KinonBJ , NoordsyDL , Liu‐SeifertH , GulliverAH , Ascher‐SvanumH , Kollack‐WalkerS . Randomized, double‐blind 6‐month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology2006;26(5):453‐61. ">Kinon 2006b</a>; <a href="./references#CD006625-bbs2-0012" title="LiCH . A study of quetiapine and clozapine in treatment of schizophrenia. Chinese Journal of Nervous and Mental Diseases2003;29:306‐7. ">Li 2003</a>; <a href="./references#CD006625-bbs2-0106" title="LiG , ChenQ‐G , ZhangQ‐H . A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia. Chinese Journal of Behavioral Medical Science2005;14(11):1007‐8, 1036. ">Li 2005b</a>; <a href="./references#CD006625-bbs2-0015" title="LiuY , XuM , ChenX . A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry2004;17(1):6‐8. ">Liu 2004</a>; <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a>; <a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a>; <a href="./references#CD006625-bbs2-0021" title="OzguvenHd , OnerO , BaskakB , OnerP , AtbasogluEC . The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single‐blind trial in patients with schizophrenia. Schizophrenia Research2004;67(1):190‐1. ">Ozguven 2004</a>; <a href="./references#CD006625-bbs2-0024" title="RiedelM , MullerN , StrassnigM , SpellmannI , EngelRR , MusilR , et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2005;255(6):432‐7. RiedelM , SpellmannI , MullerN , StrassnigM , Muller‐ArendsA , DehningS , MollerHJ . Cognitive benefits of quetiapine versus risperidone in schizophrenia. Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21‐26, 2005. RiedelM , SpellmannI , StrassnigM , DouhetA , DehningS , Opgen‐RheinM , et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2007;257:360‐70. ">Riedel 2005</a>; <a href="./references#CD006625-bbs2-0025" title="RiedelM , MüllerN , SpellmannI , EngelRR , MusilR , ValdevitR , et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia. European Archieves of Psychiatry and Clinical Neuroscience2007;257(7):402‐12. ">Riedel 2007</a>; <a href="./references#CD006625-bbs2-0026" title='SacchettiE , ValsecchiP , ReginiC , Galluzoa , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Schizophrenia Research2004;67(1):150. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP . Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update", Florence, Italy, November 10‐13, 2004. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Journal of the European College of Neuropsychopharmacology2003;13(4):S350. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine, and risperidone in schizophrenia. Journal of the European College of Neuropsychopharmacology2004;14(Suppl 3):S286. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , et al. Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Proceedings of the 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, September 20‐24, 2003. '>Sacchetti 2004</a>, <a href="./references#CD006625-bbs2-0027" title="SirotaP , PannetI , KorenA , TchernichovskyE . Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Human Psychopharmacology2006;21(4):227‐34. SirotaP , TchernichowskyE , PanetI , KorenA . The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia. Schizophrenia Research2004;67(1):170. ">Sirota 2006</a>; <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a>; <a href="./references#CD006625-bbs2-0030" title="SvestkaJ , SynekO , ZourkovaA . A double‐blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders. Journal of the European College of Neuropsychopharmacology2003;13(4):S291. ">Svestka 2003b</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>). In other studies, only adverse events that occurred in at least 5% or 10% of participants, or that were moderately severe, have been reported (<a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a>; <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a>; <a href="./references#CD006625-bbs2-0035" title="HarveyPD , PattersonTL , PotterLS , ZhongK , BrecherM . Improvement in social competence with short‐term atypical antipsychotic treatment: a randomized, double‐blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. American Journal of Psychiatry2006;163(11):1918‐25. ZhongKX , SweitzerDE , HamerRM , LiebermanJA . Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double‐blind, flexible‐dose, 8‐week study. Journal of Clinical Psychiatry2006;67(7):1093‐103. ">Zhong 2006</a>). The former method is problematic because rare but important adverse effects may have been missed. In <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>, all data from one site were excluded before analysis because of concerns about their integrity. </p> </section> <section id="CD006625-sec3-0025"> <h4 class="title">Other potential sources of bias</h4> <p>No study was clearly free of other potential sources of bias. In six studies, the risk of ‘other bias’ was, however, unclear. Nine studies were industry sponsored (<a href="./references#CD006625-bbs2-0010" title="KinonBJ , Liu‐SiefertH , HillAL , RoychowdhuryS , EdwardsSB . Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20‐24, 2003. KinonBJ , NoordsyDL , Liu‐SeifertH , GulliverAH , Ascher‐SvanumH , Kollack‐WalkerS . Randomized, double‐blind 6‐month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology2006;26(5):453‐61. ">Kinon 2006b</a>; <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a>; <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a>; <a href="./references#CD006625-bbs2-0024" title="RiedelM , MullerN , StrassnigM , SpellmannI , EngelRR , MusilR , et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2005;255(6):432‐7. RiedelM , SpellmannI , MullerN , StrassnigM , Muller‐ArendsA , DehningS , MollerHJ . Cognitive benefits of quetiapine versus risperidone in schizophrenia. Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21‐26, 2005. RiedelM , SpellmannI , StrassnigM , DouhetA , DehningS , Opgen‐RheinM , et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2007;257:360‐70. ">Riedel 2005</a>; <a href="./references#CD006625-bbs2-0025" title="RiedelM , MüllerN , SpellmannI , EngelRR , MusilR , ValdevitR , et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia. European Archieves of Psychiatry and Clinical Neuroscience2007;257(7):402‐12. ">Riedel 2007</a>; <a href="./references#CD006625-bbs2-0026" title='SacchettiE , ValsecchiP , ReginiC , Galluzoa , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Schizophrenia Research2004;67(1):150. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP . Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update", Florence, Italy, November 10‐13, 2004. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Journal of the European College of Neuropsychopharmacology2003;13(4):S350. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , MencacciC . Comparison of quetiapine, olanzapine, and risperidone in schizophrenia. Journal of the European College of Neuropsychopharmacology2004;14(Suppl 3):S286. SacchettiE , ValsecchiP , ReginiC , GalluzzoA , CaccianiP , AgrimiE , et al. Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater‐blinded study. Proceedings of the 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, September 20‐24, 2003. '>Sacchetti 2004</a>; <a href="./references#CD006625-bbs2-0027" title="SirotaP , PannetI , KorenA , TchernichovskyE . Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Human Psychopharmacology2006;21(4):227‐34. SirotaP , TchernichowskyE , PanetI , KorenA . The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia. Schizophrenia Research2004;67(1):170. ">Sirota 2006</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>; <a href="./references#CD006625-bbs2-0035" title="HarveyPD , PattersonTL , PotterLS , ZhongK , BrecherM . Improvement in social competence with short‐term atypical antipsychotic treatment: a randomized, double‐blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. American Journal of Psychiatry2006;163(11):1918‐25. ZhongKX , SweitzerDE , HamerRM , LiebermanJA . Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double‐blind, flexible‐dose, 8‐week study. Journal of Clinical Psychiatry2006;67(7):1093‐103. ">Zhong 2006</a>). Evidence suggests that pharmaceutical companies sometimes highlight the benefits of their compounds and tend to suppress their disadvantages (<a href="./references#CD006625-bbs2-0263" title="HeresS , DavisJ , MainoK , JetzingerE , KisslingW , LeuchtS . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry2006;163:185‐94. ">Heres 2006</a>). Other reasons for potential bias included heterogeneity of pre‐study treatment (<a href="./references#CD006625-bbs2-0002" title="AtmacaM , KulogluM , TezcanE , UstundagB . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry2003;64(5):598‐604. ">Atmaca 2003</a>; <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a>), lack of or only short wash‐out phases (<a href="./references#CD006625-bbs2-0106" title="LiG , ChenQ‐G , ZhangQ‐H . A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia. Chinese Journal of Behavioral Medical Science2005;14(11):1007‐8, 1036. ">Li 2005b</a>; <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>; <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a>; <a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>), baseline imbalance in terms of numbers of previous hospitalisations (<a href="./references#CD006625-bbs2-0005" title="ConleyRR , KellyDL , NelsonMW , RichardsonCM , FeldmanS , BenhamR , et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy‐refractory schizophrenia. Clinical Neuropharmacology2005;28(4):163‐8. KellyDL , ConleyRR . A randomized double‐blind 12‐week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology2006;31(3):340‐6. KellyDL , ConleyRR . Thyroid function in treatment‐resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry2005;66:80‐4. RichardsonCM , KellyDL , GoldJM , McMahonR , YuY , ConleyRR . Risperidone vs quetiapine vs fluphenazine in treatment‐resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin2005;31:501‐2. ">Conley 2005</a>), no information on the allowed dose range (<a href="./references#CD006625-bbs2-0002" title="AtmacaM , KulogluM , TezcanE , UstundagB . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry2003;64(5):598‐604. ">Atmaca 2003</a>; <a href="./references#CD006625-bbs2-0012" title="LiCH . A study of quetiapine and clozapine in treatment of schizophrenia. Chinese Journal of Nervous and Mental Diseases2003;29:306‐7. ">Li 2003</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>) and too‐fast titration of clozapine, which may be associated with a greater number of adverse events (<a href="./references#CD006625-bbs2-0015" title="LiuY , XuM , ChenX . A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry2004;17(1):6‐8. ">Liu 2004</a>). </p> </section> </section> <section id="CD006625-sec2-0010"> <h3 class="title" id="CD006625-sec2-0010">Effects of interventions</h3> <p>See: <a href="./full#CD006625-tbl-0001"><b>Summary of findings for the main comparison</b> QUETIAPINE versus ARIPIPRAZOLE for schizophrenia</a>; <a href="./full#CD006625-tbl-0002"><b>Summary of findings 2</b> QUETIAPINE versus CLOZAPINE ‐ all data short term for schizophrenia</a>; <a href="./full#CD006625-tbl-0003"><b>Summary of findings 3</b> QUETIAPINE versus OLANZAPINE for schizophrenia</a>; <a href="./full#CD006625-tbl-0004"><b>Summary of findings 4</b> QUETIAPINE versus PALIPERIDONE for schizophrenia</a>; <a href="./full#CD006625-tbl-0005"><b>Summary of findings 5</b> QUETIAPINE versus RISPERIDONE for schizophrenia</a>; <a href="./full#CD006625-tbl-0006"><b>Summary of findings 6</b> QUETIAPINE versus ZIPRASIDONE for schizophrenia</a> </p> <section id="CD006625-sec3-0026"> <h4 class="title">1. Comparison 1. QUETIAPINE versus ARIPIPRAZOLE</h4> <p>Four studies met the inclusion criteria for the comparison of quetiapine with aripiprazole.</p> <section id="CD006625-sec4-0028"> <h5 class="title">1.1 Leaving the study early</h5> <p>On the basis of two studies, no significant difference was noted in the numbers of participants leaving the studies early for any reason (2 RCTs, n = 149, RR 1.00, CI 0.59 to 1.70; <a href="./references#CD006625-fig-00101" title="">Analysis 1.1</a>). </p> </section> <section id="CD006625-sec4-0029"> <h5 class="title">1.2 Mental state: 1. General ‐ average endpoint score (PANSS total)</h5> <p>No significant difference was noted in the average endpoint total PANSS score between quetiapine and aripiprazole (4 RCTs, n = 297, MD 1.62, CI ‐0.89 to 4.14; <a href="./references#CD006625-fig-00102" title="">Analysis 1.2</a>). Exclusion of potentially skewed data (<a href="./references#CD006625-bbs2-0017" title="LuoX , AnBF . Comperison of quetiapine and aripiprazole in the treatment of first episode schizophrenia. Journal of Clinical Psychological Medicine2008;18(3):191‐2. ">Luo Xin 2008</a>; <a href="./references#CD006625-bbs2-0022" title="PengX , HuangY , LiuXY . A clinical analysis of aripiprazole and quetiapine in treatment of first episode schizophrenia. Journal of Clinical Psychological Medicine2007;17(5):329‐30. ">Peng 2007</a>) did not significantly change the results (2 RCTs, n = 142, MD 1.24, CI ‐1.91 to 4.39; <a href="./references#CD006625-fig-00701" title="">Analysis 7.1</a>). </p> </section> <section id="CD006625-sec4-0030"> <h5 class="title">1.3 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore)</h5> <p>No significant difference was noted in the average endpoint PANSS positive subscore (4 RCTs, n = 297, MD 0.62, CI ‐1.13 to 2.38; <a href="./references#CD006625-fig-00103" title="">Analysis 1.3</a>). However, data from all studies for this outcome were potentially skewed, and a sensitivity analysis could not be performed. </p> </section> <section id="CD006625-sec4-0031"> <h5 class="title">1.4 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore)</h5> <p>No significant difference was noted in the average endpoint PANSS negative subscore (4 RCTs, n = 297, MD 1.00, CI ‐0.25 to 2.25; <a href="./references#CD006625-fig-00104" title="">Analysis 1.4</a>). Again, data from all studies for this outcome were potentially skewed, and a sensitivity analysis could not be performed. </p> </section> <section id="CD006625-sec4-0032"> <h5 class="title">1.5 General functioning</h5> <p>No significant difference was noted in the general average endpoint score (GAF total score, 1 RCT, n = 41, MD ‐1.20, CI ‐14.43 to 12.03; <a href="./references#CD006625-fig-00105" title="">Analysis 1.5</a>). </p> </section> <section id="CD006625-sec4-0033"> <h5 class="title">1.6 Adverse effects: 1. Numbers of participants with at least one adverse effect</h5> <p>No significant difference was noted (3 RCTs, n = 215, RR 0.91, CI 0.71 to 1.17; <a href="./references#CD006625-fig-00106" title="">Analysis 1.6</a>). </p> </section> <section id="CD006625-sec4-0034"> <h5 class="title">1.7 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation</h5> <p>No significant difference in QTc prolongation was noted (1 RCT, n = 85, RR 3.21, CI 0.13 to 76.74; <a href="./references#CD006625-fig-00107" title="">Analysis 1.7</a>). </p> </section> <section id="CD006625-sec4-0035"> <h5 class="title">1.8 Adverse effects: 2b. Cardiac effects ‐ tachycardia</h5> <p>A trend towards quetiapine producing fewer tachycardia events was noted on the basis of one trial (1 RCT, n = 85, RR 7.50, CI 0.40 to 140.91; <a href="./references#CD006625-fig-00108" title="">Analysis 1.8</a>). </p> </section> <section id="CD006625-sec4-0036"> <h5 class="title">1.9 Adverse effects: 3. Extrapyramidal effects</h5> <p>No significant difference was noted in akathisia (3 RCTs, n = 196, RR 0.57, CI 0.08 to 4.02), tremor (2 RCTs, n = 155, RR 1.68, CI 0.08 to 35.92), dystonia (2 RCTs, n = 126, RR 1.42, CI 0.10 to 20.77), dyskinesia (1 RCT, n = 41, RR 3.14, CI 0.14 to 72.92), parkinsonism (1 RCT, n = 41, RR 0.75, CI 0.28 to 1.98) or use of antiparkinson medication (1 RCT, n = 40, RR 0.67, CI 0.12 to 3.57; <a href="./references#CD006625-fig-00109" title="">Analysis 1.9</a>). </p> </section> <section id="CD006625-sec4-0037"> <h5 class="title">1.10 Adverse effects: 4. Prolactin ‐ associated side effects</h5> <p>Quetiapine was associated with increased risk of galactorrhea on the basis of one trial (n = 85, RR 3.21, CI 0.13 to 76.74; <a href="./references#CD006625-fig-00110" title="">Analysis 1.10</a>). </p> </section> <section id="CD006625-sec4-0038"> <h5 class="title">1.11 Adverse effects: 5a. Metabolic ‐ weight gain of 7% or more of total body weight</h5> <p>On the basis of limited data, no significant difference was noted in the number of participants with significant weight gain (2 RCTs, n = 155, RR 0.52, CI 0.10 to 2.74; <a href="./references#CD006625-fig-00111" title="">Analysis 1.11</a>). </p> </section> <section id="CD006625-sec4-0039"> <h5 class="title">1.12 Adverse effects: 5b. Metabolic ‐ weight gain (change from baseline in kilograms</h5> <p>No difference or significant change in weight was noted from baseline (1 RCT, n = 41, MD 1.70, CI ‐0.14 to 3.54; <a href="./references#CD006625-fig-00112" title="">Analysis 1.12</a>). </p> </section> <section id="CD006625-sec4-0040"> <h5 class="title">1.13 Adverse effects: 5c. Metabolic ‐ cholesterol (change from baseline in mg/dL)</h5> <p>No significant difference was noted on the basis of one study (1 RCT, n = 41, MD 8.20, CI ‐12.24 to 28.64; <a href="./references#CD006625-fig-00113" title="">Analysis 1.13</a>).  </p> </section> <section id="CD006625-sec4-0041"> <h5 class="title">1.14 Adverse effects: 5d. Metabolic ‐ glucose (change from baseline in mg/dL)</h5> <p>One small study showed an advantage of quetiapine (1 RCT, n = 41, MD ‐9.40, CI ‐17.90 to ‐0.90; <a href="./references#CD006625-fig-00114" title="">Analysis 1.14</a>). </p> </section> <section id="CD006625-sec4-0042"> <h5 class="title">1.15 Adverse effects: 6. Death</h5> <p>One study recorded no deaths from suicide or natural causes in the quetiapine and aripiprazole groups (1 RCT, n = 37, RR not estimable; <a href="./references#CD006625-fig-00115" title="">Analysis 1.15</a>). </p> </section> <section id="CD006625-sec4-0043"> <h5 class="title">1.16 Publication bias</h5> <p>We did not perform a funnel plot analysis because so few studies were identified.</p> </section> </section> <section id="CD006625-sec3-0027"> <h4 class="title">2. Comparison 2. QUETIAPINE versus CLOZAPINE</h4> <p>Five studies met the inclusion criteria for the comparison of quetiapine with clozapine. All data were short term </p> <section id="CD006625-sec4-0044"> <h5 class="title">2.1 Leaving the study early</h5> <p>No significant difference was noted in the number of participants leaving the studies early for any reason (2 RCTs, n = 95, RR 0.67, CI 0.18 to 2.43), because of adverse events (1 RCT, n = 72, RR 0.14, CI 0.01 to 2.6) or as the result of inefficacy of treatment (1 RCT, n = 72, RR not estimable; <a href="./references#CD006625-fig-00201" title="">Analysis 2.1</a>). </p> </section> <section id="CD006625-sec4-0045"> <h5 class="title">2.2 Global state: 1a. No clinically significant response (as defined by original studies)</h5> <p>No significant difference was noted in clinical response as defined by the original studies (1 RCT, n = 72, RR 0.94, CI 0.78 to 1.13; <a href="./references#CD006625-fig-00202" title="">Analysis 2.2</a>). </p> </section> <section id="CD006625-sec4-0046"> <h5 class="title">2.3 Global state: 1b. No clinically important change ‐ short term (CGI)</h5> <p>No significant difference was noted in clinical change using the CGI (1 RCT, n = 72, RR 0.94, CI 0.74 to 1.18; <a href="./references#CD006625-fig-00203" title="">Analysis 2.3</a>). </p> </section> <section id="CD006625-sec4-0047"> <h5 class="title">2.4 Mental state: 1a. General ‐ no clinically important change (&lt; 50% PANSS total score reduction from baseline) </h5> <p>No clear difference was found (1 RCT, n = 63, RR 1.07, CI 0.53 to 2.14; <a href="./references#CD006625-fig-00204" title="">Analysis 2.4</a>). </p> </section> <section id="CD006625-sec4-0048"> <h5 class="title">2.5 Mental state: 1b. General ‐ average endpoint score (PANSS total)</h5> <p>Four short‐term studies did not indicate a significant difference (4 RCTs, n = 232, MD ‐0.5, CI ‐2.85 to 1.86; <a href="./references#CD006625-fig-00205" title="">Analysis 2.5</a>). </p> </section> <section id="CD006625-sec4-0049"> <h5 class="title">2.6 Mental state: 1c. General ‐ average endpoint score (BPRS total)</h5> <p>No significant difference was found at short term (1 RCT, n = 67, MD ‐0.89, CI ‐3.20 to 1.42; <a href="./references#CD006625-fig-00206" title="">Analysis 2.6</a>). </p> </section> <section id="CD006625-sec4-0050"> <h5 class="title">2.7 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore)</h5> <p>No significant difference was found (2 RCTs, n = 142, MD ‐0.7, CI ‐2.07 to 0.68; <a href="./references#CD006625-fig-00207" title="">Analysis 2.7</a>). </p> </section> <section id="CD006625-sec4-0051"> <h5 class="title">2.8 Mental state: 3a. Negative symptom ‐ average endpoint score (PANSS negative subscore)</h5> <p>Two small Chinese studies showed significant superiority of quetiapine (2 RCTs, n = 142, MD ‐2.23, CI ‐3.48 to ‐0.99; <a href="./references#CD006625-fig-00208" title="">Analysis 2.8</a>). </p> </section> <section id="CD006625-sec4-0052"> <h5 class="title">2.9 Mental state: 3b. Negative symptoms ‐ no clinically important change (&lt; 50% SANS total score reduction from baseline) </h5> <p>No significant difference was found (1 RCT, n = 72, RR 0.94, CI 0.78 to 1.13; <a href="./references#CD006625-fig-00209" title="">Analysis 2.9</a>). </p> </section> <section id="CD006625-sec4-0053"> <h5 class="title">2.10 Mental state: 3c. Negative symptoms ‐ average endpoint score (SANS total)</h5> <p>No significant difference was found (1 RCT, n = 67, MD ‐1.64, CI ‐8.17 to 4.89; <a href="./references#CD006625-fig-00210" title="">Analysis 2.10</a>). </p> </section> <section id="CD006625-sec4-0054"> <h5 class="title">2.11 Adverse effects: 1. General ‐ numbers of participants with at least one adverse effect </h5> <p>A significant difference noted on the basis of data from <a href="./references#CD006625-bbs2-0011" title="LiY , WangCH , ZhangDH , WangLH , ZhaoZ . A study of quetiapine and clozapine in treatment of first‐episode schizophrenia. Chinese Journal of Nervous and Mental Diseases2002;28:219‐20. ">Li 2002</a>, favoured the treatment group (1 RCT, n = 63, RR 0.42, CI 0.26 to 0.66, NNTH 2, CI 1 to 3; <a href="./references#CD006625-fig-00211" title="">Analysis 2.11</a>). </p> </section> <section id="CD006625-sec4-0055"> <h5 class="title">2.12 Adverse effects: 2. Cardiac effects ‐ ECG abnormalities</h5> <p>A significant difference favoured quetiapine (1 RCT, n = 72, RR 0.13, CI 0.02 to 0.95; <a href="./references#CD006625-fig-00212" title="">Analysis 2.12</a>). </p> </section> <section id="CD006625-sec4-0056"> <h5 class="title">2.13 Adverse effects: 3. Central nervous system ‐sedation</h5> <p>Fewer participants in the quetiapine group reported this outcome (2 RCTs, n = 135, RR 0.22, CI 0.11 to 0.47; <a href="./references#CD006625-fig-00213" title="">Analysis 2.13</a>). </p> </section> <section id="CD006625-sec4-0057"> <h5 class="title">2.14 Adverse effects: 4. Extrapyramidal effects</h5> <p>No significant difference was noted in akathisia (2 RCTs, n = 135, RR 0.4, CI 0.08 to 1.99), rigour (1 RCT, n = 63, RR 1.94, CI 0.18 to 20.3), tremor (2 RCTs, n = 135, RR 0.99, CI 0.29 to 3.34) or use of antiparkinson medication (1 RCT, n = 28, RR not estimable; <a href="./references#CD006625-fig-00214" title="">Analysis 2.14</a>). </p> </section> <section id="CD006625-sec4-0058"> <h5 class="title">2.15 Adverse effects: 5 Haematological ‐ important decline in white blood cells</h5> <p>No significant difference was noted (1 RCT, n = 33, RR 0.19, CI 0.01 to 3.88; <a href="./references#CD006625-fig-00215" title="">Analysis 2.15</a>). </p> </section> <section id="CD006625-sec4-0059"> <h5 class="title">2.16 Adverse effects: 6a Metabolic ‐ weight gain (number of participants with significant weight gain) </h5> <p>No significant difference was noted (2 RCTs, n = 135, RR 0.53, CI 0.25 to 1.11; <a href="./references#CD006625-fig-00216" title="">Analysis 2.16</a>). </p> </section> <section id="CD006625-sec4-0060"> <h5 class="title">2.17 Adverse effects: 6b. Metabolic ‐ weight gain (change from baseline in kilograms)</h5> <p>One small study reported a trend in favour of quetiapine (1 RCT, n = 27, MD ‐2.11, CI ‐4.3 to 0.08; <a href="./references#CD006625-fig-00217" title="">Analysis 2.17</a>). </p> </section> <section id="CD006625-sec4-0061"> <h5 class="title">2.18 Publication bias</h5> <p>We did not perform a funnel plot analysis because so few studies were identified.</p> </section> <section id="CD006625-sec4-0062"> <h5 class="title">2.19 Investigation for heterogeneity and sensitivity analysis</h5> <p>The exclusion of <a href="./references#CD006625-bbs2-0011" title="LiY , WangCH , ZhangDH , WangLH , ZhaoZ . A study of quetiapine and clozapine in treatment of first‐episode schizophrenia. Chinese Journal of Nervous and Mental Diseases2002;28:219‐20. ">Li 2002</a>; <a href="./references#CD006625-bbs2-0104" title="LiX , LaoG , CaoL . Comparison of efficacy and safety of seroquel and resperidone in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science2003;12(1):45‐6. ">Li 2003b</a> and <a href="./references#CD006625-bbs2-0106" title="LiG , ChenQ‐G , ZhangQ‐H . A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia. Chinese Journal of Behavioral Medical Science2005;14(11):1007‐8, 1036. ">Li 2005b</a> from analysis of the PANSS total score because of possibly skewed data did not change the results to a marked extent (<a href="./references#CD006625-fig-00801" title="">Analysis 8.1</a>). </p> </section> </section> <section id="CD006625-sec3-0028"> <h4 class="title">3. Comparison 3. QUETIAPINE versus OLANZAPINE</h4> <p>Fourteen studies met the inclusion criteria for this comparison.</p> <section id="CD006625-sec4-0063"> <h5 class="title">3.1 Leaving the study early</h5> <p>Fewer participants in the olanzapine group (54%) compared with the quetiapine group (69%) left the studies early for ‘any reason’ (12 RCTs, n = 1821, RR 1.26, CI 1.12 to 1.42) or because of ‘inefficacy’ (14% vs 25%, 9 RCTs, n = 1600, RR 1.83, CI 1.42 to 2.36) but not as the result of adverse events (12% vs 11%, 9 RCTs, n = 1610, RR 0.90, CI 0.69 to 1.18; <a href="./references#CD006625-fig-00301" title="">Analysis 3.1</a>). </p> </section> <section id="CD006625-sec4-0064"> <h5 class="title">3.2 Global state: 1a. No clinically significant response ‐ as defined by the original studies </h5> <p>No significant difference was noted (3 RCTs, n = 339, RR 1.11, CI 0.86 to 1.43; <a href="./references#CD006625-fig-00302" title="">Analysis 3.2</a>). </p> </section> <section id="CD006625-sec4-0065"> <h5 class="title">3.3 Global state: 1b. No clinically important change ‐ as defined by the original studies </h5> <p>No significant difference was noted (2 RCTs, n = 309, RR 1.18, CI 0.89 to 1.57; <a href="./references#CD006625-fig-00303" title="">Analysis 3.3</a>). </p> </section> <section id="CD006625-sec4-0066"> <h5 class="title">3.4 Mental state: 1a. General mental state ‐ no clinically important change ‐ short term (&lt; 50% PANSS total score reduction) </h5> <p>No significant difference was noted (1 RCT, n = 42, RR 0.91, CI 0.54 to 1.53; <a href="./references#CD006625-fig-00304" title="">Analysis 3.4</a>). </p> </section> <section id="CD006625-sec4-0067"> <h5 class="title">3.5 Mental state: 1b. General mental state ‐ average endpoint score (PANSS total)</h5> <p>A significant difference favoured olanzapine overall (11 RCTs, n = 1486, MD 3.67, CI 1.95 to 5.39), medium term (3 RCTs, n = 482, MD 5.57, CI 1.97 to 9.17) and long term (3 RCTs, n = 825, MD 3.40, CI 0.91 to 5.88). A difference was not seen in the short term (5 RCTs, n = 179, MD 2.29, CI ‐1.30 to 5.87; <a href="./references#CD006625-fig-00305" title="">Analysis 3.5</a>). Exclusion of <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>, which potentially contributed skewed data to the long‐term studies, favoured olanzapine further (2 RCTs, n = 740, MD 4.31, CI 1.60 to 7.01; <a href="./references#CD006625-fig-00901" title="">Analysis 9.1</a>). </p> </section> <section id="CD006625-sec4-0068"> <h5 class="title">3.6 Mental state: 2a. Positive symptoms ‐ no clinically important change ‐ short term (&lt; 20% SAPS total score reduction) </h5> <p>No difference was identified with confidence (1 RCT, n = 30, RR 15.0, CI 0.93 to 241.2; <a href="./references#CD006625-fig-00306" title="">Analysis 3.6</a>). </p> </section> <section id="CD006625-sec4-0069"> <h5 class="title">3.7 Mental state: 2b. Positive symptoms ‐ average endpoint (PANSS positive subscore)</h5> <p>Overall data on PANSS positive average endpoint score did not show a statistically significant difference between groups (9 RCTs, n = 801, MD 1.02, CI ‐0.81 to 2.85), short term (4 RCTs, n = 152, MD 1.24, CI ‐0.48 to 2.96), medium term (3 RCTs, n = 483, MD 2.21, CI 0.90 to 3.52) or long term (2 RCT, n = 166, MD 3.70, CI ‐0.48 to 7.88; <a href="./references#CD006625-fig-00307" title="">Analysis 3.7</a>). However, exclusion of potentially skewed data (<a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>) revealed an overall significant difference in favour of olanzapine (7 RCTs, n = 676, MD 1.84, CI 1.02 to 2.67; <a href="./references#CD006625-fig-00902" title="">Analysis 9.2</a>).  </p> </section> <section id="CD006625-sec4-0070"> <h5 class="title">3.8 Mental state: 2c. Positive symptoms ‐ average change in score ‐ short term (SAPS total score ‐ percentage change from baseline) </h5> <p>A significant difference favoured olanzapine (1 RCT, n = 30, MD 40.84, CI 23.97 to 57.71; <a href="./references#CD006625-fig-00308" title="">Analysis 3.8</a>). </p> </section> <section id="CD006625-sec4-0071"> <h5 class="title">3.9 Mental state: 3a. Negative symptoms ‐ no clinically important change ‐ short term (&lt; 20% SANS total score reduction from baseline) </h5> <p>No significant difference was noted (1 RCT, n = 30, RR 1.5, CI 0.53 to 4.26; <a href="./references#CD006625-fig-00309" title="">Analysis 3.9</a>). </p> </section> <section id="CD006625-sec4-0072"> <h5 class="title">3.10 Mental state: 3b. Negative symptoms ‐ average endpoint score (PANSS negative subscore) </h5> <p>No significant difference was noted between groups (9 RCTs, n = 801, MD 0.86, CI ‐0.32 to 2.03), short term (4 RCTs, n = 152, MD ‐0.07, CI ‐1.70 to 1.56), medium term (3 RCTs, n = 483, MD 0.40, CI ‐0.67 to 1.47) or long term (2 RCTs, n = 166, MD 2.64, CI ‐1.29 to 6.56; <a href="./references#CD006625-fig-00310" title="">Analysis 3.10</a>). Exclusion of potentially skewed data (<a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>) yielded no significant difference in the results of long‐term data studies (1 RCT, n = 81, MD 0.7, CI 0.73 to 2.13; <a href="./references#CD006625-fig-00903" title="">Analysis 9.3</a>). </p> </section> <section id="CD006625-sec4-0073"> <h5 class="title">3.11 Mental state: 3c. Negative symptoms ‐ average endpoint score (SANS total)</h5> <p>No significant difference was noted (1 RCT, n = 335, MD 3.7, CI ‐0.48 to 7.88; <a href="./references#CD006625-fig-00311" title="">Analysis 3.11</a>). </p> </section> <section id="CD006625-sec4-0074"> <h5 class="title">3.12 Mental state: 3d. Negative symptoms ‐ average change in endpoint score (SANS total ‐ percent change from baseline) </h5> <p>No significant difference was noted (1 RCT, n = 30, MD 2.46, CI ‐31.9 to 36.82; <a href="./references#CD006625-fig-00312" title="">Analysis 3.12</a>). </p> </section> <section id="CD006625-sec4-0075"> <h5 class="title">3.13 General functioning ‐ average endpoint score ‐ medium term (GAF total)</h5> <p>A significant difference favoured olanzapine (3 RCT, n = 400, MD 2.55, CI 0.33 to 4.76; <a href="./references#CD006625-fig-00313" title="">Analysis 3.13</a>). </p> </section> <section id="CD006625-sec4-0076"> <h5 class="title">3.14 Quality of life ‐ average endpoint score ‐ medium term (QLS total)</h5> <p>No significant difference was noted (1 RCT, n = 286, MD 1.8, CI ‐2.42 to 6.02; <a href="./references#CD006625-fig-00314" title="">Analysis 3.14</a>). </p> </section> <section id="CD006625-sec4-0077"> <h5 class="title">3.15 Service use ‐ number of participants re‐hospitalised</h5> <p>A significant difference favoured olanzapine (3 RCTs, n = 1009, RR 1.83, CI 1.33 to 2.52; <a href="./references#CD006625-fig-00315" title="">Analysis 3.15</a>). </p> </section> <section id="CD006625-sec4-0078"> <h5 class="title">3.16 Adverse effects: 1. General ‐ at least one adverse effect</h5> <p>No significant difference was noted in the number of participants experiencing at least one adverse effect (7 RCTs, n = 1306, RR 0.96, CI 0.88 to 1.05; <a href="./references#CD006625-fig-00316" title="">Analysis 3.16</a>). </p> </section> <section id="CD006625-sec4-0079"> <h5 class="title">3.17 Adverse effects: 2. Death</h5> <p>No significant difference was noted (4 RCTs, n = 1450, RR 0.74, CI 0.13 to 4.23; <a href="./references#CD006625-fig-00317" title="">Analysis 3.17</a>). </p> </section> <section id="CD006625-sec4-0080"> <h5 class="title">3.18 Adverse effects: 3a. Cardiac effects ‐ number of participants with QTc prolongation</h5> <p>No significant difference was noted (1 RCT, n = 673, RR 12.96, CI 0.73 to 229.17; <a href="./references#CD006625-fig-00318" title="">Analysis 3.18</a>). </p> </section> <section id="CD006625-sec4-0081"> <h5 class="title">3.19 Adverse effects: 3b. Cardiac effects ‐ mean change of QTc interval from baseline in ms </h5> <p>A significant difference favoured olanzapine (3 RCTs, n = 643, MD 4.81, CI 0.34 to 9.28; <a href="./references#CD006625-fig-00319" title="">Analysis 3.19</a>). </p> </section> <section id="CD006625-sec4-0082"> <h5 class="title">3.20 Adverse effects: 4a. Central nervous system ‐ sedation</h5> <p>No significant difference was noted (7 RCTs, n = 1615, RR 0.97, CI 0.78 to 1.2; <a href="./references#CD006625-fig-00320" title="">Analysis 3.20</a>). </p> </section> <section id="CD006625-sec4-0083"> <h5 class="title">3.21 Adverse effects: 4b. Central nervous system ‐ seizures</h5> <p>No significant difference was noted (1 RCT, n = 40, RR 3.3, CI 0.14 to 76.46; <a href="./references#CD006625-fig-00321" title="">Analysis 3.21</a>). </p> </section> <section id="CD006625-sec4-0084"> <h5 class="title">3.22 Adverse effects: 5a. Extrapyramidal effects</h5> <p>Fewer participants in the quetiapine group used antiparkinson medication at least once (7 RCTs, n = 1127, RR 0.51, CI 0.32 to 0.81). Apart from this, no significant differences in extrapyramidal symptoms (EPS) were found for akathisia (7 RCTs, n = 1314, RR 0.97, CI 0.68 to 1.38), akinesia (1 RCT, n = 267, RR 1.02, CI 0.67 to 1.56), dystonia (3 RCTs, n = 752 RR 1.13, CI 0.21 to 6.23), any EPS (2 RCTs, n = 245, RR 1.62, CI 0.72 to 3.67), parkinsonism (2 RCTs, n = 77, RR 0.77, CI 0.34 to 1.74) or tremor (1 RCT, n = 42, RR 0.39, CI 0.12 to 1.31; <a href="./references#CD006625-fig-00322" title="">Analysis 3.22</a>). </p> </section> <section id="CD006625-sec4-0085"> <h5 class="title">3.23 Adverse effects: 5b. Scale measured</h5> <p>Extrapyramidal adverse effects were evaluated with the Barnes Akathisia Scale, the Extrapyramidal Side Effects Rating Scale and the Simpson‐Angus Scale. None of these indicated a significant difference between groups (<a href="./references#CD006625-fig-00323" title="">Analysis 3.23</a>). </p> </section> <section id="CD006625-sec4-0086"> <h5 class="title">3.24 Adverse effects: 6a. Prolactin‐associated side effects</h5> <p>Fewer participants in the quetiapine group suffered from sexual dysfunction (4 RCTs, n = 1177, RR 0.8, CI 0.64 to 0.99). No significant difference was noted in abnormally high prolactin (1 RCT, n = 42, RR 0.10, CI 0.01 to 1.77), amenorrhoea (3 RCTs, n = 252, RR 0.66, CI 0.36 to 1.21), galactorrhoea (4 RCTs, n = 1025, RR 0.66, CI 0.25 to 1.73) and gynaecomastia (1 RCT, n = 267, RR 0.33, CI 0.09 to 1.20; <a href="./references#CD006625-fig-00324" title="">Analysis 3.24</a>). </p> </section> <section id="CD006625-sec4-0087"> <h5 class="title">3.25 Adverse effects: 6b. Prolactin ‐ change from baseline in ng/mL</h5> <p>Quetiapine was associated with less prolactin increase than olanzapine (5 RCTs, n = 1021, RR ‐5.89, CI ‐11.62 to ‐0.16), but the data were heterogeneous (<a href="./references#CD006625-fig-00325" title="">Analysis 3.25</a>). Nevertheless, the single studies reported a consistent effect in favour of quetiapine (<a href="./references#CD006625-bbs2-0030" title="SvestkaJ , SynekO , ZourkovaA . A double‐blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders. Journal of the European College of Neuropsychopharmacology2003;13(4):S291. ">Svestka 2003b</a>: n = 35, MD ‐40.07, CI ‐64.10 to ‐16.04; <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>: n = 673, MD ‐3.20, CI ‐ 6.81 to 0.41; <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a>: n = 29, MD ‐9.10, CI ‐19.88 to 1.68; <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a>: n = 203, MD ‐3.20, CI ‐11.17 to 4.77 and <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a>: n = 81, MD ‐2.80, CI ‐10.03 to 4.43). Heterogeneity seems more likely to be due to differences in degree of prolactin increase rather than to direction of effect. </p> </section> <section id="CD006625-sec4-0088"> <h5 class="title">3.26 Adverse effects: 7a. Metabolic ‐ cholesterol ‐ significant cholesterol increase</h5> <p>No significant difference was noted in the number of participants with an abnormally high cholesterol increase (1 RCT, n = 267, RR 0.99, CI 0.59 to 1.68; <a href="./references#CD006625-fig-00326" title="">Analysis 3.26</a>). </p> </section> <section id="CD006625-sec4-0089"> <h5 class="title">3.27 Adverse effects: 7b. Metabolic ‐ cholesterol ‐ mean change from baseline in mg/dL</h5> <p>Overall data on cholesterol change from baseline did not show a statistically significant difference between groups (6 RCTs, n = 1156, MD ‐2.73, CI ‐8.05 to 2.59; <a href="./references#CD006625-fig-00327" title="">Analysis 3.27</a>). </p> </section> <section id="CD006625-sec4-0090"> <h5 class="title">3.28 Adverse effects: 7c. Metabolic ‐ glucose ‐ number of participants with abnormally high fasting glucose </h5> <p>No significant difference was noted (3 RCTs, n = 1025, RR 0.47, CI 0.21 to 1.02; <a href="./references#CD006625-fig-00328" title="">Analysis 3.28</a>). </p> </section> <section id="CD006625-sec4-0091"> <h5 class="title">3.29 Adverse effects: 7d. Metabolic ‐ glucose ‐ change from baseline in mg/dL</h5> <p>The mean increase in glucose from baseline was lower in the quetiapine group than in the olanzapine group (6 RCTs, n = 1156, MD ‐4.67, CI ‐9.41.to 0.07; <a href="./references#CD006625-fig-00329" title="">Analysis 3.29</a>). Although significant heterogeneity was noted between the studies, all favoured quetiapine. </p> </section> <section id="CD006625-sec4-0092"> <h5 class="title">3.30 Adverse effects: 7e. Metabolic ‐ weight gain</h5> <p>Fewer participants in the quetiapine group had a significant weight gain (8 RCTs, n = 1667, RR 0.68, CI 0.51 to 0.92; <a href="./references#CD006625-fig-00330" title="">Analysis 3.30</a>). </p> </section> <section id="CD006625-sec4-0093"> <h5 class="title">3.31 Adverse effects: 7f. Metabolic ‐ weight change from baseline in kilograms</h5> <p>Overall, participants in the quetiapine group gained less weight than those in the olanzapine group (10 RCTs, n = 1428, MD ‐2.54, CI ‐3.82 to ‐1.26; <a href="./references#CD006625-fig-00331" title="">Analysis 3.31</a>). Again, significant heterogeneity was noted, but the results of the single studies consistently favoured quetiapine (<a href="./references#CD006625-bbs2-0002" title="AtmacaM , KulogluM , TezcanE , UstundagB . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry2003;64(5):598‐604. ">Atmaca 2003</a>: n = 27, MD ‐4.51, CI ‐6.57 to ‐2.45; <a href="./references#CD006625-bbs2-0006" title="DeberdtW , LipkovichI , HeinlothAN , LiuL , Kollack‐WalkerS , EdwardsSE , et al. Double‐blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Therapeutics and Clinical Risk Management2008;4(4):713–20. ">Deberdt 2008</a>: n = 133, MD ‐1.81, CI ‐3.70 to 0.08; <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>: n = 612, MD ‐3.8, CI ‐4.91 to ‐2.69; <a href="./references#CD006625-bbs2-0010" title="KinonBJ , Liu‐SiefertH , HillAL , RoychowdhuryS , EdwardsSB . Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20‐24, 2003. KinonBJ , NoordsyDL , Liu‐SeifertH , GulliverAH , Ascher‐SvanumH , Kollack‐WalkerS . Randomized, double‐blind 6‐month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. Journal of Clinical Psychopharmacology2006;26(5):453‐61. ">Kinon 2006b</a>: n = 346, MD ‐0.64, CI ‐1.76 to 0.48); <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a>: n = 34, MD ‐2.3, CI ‐10.18 to 5.58; <a href="./references#CD006625-bbs2-0027" title="SirotaP , PannetI , KorenA , TchernichovskyE . Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Human Psychopharmacology2006;21(4):227‐34. SirotaP , TchernichowskyE , PanetI , KorenA . The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia. Schizophrenia Research2004;67(1):170. ">Sirota 2006</a>: n = 40, MD ‐3.2, CI ‐5.51 to ‐0.89; <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a>: n = 81, MD ‐5.18, CI ‐10.00 to ‐0.36; <a href="./references#CD006625-bbs2-0025" title="RiedelM , MüllerN , SpellmannI , EngelRR , MusilR , ValdevitR , et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia. European Archieves of Psychiatry and Clinical Neuroscience2007;257(7):402‐12. ">Riedel 2007</a>: n = 33, MD ‐0.48, CI ‐2.52 to 1.56; <a href="./references#CD006625-bbs2-0008" title="HattaK , SatoK , HamakawaH , TakebayashiH , KimuraN , OchiS , et al. Effectiveness of second‐generation antipsychotics with acute‐phase schizophrenia. Schizophrenia Research2009;113:49‐55. ">Hatta 2009</a>: n = 37, MD 0.1, CI ‐2.19 to 2.39 and <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>: n = 85, MD ‐4.40, CI ‐5.30 to ‐3.50). </p> </section> <section id="CD006625-sec4-0094"> <h5 class="title">3.32 Publication bias</h5> <p>Funnel plots did not suggest a possible publication bias.</p> </section> <section id="CD006625-sec4-0095"> <h5 class="title">3.33 Investigation for heterogeneity and sensitivity analysis</h5> <p>When <a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a> was excluded from the evaluation of the PANSS positive score because of possibly skewed data, olanzapine remained more effective. </p> </section> </section> <section id="CD006625-sec3-0029"> <h4 class="title">4. Comparison 4. QUETIAPINE versus PALIPERIDONE</h4> <p>Only two short‐term studies with limited outcome measures met the inclusion criteria for the comparison of quetiapine with paliperidone. </p> <section id="CD006625-sec4-0096"> <h5 class="title">4.1 Leaving the study early</h5> <p>No significant difference was noted in the number of participants who left the study early in the paliperidone group compared with the quetiapine group for ‘any reason’ (2 RCTs, n = 406, RR 1.03, CI 0.61 to 1.73), because of ‘inefficacy’ (1 RCT, n = 319, RR 4.97, CI 0.59 to 42.05) or as the result of adverse events (2 RCTs, n = 406, RR 0.90, CI 0.37 to 2.17; <a href="./references#CD006625-fig-00401" title="">Analysis 4.1</a>). </p> </section> <section id="CD006625-sec4-0097"> <h5 class="title">4.2 Mental state: 1. General ‐ average endpoint score (PANSS total)</h5> <p>A significant difference favoured paliperidone on the basis of one RCT (n = 319, MD 6.30, CI 2.77 to 9.83; <a href="./references#CD006625-fig-00402" title="">Analysis 4.2</a>). </p> </section> <section id="CD006625-sec4-0098"> <h5 class="title">4.3 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore)</h5> <p>A significant difference favoured paliperidone (1 RCT, n = 319, MD 1.60, CI 0.42 to 2.78; <a href="./references#CD006625-fig-00403" title="">Analysis 4.3</a>). </p> </section> <section id="CD006625-sec4-0099"> <h5 class="title">4.4 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore)</h5> <p>A significant difference favoured paliperidone (1 RCT, n = 319, MD 1.30, CI 0.52 to 2.08; <a href="./references#CD006625-fig-00404" title="">Analysis 4.4</a>). </p> </section> <section id="CD006625-sec4-0100"> <h5 class="title">4.5 Adverse effects: 1. Numbers of participants with at least one adverse effect</h5> <p>A significant difference favoured paliperidone (1 RCT, n = 87, RR 1.27, CI 1.06 to 1.53; <a href="./references#CD006625-fig-00405" title="">Analysis 4.5</a>). </p> </section> <section id="CD006625-sec4-0101"> <h5 class="title">4.6 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation</h5> <p>Only one study examined for this side effect, and the risk ratio was not estimable because of a low event rate (<a href="./references#CD006625-fig-00406" title="">Analysis 4.6</a>). </p> </section> <section id="CD006625-sec4-0102"> <h5 class="title">4.7 Adverse effects: 2b. Cardiac effects ‐ QTc abnormalities (change from baseline in ms) </h5> <p>No significant difference was noted (1 RCT, n = 87, RR 2.30, CI ‐2.50 to 7.10; <a href="./references#CD006625-fig-00407" title="">Analysis 4.7</a>). </p> </section> <section id="CD006625-sec4-0103"> <h5 class="title">4.8 Adverse effects: 3a. Extrapyramidal effects</h5> <p>More participants in the paliperidone group used antiparkinson medication at least once (1 RCT, n = 319, RR 0.64, CI 0.45 to 0.91). The paliperidone group was significantly more likely to experience rigidity (2 RCTs, n = 406, RR 0.34, CI 0.12 to 0.92) and tremor (1 RCT, n = 319, RR 0.37, CI 0.17 to 0.80). No difference was noted in dystonia (1 RCT, n = 87 RR 1.02, CI 0.15 to 6.94) or akathisia (2 RCTs, n = 406, RR 1.35, CI 0.55 to 3.34; <a href="./references#CD006625-fig-00408" title="">Analysis 4.8</a>). </p> </section> <section id="CD006625-sec4-0104"> <h5 class="title">4.9 Adverse effects: 3b. Extrapyramidal effects ‐ scale measured</h5> <p>Extrapyramidal adverse effects were evaluated in one RCT with the Barnes Akathisia Scale, the Extrapyramidal Side Effects Rating Scale and the Simpson‐Angus Scale. None of these scales reported a significant difference between groups (<a href="./references#CD006625-fig-00409" title="">Analysis 4.9</a>). </p> </section> <section id="CD006625-sec4-0105"> <h5 class="title">4.10 Adverse effects: 4a. Prolactin ‐ associated effects ‐ sexual dysfunction</h5> <p>No difference was noted in the number of participants who suffered from sexual dysfunction (1 RCT, n = 317, RR 0.02, CI 0.01 to 4.16; <a href="./references#CD006625-fig-00410" title="">Analysis 4.10</a>). </p> </section> <section id="CD006625-sec4-0106"> <h5 class="title">4.11 Adverse effects: 4b. Prolactin ‐ change from baseline (ng/mL)</h5> <p>On the basis of one study, quetiapine was associated with significantly less prolactin increase than paliperidone (1 RCT, n = 317, MD ‐49.30, CI ‐57.80 to ‐40.80; <a href="./references#CD006625-fig-00411" title="">Analysis 4.11</a>). </p> </section> <section id="CD006625-sec4-0107"> <h5 class="title">4.12 Adverse effects: 5a. Metabolic ‐ weight gain ‐ number of participants with weight gain of 7% or more of total body weight </h5> <p>Participants in the paliperidone group were not more likely to experience significant weight gain as defined by the study investigators (1 RCT, n = 319, RR 2.52, CI 0.50 to 12.78; <a href="./references#CD006625-fig-00412" title="">Analysis 4.12</a>). </p> </section> <section id="CD006625-sec4-0108"> <h5 class="title">4.13 Adverse effects: 5b. Metabolicweight gain ‐ mean change from baseline in kilograms</h5> <p>Paliperidone did cause a significantly greater weight gain in terms of change from baseline in kilograms (1 RCT, n = 319, MD 0.40, CI 0.20 to 0.60; <a href="./references#CD006625-fig-00413" title="">Analysis 4.13</a>). </p> </section> <section id="CD006625-sec4-0109"> <h5 class="title">4.13 Publication bias</h5> <p>Funnel plots were not performed because of the paucity of studies.</p> </section> </section> <section id="CD006625-sec3-0030"> <h4 class="title">5. Comparison 5. QUETIAPINE versus RISPERIDONE</h4> <p>Nineteen studies met the inclusion criteria for the comparison of quetiapine with risperidone. </p> <section id="CD006625-sec4-0110"> <h5 class="title">5.1 Leaving the study early</h5> <p>Leaving the studies early for any reason showed an almost significant superiority of risperidone (quetiapine 54%, risperidone 49%; 13 RCTs, n = 2784, RR 1.09, CI 1.00 to 1.19). Leaving early because of inefficacy showed a small significant advantage of risperidone over quetiapine (25% vs 19%; 8 RCTs, n = 1891, RR 1.32, CI 1.02 to 1.71). No significant difference was noted in the number of participants leaving early as the result of adverse events (10% vs 9%; 9 RCTs, n = 2299, RR 1.12, CI 0.80 to 1.57; <a href="./references#CD006625-fig-00501" title="">Analysis 5.1</a>). </p> </section> <section id="CD006625-sec4-0111"> <h5 class="title">5.2 Global state: 1a. No clinically significant response ‐ as defined by the original studies </h5> <p>Overall, no significant difference was evident when all studies were considered (4 RCTs, n = 1264, RR 1.07, CI 0.95 to 1.22; <a href="./references#CD006625-fig-00502" title="">Analysis 5.2</a>). The first three studies reported short‐term data, and only <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a> reported long‐term data. Heterogeneity was moderate (I<sup>2</sup> = 57%<i>);</i> however, on exclusion of potentially skewed data from <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a>, there remained no significant difference between groups (3 RCTs, n = 965, RR 1.01, CI 0.93 to 1.09; <a href="./references#CD006625-fig-01001" title="">Analysis 10.1</a>). </p> </section> <section id="CD006625-sec4-0112"> <h5 class="title">5.3 Global state: 1b. No clinically important change ‐ as defined by the original studies </h5> <p>A small superiority of risperidone was noted, but it did not reach statistical significance (5 RCTs, n = 1342, RR 1.10, CI 0.98 to 1.25; <a href="./references#CD006625-fig-00503" title="">Analysis 5.3</a>). </p> </section> <section id="CD006625-sec4-0113"> <h5 class="title">5.4 Mental state: 1a. General ‐ no clinically important change ‐ short term (&lt; 30% PANSS total score reduction from baseline) </h5> <p>No significant difference was noted (2 RCTs, n = 982, RR 1.11, CI 0.87 to 1.42), but the results were heterogeneous (<a href="./references#CD006625-fig-00504" title="">Analysis 5.4</a>). We therefore present the single studies separately: <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a> (n = 177, RR 1.27, CI 1.05 to 1.55) and <a href="./references#CD006625-bbs2-0224" title="ZhongZ‐Y , TaoJ , WangX‐L , WuX‐L , ZhangJ‐B . Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia. Zhongguo Linchuang Kangfu2006;10(2):30‐2. ">Zhong 2006a</a> (n = 495, RR 1.0, CI 0.91 to 1.09). </p> </section> <section id="CD006625-sec4-0114"> <h5 class="title">5.5 Mental state: 1b. General: no clinically important change ‐ short term (&lt; 20% BPRS total score reduction) </h5> <p>No significant difference was noted (1 RCT, n = 25, RR 0.98, CI 0.63 to 1.52; <a href="./references#CD006625-fig-00505" title="">Analysis 5.5</a>). </p> </section> <section id="CD006625-sec4-0115"> <h5 class="title">5.6 Mental state: 1c. General: average endpoint score (PANSS total)</h5> <p>A significant difference favoured risperidone: overall (14 RCTs, n = 2302, MD 1.67, CI 0.39 to 2.96), short term (8 RCTs, n = 1232, MD 1.37, CI ‐0.28 to 3.01) and long term (2 RCTs, n = 743, MD 3.11, CI 0.40 to 5.82; <a href="./references#CD006625-fig-00506" title="">Analysis 5.6</a>).  Medium‐term studies displayed considerable heterogeneity; the results are therefore presented separately. <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a> reported a significant difference in favour of risperidone (n = 132, MD 10, CI 2.38 to 17.62); <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a> (n = 14, MD ‐1.0, CI ‐15.41 to 13.41), <a href="./references#CD006625-bbs2-0033" title="WeiQW , FangYR , ShenXL , TianT , LiaoJG , FangXG . A comparative study of social function in first‐episode schizophrenic patients treated with quetiapine and risperidone. Shandong Archives of Psychiatry2006;19(1):34‐6. ">Wei 2006a</a> (n = 51, MD 1.60, CI ‐5.69 to 2.49) and <a href="./references#CD006625-bbs2-0016" title="LuX , ChengH , SongS , SunL , ZhangY , FanY . A study of quetiapine and risperidone and clozapine in the treatment of schizophrenia. China and Foreign Medical Journal2006;4(6):62‐4. ">Lu 2006</a> (n = 64, MD 3.82, CI ‐2.51 to 10.15) found no significant difference between groups.  </p> </section> <section id="CD006625-sec4-0116"> <h5 class="title">5.7 Mental state: 1d. General mental state: average endpoint score ‐ short term (BPRS total) </h5> <p>No significant difference was noted (1 RCT, n = 25, MD 1.68, CI ‐8.33 to 11.69; <a href="./references#CD006625-fig-00507" title="">Analysis 5.7</a>). </p> </section> <section id="CD006625-sec4-0117"> <h5 class="title">5.8 Mental state: 2a. Positive symptoms ‐ no clinically important change in PANSS positive subscore </h5> <p>No significant difference was noted in the number of people with no clinically important change in PANSS score in the short term, as measured by &lt; 40% PANSS positive score reduction from baseline (1 RCT, n = 673, RR 1.00, CI 0.9 to 1.12; <a href="./references#CD006625-fig-00508" title="">Analysis 5.8</a>). </p> </section> <section id="CD006625-sec4-0118"> <h5 class="title">5.9 Mental state: 2b. Positive symptoms ‐ average endpoint score (PANSS positive subscore)</h5> <p>A significant difference favoured risperidone overall (11 RCTs, n = 1639, MD 1.22, CI 0.51 to 1.94), medium term (5 RCTs, n = 327, MD 1.21, CI ‐0.21 to 2.63) and long term (1 RCT, n = 81, MD 1.30, CI ‐0.13 to 2.73; <a href="./references#CD006625-fig-00509" title="">Analysis 5.9</a>). Despite considerable heterogeneity, short‐term studies tended to favour risperidone: <a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a> (n = 39, MD 2.5, CI 0.37 to 4.63), <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a> (n = 308, MD 2.80, CI 1.42 to 4.18), <a href="./references#CD006625-bbs2-0024" title="RiedelM , MullerN , StrassnigM , SpellmannI , EngelRR , MusilR , et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2005;255(6):432‐7. RiedelM , SpellmannI , MullerN , StrassnigM , Muller‐ArendsA , DehningS , MollerHJ . Cognitive benefits of quetiapine versus risperidone in schizophrenia. Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21‐26, 2005. RiedelM , SpellmannI , StrassnigM , DouhetA , DehningS , Opgen‐RheinM , et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience2007;257:360‐70. ">Riedel 2005</a> (n = 44, MD 3.80, CI ‐0.51 to 8.11), <a href="./references#CD006625-bbs2-0028" title="SongGM , LiJH , ZhongH , LuSL . Control study of risperidone oral solution and quetiapine on schizophrenia. Modern Journal of Integrated Traditional Chinese and Western Medicine2008;17(32):4961‐3. ">Song 2008</a> (n = 66, MD 0.16, CI ‐1.12 to 1.44) and <a href="./references#CD006625-bbs2-0032" title="WangDF , WangXR . A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health2006;35(18):1697‐8. ">Wang 2006</a> (n = 60, MD 0.1, CI ‐1.87 to 2.07). <a href="./references#CD006625-bbs2-0009" title="HuGH , WuYJ , LiQX . A comparative study between quetiapine and risperidone in the treatment of first‐episode schizophrenia. Chinese Medical Journal of Metallurgical Industry2008;25(1):16‐7. ">Hu 2008</a> favoured quetiapine but had a wide CI (n = 68, MD‐0.50, CI ‐3.81 to 2.81). Excluding data from potentially skewed short‐term (<a href="./references#CD006625-bbs2-0009" title="HuGH , WuYJ , LiQX . A comparative study between quetiapine and risperidone in the treatment of first‐episode schizophrenia. Chinese Medical Journal of Metallurgical Industry2008;25(1):16‐7. ">Hu 2008</a>; <a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a>; <a href="./references#CD006625-bbs2-0028" title="SongGM , LiJH , ZhongH , LuSL . Control study of risperidone oral solution and quetiapine on schizophrenia. Modern Journal of Integrated Traditional Chinese and Western Medicine2008;17(32):4961‐3. ">Song 2008</a>; <a href="./references#CD006625-bbs2-0032" title="WangDF , WangXR . A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health2006;35(18):1697‐8. ">Wang 2006</a>) and medium‐term (<a href="./references#CD006625-bbs2-0016" title="LuX , ChengH , SongS , SunL , ZhangY , FanY . A study of quetiapine and risperidone and clozapine in the treatment of schizophrenia. China and Foreign Medical Journal2006;4(6):62‐4. ">Lu 2006</a>; <a href="./references#CD006625-bbs2-0028" title="SongGM , LiJH , ZhongH , LuSL . Control study of risperidone oral solution and quetiapine on schizophrenia. Modern Journal of Integrated Traditional Chinese and Western Medicine2008;17(32):4961‐3. ">Song 2008</a>; <a href="./references#CD006625-bbs2-0033" title="WeiQW , FangYR , ShenXL , TianT , LiaoJG , FangXG . A comparative study of social function in first‐episode schizophrenic patients treated with quetiapine and risperidone. Shandong Archives of Psychiatry2006;19(1):34‐6. ">Wei 2006a</a>) studies in a sensitivity analysis maintained a significant difference in favour of risperidone (6 RCTs, n = 1225, MD 1.76, CI 1.04 to 2.48). </p> </section> <section id="CD006625-sec4-0119"> <h5 class="title">5.10 Mental state: 2c. Positive symptoms ‐ average change endpoint score ‐ short term (BPRS positive subscore) </h5> <p>A significant difference favoured risperidone (1 RCT, n = 25, MD 1.1, CI 0.18 to 2.02; <a href="./references#CD006625-fig-00510" title="">Analysis 5.10</a>). </p> </section> <section id="CD006625-sec4-0120"> <h5 class="title">5.11 Mental state: 3a. Negative symptoms ‐ no clinically important change ‐ PANSS negative subscore short term (&lt; 40% PANSS negative score reduction from baseline) </h5> <p>No significant difference was noted in the number of people with no clinically important change in the PANSS negative subscore in the short term, as measured by &lt; 40% PANSS negative score reduction from baseline (1 RCT, n = 673, RR 0.98, CI 0.93 to 1.04; <a href="./references#CD006625-fig-00511" title="">Analysis 5.11</a>). </p> </section> <section id="CD006625-sec4-0121"> <h5 class="title">5.12 Mental state: 3b. Negative symptoms ‐ average endpoint score (PANSS negative subscore) </h5> <p>No significant difference was noted in short‐term studies (6 RCTs, n = 1106, MD 0.55, CI ‐0.25 to 1.34), medium‐term studies (5 RCTs, n = 327, MD 1.05, CI ‐0.24 to 2.34) and long‐term studies (1 RCT, n = 81, MD 0.8, CI ‐0.64 to 2.24; <a href="./references#CD006625-fig-00512" title="">Analysis 5.12</a>). Exclusion of potentially skewed data in a sensitivity analysis for short‐term and medium‐term studies yielded no significant difference in results (<a href="./references#CD006625-fig-01004" title="">Analysis 10.4</a>). </p> </section> <section id="CD006625-sec4-0122"> <h5 class="title">5.13 Mental state: 3c. Negative symptoms ‐ average change endpoint score ‐ short term (BPRS negative subscore) </h5> <p>A significant difference favoured risperidone (1 RCT, n = 25, MD 0.57, CI 0.17 to 0.97; <a href="./references#CD006625-fig-00513" title="">Analysis 5.13</a>). </p> </section> <section id="CD006625-sec4-0123"> <h5 class="title">5.14 Quality of life ‐ average endpoint score (QLS total score)</h5> <p>A significant difference favoured quetiapine (3 RCTs, n = 152, MD ‐3.44, CI ‐4.46 to ‐2.43; <a href="./references#CD006625-fig-00514" title="">Analysis 5.14</a>). </p> </section> <section id="CD006625-sec4-0124"> <h5 class="title">5.15 Service use: 1. Number of participants re‐hospitalised</h5> <p>The difference almost reached statistical significance, with a slight benefit for the risperidone group (2 RCTs, n = 877, RR 1.34, CI 1.0 to 1.79; <a href="./references#CD006625-fig-00515" title="">Analysis 5.15</a>). </p> </section> <section id="CD006625-sec4-0125"> <h5 class="title">5.16 Adverse effects: 1. General ‐ at least one adverse effect</h5> <p>No significant difference was noted (13 RCTs, n = 2868, RR 1.01, CI 0.91 to 1.13; <a href="./references#CD006625-fig-00516" title="">Analysis 5.16</a>). </p> </section> <section id="CD006625-sec4-0126"> <h5 class="title">5.17 Adverse effects: 2. Death</h5> <p>No significant difference was noted (6 RCTs, n = 3146, RR 0.73, CI 0.17 to 3.09; <a href="./references#CD006625-fig-00517" title="">Analysis 5.17</a>). </p> </section> <section id="CD006625-sec4-0127"> <h5 class="title">5.18 Adverse effects: 3a. Cardiac effects ‐ number of participants with QTc prolongation</h5> <p>No significant difference was noted (3 RCTs, n = 1419, RR 1.34, CI 0.36 to 5.04; <a href="./references#CD006625-fig-00518" title="">Analysis 5.18</a>). </p> </section> <section id="CD006625-sec4-0128"> <h5 class="title">5.19 Adverse effects: 3b. Mean change in QTc interval from baseline in ms</h5> <p>Overall, no significant difference was noted (3 RCTs, n = 940, MD 2.21, CI ‐5.05 to 9.48). The data were heterogeneous. In the individual studies, <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a> found a significant difference in favour of risperidone (n = 432, MD 5.7, CI 0.57 to 10.83), but <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a> (n = 166, MD 6.3, CI ‐3.41 to 16.01) and <a href="./references#CD006625-bbs2-0224" title="ZhongZ‐Y , TaoJ , WangX‐L , WuX‐L , ZhangJ‐B . Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia. Zhongguo Linchuang Kangfu2006;10(2):30‐2. ">Zhong 2006a</a> (n = 342, MD ‐3.6, CI ‐7.55 to 0.35) found no significant difference between groups (<a href="./references#CD006625-fig-00519" title="">Analysis 5.19</a>). </p> </section> <section id="CD006625-sec4-0129"> <h5 class="title">5.20 Adverse effect: 4. Central nervous system ‐ sedation</h5> <p>A significant difference favoured risperidone (8 RCTs, n = 2226, RR 1.21, CI 1.06 to 1.38; <a href="./references#CD006625-fig-00520" title="">Analysis 5.20</a>). </p> </section> <section id="CD006625-sec4-0130"> <h5 class="title">5.21 Adverse effects: 5a. Extrapyramidal effects</h5> <p>Quetiapine produced fewer movement disorders than risperidone in terms of 'extrapyramidal symptoms' (2 RCTs, n = 872, RR 0.59, CI 0.43 to 0.81), dystonia (4 RCTs, n = 1451, RR 0.13, CI 0.04 to 0.43), use of antiparkinson medication at least once (8 RCTs, n = 2163, RR 0.50, CI 0.36 to 0.69), akathisia (8 RCTs, n = 2270, RR 0.55, CI 0.32 to 0.95), akinesia (1 RCT, n = 267, RR 0.91, CI 0.61 to 1.37) and lesser parkinsonism (4 RCTs, n = 825, RR 0.39, CI 0.19 to 0.78; <a href="./references#CD006625-fig-00521" title="">Analysis 5.21</a>). </p> </section> <section id="CD006625-sec4-0131"> <h5 class="title">5.22 Adverse effects: 5c. Extrapyramidal effects as measured by scales</h5> <p>Quetiapine produced fewer extrapyramidal side effects than risperidone according to the Simpson‐Angus Scale (5 RCTs, n = 1077, MD ‐0.59, CI ‐1.16 to ‐0.02). No significant difference was noted in dyskinesia (AIMS, 2 RCTs, n = 958, MD ‐0.34, CI ‐0.76 to 0.08) and akathisia (BAS, 2 RCTs, n = 700, MD ‐0.73, CI ‐2.0 to 0.54; <a href="./references#CD006625-fig-00522" title="">Analysis 5.22</a>). </p> </section> <section id="CD006625-sec4-0132"> <h5 class="title">5.23 Adverse effects: 6. Haematological ‐ important decline in white blood cells</h5> <p>No significant difference was noted (1 RCT, n = 673, RR 2.97, CI 0.12 to 72.73; <a href="./references#CD006625-fig-00523" title="">Analysis 5.23</a>). </p> </section> <section id="CD006625-sec4-0133"> <h5 class="title">5.24 Adverse effects: 7a. Prolactin associated adverse effects</h5> <p>Quetiapine produced significantly fewer cases of amenorrhoea (5 RCTs, n = 427, RR 0.55, CI 0.32 to 0.96), galactorrhoea (5 RCTs, n = 1188, RR 0.37, CI 0.16 to 0.85) and gynaecomastia (1 RCT, n = 78, RR 0.23, CI 0.07 to 0.75) but not dysmenorrhoea (1 RCT, n = 163, RR 0.45, CI 0.08 to 2.38). Data on sexual dysfunction showed an almost significant superiority of quetiapine (6 RCTs, n = 2157, RR 0.70, CI 0.48 to 1.01; <a href="./references#CD006625-fig-00524" title="">Analysis 5.24</a>). </p> </section> <section id="CD006625-sec4-0134"> <h5 class="title">5.25 Adverse effects: 7b. Prolactin ‐ change from baseline in ng/mL</h5> <p>A significant and consistent difference favoured quetiapine, although the extent of the difference varied, leading to statistical heterogeneity (7 RCTs, n = 1773, MD ‐35.25, CI ‐43.59 to ‐26.91; the results of the single studies were as follows: <a href="./references#CD006625-bbs2-0003" title="ByerlyMJ , NakoneznyPA , RushAJ . Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double‐blind pilot trial. Psychiatry Research2008;159:115‐20. ">Byerly 2008</a>: n = 44, MD ‐35.10, CI ‐50.68 to ‐19.52; <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>: n = 678, MD ‐24.70, CI ‐28.72 to ‐20.68; <a href="./references#CD006625-bbs2-0018" title="McEvoyJP , LiebermanJA , StroupTS , DavisSM , MeltzerHY , RosenheckRA , et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry2006;163(4):600‐10. ">McEvoy 2006</a>: n = 24, MD ‐28.6, CI ‐43.02 to ‐14.18; <a href="./references#CD006625-bbs2-0023" title="GharabawiGM , GreenspanA , RupnowMFT , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double‐blind trial. BMC Psychiatry2006;6(45):1‐7. GreenspanA , Kosik‐GonzalezC , Moreau‐MalletV , BossieCA , RupnowMFT , ZhuY , GharabawiGM . Risperidone vs quetiapine in inpatients with schizophrenia: a double‐blind placebo‐controlled study. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S503. PotkinSG , GharabawiGM , GreenspanAJ , MahmoudR , Kosik‐GonzalezC , RupnowMFT , et al. A double‐blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research2006;85(1‐3):254‐65. PotkinSG , GreenspanA , Kosik‐GonzalezC , BossieC , RupnowM , ZhuY , et al. A placebo‐controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin2005;31:501. ">Potkin 2006</a>: n = 309, MD ‐50.4, CI ‐60.24 to ‐40.56; <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a>: n = 199, MD ‐30.3, CI ‐37.1 to ‐23.5; <a href="./references#CD006625-bbs2-0224" title="ZhongZ‐Y , TaoJ , WangX‐L , WuX‐L , ZhangJ‐B . Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia. Zhongguo Linchuang Kangfu2006;10(2):30‐2. ">Zhong 2006a</a>: n = 440, MD ‐47.0, CI ‐52.97 to ‐41.03and <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a>: n = 81, MD ‐30.8, CI ‐38.1 to ‐23.5; <a href="./references#CD006625-fig-00525" title="">Analysis 5.25</a>). </p> </section> <section id="CD006625-sec4-0135"> <h5 class="title">5.26 Adverse effects: 8a. Metabolic ‐ cholesterol ‐ number of participants with a significant cholesterol increase </h5> <p>No significant difference was noted (2 RCTs, n = 940, RR 1.27, CI 0.72 to 2.24; <a href="./references#CD006625-fig-00526" title="">Analysis 5.26</a>). </p> </section> <section id="CD006625-sec4-0136"> <h5 class="title">5.27 Adverse effects: 8b. Metabolic ‐ cholesterol ‐ mean change from baseline in mg/dL</h5> <p>A significant difference favoured risperidone (6 RCTs, n = 1473, MD 8.57, CI 4.85 to 12.29; <a href="./references#CD006625-fig-00527" title="">Analysis 5.27</a>). </p> </section> <section id="CD006625-sec4-0137"> <h5 class="title">5.28 Adverse effects: 8c. Metabolic ‐ glucose ‐ number of participants with abnormally high fasting glucose </h5> <p>No significant difference was noted (3 RCTs, n = 1618, RR 0.89, CI 0.47 to 1.69; <a href="./references#CD006625-fig-00528" title="">Analysis 5.28</a>). </p> </section> <section id="CD006625-sec4-0138"> <h5 class="title">5.29 Adverse effects: 8d. Metabolic ‐ glucose ‐ mean change from baseline in mg/dL</h5> <p>No significant difference was noted (6 RCTs, n = 1476, MD 0.30, CI ‐2.45 to 3.05; <a href="./references#CD006625-fig-00529" title="">Analysis 5.29</a>). </p> </section> <section id="CD006625-sec4-0139"> <h5 class="title">5.30 Adverse effects: 8e. Metabolic ‐ weight gain ‐ number of participants with weight gain of 7% or more of total body weight </h5> <p>No significant difference was noted (9 RCTs, n = 2070, RR 0.96, CI 0.82 to 1.14; <a href="./references#CD006625-fig-00530" title="">Analysis 5.30</a>). </p> </section> <section id="CD006625-sec4-0140"> <h5 class="title">5.31 Adverse effects: 8f. Metabolic ‐ weight gain ‐ mean change from baseline in kilograms</h5> <p>Overall, no significant difference was noted, but the data were highly heterogeneous, presumably because of one small outlier study (<a href="./references#CD006625-bbs2-0002" title="AtmacaM , KulogluM , TezcanE , UstundagB . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry2003;64(5):598‐604. ">Atmaca 2003</a>) that showed a dramatic advantage of risperidone (8 RCTs, n = 1486, MD 0.94, CI ‐0.59 to 2.46; <a href="./references#CD006625-fig-00531" title="">Analysis 5.31</a>). Nevertheless, excluding this study did not change the overall result. </p> </section> <section id="CD006625-sec4-0141"> <h5 class="title">5.32 Publication bias</h5> <p>A reasonable funnel plot analysis was possible only for the PANSS total score (&gt; 10 included studies). It did not suggest a possible publication bias. </p> </section> <section id="CD006625-sec4-0142"> <h5 class="title">5.33 Investigation for heterogeneity and sensitivity analysis</h5> <p>Exclusion of <a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a> from the evaluation of the PANSS positive subscore as the result of possibly skewed data did not reveal markedly different results. The data on akathisia (Barnes Akathisia Scale) indicated considerable heterogeneity, but clear reasons to explain this could not be found. </p> </section> </section> <section id="CD006625-sec3-0031"> <h4 class="title">6. Comparison 6. QUETIAPINE versus ZIPRASIDONE</h4> <p>Two studies met the inclusion criteria for the comparison of quetiapine versus ziprasidone.</p> <section id="CD006625-sec4-0143"> <h5 class="title">6.1 Leaving the study early</h5> <p>No significant difference was noted in the number of participants leaving the studies early for any reason (2 RCTs, n = 722, RR 1.05, CI 0.97 to 1.13), because of adverse events (2 RCTs, n = 722, RR 1.04, CI 0.72 to 1.49) or as the result of inefficacy of treatment (2 RCTs, n = 722, RR 1.14, CI 0.89 to 1.47). </p> </section> <section id="CD006625-sec4-0144"> <h5 class="title">6.2 Mental state: 1. General mental state ‐ average endpoint score (PANSS total)</h5> <p>No significant difference was noted, but the data from two studies were heterogeneous and therefore are presented separately. Neither <a href="./references#CD006625-bbs2-0029" title="StroupTS , LiebermanJA , McEvoyJP , SwartzMS , DavisSM , RosenheckRA , et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry2006;163(4):611‐22. ">Stroup 2006</a> (medium‐term data, n = 198, MD 3.7, CI ‐2.97 to 10.37) nor <a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a> (long‐term data, n = 512, MD ‐2.78, CI ‐6.81 to 1.25) found a significant difference between groups (<a href="./references#CD006625-fig-00602" title="">Analysis 6.2</a>). </p> </section> <section id="CD006625-sec4-0145"> <h5 class="title">6.3 Mental state: 2. Positive symptoms ‐ average endpoint score ‐ medium term (PANSS positive subscore) </h5> <p>No significant difference was noted (1 RCT, n = 198, MD 0.0, CI ‐2.18 to 2.18; <a href="./references#CD006625-fig-00603" title="">Analysis 6.3</a>). </p> </section> <section id="CD006625-sec4-0146"> <h5 class="title">6.4 Mental state: 3. Negative symptoms: average endpoint score ‐ medium term (PANSS negative subscore) </h5> <p>No significant difference was noted (1 RCT, n = 198, MD 1.6, CI ‐0.34 to 3.54; <a href="./references#CD006625-fig-00604" title="">Analysis 6.4</a>). </p> </section> <section id="CD006625-sec4-0147"> <h5 class="title">6.5 Service use: 1. Number of participants re‐hospitalised</h5> <p>No significant differencewas noted in the overall analysis (2 RCTs, n = 754, RR 1.17, CI 0.85 to 1.59) or in the analysis of medium‐term data (1 RCT, n = 232, RR 1.25, CI 0.71 to 2.17) or long‐term data (1 RCT, n = 522, RR 1.13, CI 0.78 to 1.65; <a href="./references#CD006625-fig-00605" title="">Analysis 6.5</a>). </p> </section> <section id="CD006625-sec4-0148"> <h5 class="title">6.6 Adverse effects: 1. General ‐ at least one adverse effect</h5> <p>No significant difference was noted (2 RCTs, n = 754, RR 1.03, CI 0.91 to 1.17; <a href="./references#CD006625-fig-00606" title="">Analysis 6.6</a>). </p> </section> <section id="CD006625-sec4-0149"> <h5 class="title">6.7 Adverse effects: 2. Death</h5> <p>No significant difference was noted (2 RCTs, n = 754, RR 0.41, CI 0.05 to 3.15; <a href="./references#CD006625-fig-00607" title="">Analysis 6.7</a>). </p> </section> <section id="CD006625-sec4-0150"> <h5 class="title">6.8 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation</h5> <p>No significant difference was noted in the number of participants with QTc prolongation (1 RCT, n = 522, RR 1.65, CI 0.34 to 8.08; <a href="./references#CD006625-fig-00608" title="">Analysis 6.8</a>). </p> </section> <section id="CD006625-sec4-0151"> <h5 class="title">6.9 Adverse effects: 3b. Cardiac effects ‐ mean change in QTc interval in ms</h5> <p>No significant difference was noted (2 RCTs, n = 549, MD 3.41, CI ‐1.37 to 8.18; <a href="./references#CD006625-fig-00609" title="">Analysis 6.9</a>). </p> </section> <section id="CD006625-sec4-0152"> <h5 class="title">6.10 Adverse effects: 4. Central nervous system ‐ sedation</h5> <p>Significantly fewer participants in the ziprasidone group than in the quetiapine group felt sedated (2 RCTs, n = 754, RR 1.36, CI 1.04 to 1.77, NNH 14, CI 7 to 100; <a href="./references#CD006625-fig-00610" title="">Analysis 6.10</a>). </p> </section> <section id="CD006625-sec4-0153"> <h5 class="title">6.11 Adverse effects: 5. Extrapyramidal effects</h5> <p>Significantly fewer people in the quetiapine group used antiparkinson medication at least once (1 RCT, n = 522, RR 0.43, CI 0.2 to 0.93), but no clear differences were noted in akathisia (2 RCTs, n = 754, RR 0.78, CI 0.42 to 1.45) or in 'any extrapyramidal symptoms' (1 RCT, n = 232, RR 2.02, CI 0.66 to 6.17; <a href="./references#CD006625-fig-00611" title="">Analysis 6.11</a>). </p> </section> <section id="CD006625-sec4-0154"> <h5 class="title">6.12 Adverse effects: 6a. Prolactin ‐ associated effects</h5> <p>No significant difference was noted in amenorrhoea (1 RCT, n = 138, RR 0.43, CI 0.15 to 1.24), galactorrhoea (2 RCTs, n = 202, RR 0.68, CI 0.23 to 2.01) or sexual dysfunction (2 RCTs, n = 754, RR 0.96, CI 0.64 to 1.42; <a href="./references#CD006625-fig-00612" title="">Analysis 6.12</a>). </p> </section> <section id="CD006625-sec4-0155"> <h5 class="title">6.13 Adverse effects: 6b. Prolactin ‐ change from baseline in ng/mL</h5> <p>A significant difference favoured quetiapine (2 RCTs, n = 754, MD ‐4.77, CI ‐8.16 to ‐1.37; <a href="./references#CD006625-fig-00613" title="">Analysis 6.13</a>). </p> </section> <section id="CD006625-sec4-0156"> <h5 class="title">6.14 Adverse effects: 7a. Metabolic ‐ cholesterol ‐ mean change from baseline in mg/dL</h5> <p>Ziprasidone was associated with significantly less cholesterol increase than quetiapine (2 RCTs, n = 754, MD 16.01, CI 8.57 to 23.46; <a href="./references#CD006625-fig-00614" title="">Analysis 6.14</a>). </p> </section> <section id="CD006625-sec4-0157"> <h5 class="title">6.15 Adverse effects: 7b. Metabolic ‐ glucose ‐ mean change from baseline in mg/dL</h5> <p>No significant difference was noted (2 RCTs, n = 754, MD 3.1, CI ‐3.99 to 10.19; <a href="./references#CD006625-fig-00615" title="">Analysis 6.15</a>). </p> </section> <section id="CD006625-sec4-0158"> <h5 class="title">6.16 Adverse effects: 7c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value</h5> <p>No significant difference was noted (1 RCT, n = 522, RR 0.64, CI 0.3 to 1.36; <a href="./references#CD006625-fig-00616" title="">Analysis 6.16</a>). </p> </section> <section id="CD006625-sec4-0159"> <h5 class="title">6.17 Adverse effects: 7d. Metabolic ‐ weight gain ‐ number of participants with weight gain of 7% or more of total body weight </h5> <p>Significantly more participants in the quetiapine group than in the ziprasidone group gained weight (2 RCTs, n = 754, RR 2.22, CI 1.35 to 3.63; <a href="./references#CD006625-fig-00617" title="">Analysis 6.17</a>). </p> </section> <section id="CD006625-sec4-0160"> <h5 class="title">6.18 Adverse effects: 7e. Metabolic ‐ weight gain ‐ change from baseline in kilograms</h5> <p>A superiority of ziprasidone almost reached statistical significance (1 RCT, n = 466, MD 1.2, CI ‐0.05 to 2.45; <a href="./references#CD006625-fig-00618" title="">Analysis 6.18</a>). </p> </section> <section id="CD006625-sec4-0161"> <h5 class="title">6.19 Publication bias</h5> <p>Because of the small number of included studies, we did not perform a funnel plot analysis. </p> </section> <section id="CD006625-sec4-0162"> <h5 class="title">6.20 Investigation for heterogeneity and sensitivity analysis</h5> <p>The reasons for the preplanned sensitivity analysis did not apply; therefore it was not performed. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006625-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006625-sec1-0006"></div> <section id="CD006625-sec2-0011"> <h3 class="title" id="CD006625-sec2-0011">Summary of main results</h3> <section id="CD006625-sec3-0032"> <h4 class="title">General</h4> <p>This analysis of the effects of quetiapine compared with other second‐generation antipsychotic drugs in the treatment of schizophrenia currently includes 37 studies reporting data on only six of nine possible comparisons. High discontinuation rates (overall 50.2%) limit the value of findings. In addition, 26 of the 37 included studies randomly assigned fewer than 100 people. The duration of the trials was usually short, and we identified only two long‐term studies. Short‐term trials are not ideal for judging the efficacy and tolerability of treatments for a chronic disease. Eighteen of the 37 studies were sponsored by a pharmaceutical industry with a clear pecuniary interest in the result. This is likely to be a further problem. </p> </section> <section id="CD006625-sec3-0033"> <h4 class="title">1. Comparison 1. QUETIAPINE versus ARIPIPRIZOLE</h4> <p>Four small short‐term studies with a total of 293 participants fell into this comparison. Data were available for only one study for a number of outcomes. Please see <a href="./full#CD006625-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD006625-sec4-0163"> <h5 class="title">1.1 Leaving the studies early</h5> <p>The overall rate of participants leaving studies early was 19.5%, with no clear difference between groups. However, this finding was based on only two small, short‐term trials, limiting interpretation (<a href="./references#CD006625-fig-00101" title="">Analysis 1.1</a>). </p> </section> <section id="CD006625-sec4-0164"> <h5 class="title">1.2 Efficacy outcomes (overall and specific mental state)</h5> <p>Four studies of low‐quality evidence found no significant difference in general mental state, positive symptoms or negative symptoms. Data from all studies measuring efficacy were potentially skewed and should be interpreted with caution (<a href="./references#CD006625-fig-00102" title="">Analysis 1.2</a>; <a href="./references#CD006625-fig-00103" title="">Analysis 1.3</a>; <a href="./references#CD006625-fig-00104" title="">Analysis 1.4</a>). </p> </section> <section id="CD006625-sec4-0165"> <h5 class="title">1.3 Adverse effects</h5> <p>We found limited data on ‘at least one adverse effect’ (<a href="./references#CD006625-fig-00106" title="">Analysis 1.6</a>), cardiac effects (<a href="./references#CD006625-fig-00107" title="">Analysis 1.7</a>), extrapyramidal symptoms (<a href="./references#CD006625-fig-00109" title="">Analysis 1.9</a>) and weight gain (<a href="./references#CD006625-fig-00111" title="">Analysis 1.11</a>;<a href="./references#CD006625-fig-00112" title="">Analysis 1.12</a>), showing no significant difference between quetiapine and aripiprazole. </p> </section> <section id="CD006625-sec4-0166"> <h5 class="title">1.4 Quality of life</h5> <p>Quality of life was not measured and was not reported in these studies.</p> </section> </section> <section id="CD006625-sec3-0034"> <h4 class="title">2. Comparison 2. QUETIAPINE versus CLOZAPINE</h4> <p>Five studies with a total of 334 participants fell into this comparison. Please see <a href="./full#CD006625-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD006625-sec4-0167"> <h5 class="title">2.1 Leaving the studies early</h5> <p>The overall rate of participants leaving studies early was remarkably low (8.4%) and showed no clear difference between groups. Nevertheless, this finding was based on only two small (n = 135), short‐term trials, limiting any interpretation (<a href="./references#CD006625-fig-00201" title="">Analysis 2.1</a>). </p> </section> <section id="CD006625-sec4-0168"> <h5 class="title">2.2 Efficacy outcomes (global state, overall and specific mental state)</h5> <p>No significant difference was noted in global state, general mental state or positive symptoms on the basis of studies of low‐quality evidence (<a href="./references#CD006625-fig-00204" title="">Analysis 2.4</a>; <a href="./references#CD006625-fig-00205" title="">Analysis 2.5</a>; <a href="./references#CD006625-fig-00206" title="">Analysis 2.6</a>; <a href="./references#CD006625-fig-00207" title="">Analysis 2.7</a>; <a href="./references#CD006625-fig-00209" title="">Analysis 2.9</a>; <a href="./references#CD006625-fig-00208" title="">Analysis 2.8</a>; <a href="./references#CD006625-fig-00210" title="">Analysis 2.10</a>). A small reduction in negative symptoms was noted in those taking quetiapine, but this result must be interpreted with caution, as it was based on two small trials with low‐quality evidence (<a href="./references#CD006625-bbs2-0104" title="LiX , LaoG , CaoL . Comparison of efficacy and safety of seroquel and resperidone in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science2003;12(1):45‐6. ">Li 2003b</a>; <a href="./references#CD006625-bbs2-0106" title="LiG , ChenQ‐G , ZhangQ‐H . A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia. Chinese Journal of Behavioral Medical Science2005;14(11):1007‐8, 1036. ">Li 2005b</a>). </p> </section> <section id="CD006625-sec4-0169"> <h5 class="title">2.3 Adverse effects</h5> <p>We found limited data on ‘at least one adverse effect’ (<a href="./references#CD006625-fig-00211" title="">Analysis 2.11</a>), cardiac effects (<a href="./references#CD006625-fig-00212" title="">Analysis 2.12</a>), sedation (<a href="./references#CD006625-fig-00213" title="">Analysis 2.13</a>), extrapyramidal symptoms (<a href="./references#CD006625-fig-00214" title="">Analysis 2.14</a>), white blood cell count (<a href="./references#CD006625-fig-00215" title="">Analysis 2.15</a>) and weight gain (<a href="./references#CD006625-fig-00216" title="">Analysis 2.16</a>; <a href="./references#CD006625-fig-00217" title="">Analysis 2.17</a>). Results on ‘at least one adverse effect’, cardiac effects and sedation indicated an advantage for quetiapine. These findings were based on only one or two studies; therefore, they cannot be considered to be robust. </p> </section> <section id="CD006625-sec4-0170"> <h5 class="title">2.4 Quality of life</h5> <p>Quality of life was not measured and was not reported in these studies.</p> </section> </section> <section id="CD006625-sec3-0035"> <h4 class="title">3. Comparison 3. QUETIAPINE versus OLANZAPINE</h4> <p>Most of the studies included in the review contributed data to this comparison (14 studies, n = 1953) (<a href="./full#CD006625-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD006625-sec4-0171"> <h5 class="title">3.1 Leaving the studies early</h5> <p>Fewer people in the olanzapine group compared with the quetiapine group left studies early for ‘any reason’ or because of ‘inefficacy of treatment’. This finding suggests that olanzapine is a more acceptable treatment than quetiapine, at least in the confines of clinical trials. Nevertheless, the overall rate of premature study discontinuations was high (61.7%), limiting the validity of all other results (<a href="./references#CD006625-fig-00301" title="">Analysis 3.1</a>). </p> </section> <section id="CD006625-sec4-0172"> <h5 class="title">3.2 Efficacy outcomes (global state, overall and specific mental state)</h5> <p>Quetiapine is probably slightly less effective than olanzapine in reducing general mental state symptoms according to studies of moderate‐quality evidence (<a href="./references#CD006625-fig-00304" title="">Analysis 3.4</a>; <a href="./references#CD006625-fig-00305" title="">Analysis 3.5</a>). No significant difference was noted in the reduction of negative symptoms or positive symptoms (<a href="./references#CD006625-fig-00306" title="">Analysis 3.6</a>; <a href="./references#CD006625-fig-00307" title="">Analysis 3.7</a>; <a href="./references#CD006625-fig-00308" title="">Analysis 3.8</a>; <a href="./references#CD006625-fig-00309" title="">Analysis 3.9</a>; <a href="./references#CD006625-fig-00310" title="">Analysis 3.10</a>; <a href="./references#CD006625-fig-00311" title="">Analysis 3.11</a>; <a href="./references#CD006625-fig-00312" title="">Analysis 3.12</a>). The latter findings should be interpreted with caution; studies measuring negative and positive symptoms were of low and very low quality, respectively. </p> </section> <section id="CD006625-sec4-0173"> <h5 class="title">3.3 Service use: number of participants re‐hospitalised</h5> <p>The number of participants re‐hospitalised was significantly higher in the quetiapine group (<a href="./references#CD006625-fig-00315" title="">Analysis 3.15</a>). This may reflect a certain efficacy advantage of olanzapine. </p> </section> <section id="CD006625-sec4-0174"> <h5 class="title">3.4 Adverse effects</h5> <p>Adverse effects were reported as at least one adverse effect, cardiac effects, QTc abnormalities and an increase in serum cholesterol, serum glucose and serum prolactin, as well as associated side effects, death, extrapyramidal symptoms, the occurrence of sedation, seizures and weight gain. Among these adverse effects, a benefit for quetiapine was found for the use of antiparkinson medication (a proxy measure for extrapyramidal adverse effects; <a href="./references#CD006625-fig-00322" title="">Analysis 3.22</a>), weight gain (<a href="./references#CD006625-fig-00330" title="">Analysis 3.30</a>; <a href="./references#CD006625-fig-00331" title="">Analysis 3.31</a>), glucose elevation (<a href="./references#CD006625-fig-00328" title="">Analysis 3.28</a>; <a href="./references#CD006625-fig-00329" title="">Analysis 3.29</a>), prolactin increase (<a href="./references#CD006625-fig-00325" title="">Analysis 3.25</a>) and some prolactin‐associated adverse effects. On the other hand, a certain superiority of olanzapine was noted in terms of QTc prolongation (<a href="./references#CD006625-fig-00318" title="">Analysis 3.18</a>). Overall, it seems that quetiapine may be more tolerable than olanzapine, but this is weighed against slightly less efficacy. </p> </section> <section id="CD006625-sec4-0175"> <h5 class="title">3.5 General functioning and quality of life</h5> <p>Very limited data on these important outcomes are available. Olanzapine may improve general functioning (GAF total score) to a greater extent than quetiapine (<a href="./references#CD006625-fig-00313" title="">Analysis 3.13</a>). One study of moderate quality reported no difference in quality of life measures between olanzapine and quetiapine (<a href="./references#CD006625-fig-00314" title="">Analysis 3.14</a>). </p> </section> </section> <section id="CD006625-sec3-0036"> <h4 class="title">4. Comparison 4. QUETIAPINE versus PALIPERIDONE</h4> <p>Only two studies (<a href="./references#CD006625-bbs2-0004" title="CanusoC , CarothersJ , DirksB , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3‐6, 2008. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia. Schizophrenia Research2008;98:158‐9. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3‐7, 2007. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress, Orlando, FL, October 11‐14, 2007. CanusoCM , DirksB , CarothersScD , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Randomized, double‐blind, placebo‐controlled study of paliperidone extended‐release and quetiapine in inpatients with recently exacerbated schizophrenia. American Journal of Psychiatry2009;AiA:1‐11. ">Canuso 2008</a>; <a href="./references#CD006625-bbs2-0007" title="EerdekensM , KramerM , CletonA , VanderboschA , NatarajanJ , EarnestJ , et al. Proceedings of the 20th European College of Neuropsychopharmacology, Vienna, Austria, October 13‐17, 2007. HoughDW , NatarajanJ , VandeboschA , RossenuS , KramerM , EerdekensM . Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;0(0):1‐10. . ">Eerdekens 2007</a>) with 406 participants provided data on this comparison. Eerdekens contributed only to adverse effects outcomes. Both studies were short term and were sponsored by the manufacturers of paliperidone. Please see <a href="./full#CD006625-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD006625-sec4-0176"> <h5 class="title">4.1 Leaving the studies early</h5> <p>The overall number of participants leaving the studies early was relatively low compared with other comparisons (14.0%). No significant difference was reported between groups or for reasons why participants left the studies (<a href="./references#CD006625-fig-00401" title="">Analysis 4.1</a>).  </p> </section> <section id="CD006625-sec4-0177"> <h5 class="title">4.2 Efficacy outcomes (global state, overall and specific mental state)</h5> <p>Paliperidone showed better efficacy than quetiapine in improving the overall mental state score and in reducing positive and negative symptoms (<a href="./references#CD006625-fig-00402" title="">Analysis 4.2</a>; <a href="./references#CD006625-fig-00403" title="">Analysis 4.3</a>; <a href="./references#CD006625-fig-00404" title="">Analysis 4.4</a>). However, this finding was based on only one small, short‐term trial, thus limiting interpretation. </p> </section> <section id="CD006625-sec4-0178"> <h5 class="title">4.3 Adverse effects</h5> <p>In one small study, more participants reported at least one side effect while taking quetiapine compared with paliperidone (<a href="./references#CD006625-fig-00405" title="">Analysis 4.5</a>). However, the <a href="./references#CD006625-bbs2-0004" title="CanusoC , CarothersJ , DirksB , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3‐6, 2008. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia. Schizophrenia Research2008;98:158‐9. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3‐7, 2007. CanusoC , DirksB , CarothersJ , ZhuY , Kosik‐GonzalezC . A double‐blind, placebo‐controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia. Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress, Orlando, FL, October 11‐14, 2007. CanusoCM , DirksB , CarothersScD , Kosik‐GonzalezC , BossieCA , ZhuY , et al. Randomized, double‐blind, placebo‐controlled study of paliperidone extended‐release and quetiapine in inpatients with recently exacerbated schizophrenia. American Journal of Psychiatry2009;AiA:1‐11. ">Canuso 2008</a> study showed an advantage of quetiapine in terms of parkinsonian side effects, prolactin levels, sexual side effects and weight gain. Further studies are required to clarify the differences in adverse effect profiles between these two medications.  </p> </section> </section> <section id="CD006625-sec3-0037"> <h4 class="title">5. Comparison 5. QUETIAPINE versus RISPERIDONE</h4> <p>Nineteen studies including 3123 participants met the inclusion criteria for this comparison. Please see <a href="./full#CD006625-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD006625-sec4-0179"> <h5 class="title">5.1 Leaving the studies early</h5> <p>No clear difference was evident in the number of participants leaving the studies early, suggesting a similar overall acceptability of quetiapine and risperidone (<a href="./references#CD006625-fig-00501" title="">Analysis 5.1</a>). Nevertheless, the overall discontinuation rate was high (51.8%), thus limiting the interpretation of all other results. </p> </section> <section id="CD006625-sec4-0180"> <h5 class="title">5.2 Efficacy outcomes (global state, overall and specific mental state)</h5> <p>Differences in efficacy were found for the general mental state, positive symptoms and, on exclusion of an outlier, negative symptoms (<a href="./references#CD006625-fig-00504" title="">Analysis 5.4</a>; <a href="./references#CD006625-fig-00505" title="">Analysis 5.5</a>; <a href="./references#CD006625-fig-00506" title="">Analysis 5.6</a>; <a href="./references#CD006625-fig-00507" title="">Analysis 5.7</a>; <a href="./references#CD006625-fig-00508" title="">Analysis 5.8</a>; <a href="./references#CD006625-fig-00509" title="">Analysis 5.9</a>; <a href="./references#CD006625-fig-00510" title="">Analysis 5.10</a>; <a href="./references#CD006625-fig-00511" title="">Analysis 5.11</a>; <a href="./references#CD006625-fig-00512" title="">Analysis 5.12</a>; <a href="./references#CD006625-fig-00513" title="">Analysis 5.13</a>). Quetiapine was less effective than risperidone in these aspects of psychopathology. Nevertheless, the differences were small (e.g. only three points on the PANSS total score). </p> </section> <section id="CD006625-sec4-0181"> <h5 class="title">5.3 Adverse effects</h5> <p>Adverse effects were reported as at least one adverse effect, cardiac effects, cholesterol increase, changes in serum glucose, increase in prolactin level and associated side effects, death, extrapyramidal adverse effects, sedation, weight gain and white blood cell count. Among these, quetiapine was better than risperidone in various measures of extrapyramidal adverse effects (<a href="./references#CD006625-fig-00521" title="">Analysis 5.21</a>; <a href="./references#CD006625-fig-00522" title="">Analysis 5.22</a>) and prolactin‐associated effects (<a href="./references#CD006625-fig-00524" title="">Analysis 5.24</a>; <a href="./references#CD006625-fig-00525" title="">Analysis 5.25</a>). On the other hand, quetiapine was associated with increased sedation (<a href="./references#CD006625-fig-00520" title="">Analysis 5.20</a>) and cholesterol (<a href="./references#CD006625-fig-00526" title="">Analysis 5.26</a>; <a href="./references#CD006625-fig-00527" title="">Analysis 5.27</a>) compared with risperidone. These differences in the adverse effect profile and the slightly lower efficacy of quetiapine may be weighed in drug selection. </p> </section> <section id="CD006625-sec4-0182"> <h5 class="title">5.4 Quality of life</h5> <p>Three studies of moderate quality assessed quality of life (<a href="./references#CD006625-fig-00514" title="">Analysis 5.14</a>). Participants treated with quetiapine reported significantly higher quality of life scores than those treated with risperidone. </p> </section> </section> <section id="CD006625-sec3-0038"> <h4 class="title">6. Comparison 6. QUETIAPINE versus ZIPRASIDONE</h4> <p>Only two studies with 722 participants provided data on this comparison. Please see <a href="./full#CD006625-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD006625-sec4-0183"> <h5 class="title">6.1 Leaving the studies early</h5> <p>The overall number of participants leaving the studies early was very high (80.7%), clearly limiting the interpretation of any findings beyond the outcome of ‘leaving the study early’. No significant difference was noted between groups, but the acceptability of both compounds seems to be poor (<a href="./references#CD006625-fig-00601" title="">Analysis 6.1</a>). </p> </section> <section id="CD006625-sec4-0184"> <h5 class="title">6.2 Efficacy outcomes (global state, overall and specific mental state)</h5> <p>No significant difference in global state, general mental state or positive symptoms was noted in studies with evidence of very low (general state) or low (positive and negative symptoms) quality (<a href="./references#CD006625-fig-00602" title="">Analysis 6.2</a>; <a href="./references#CD006625-fig-00603" title="">Analysis 6.3</a>; <a href="./references#CD006625-fig-00604" title="">Analysis 6.4</a>). </p> </section> <section id="CD006625-sec4-0185"> <h5 class="title">6.3 Adverse effects</h5> <p>Adverse effects were reported as at least one adverse effect; cardiac effects; death; extrapyramidal side effects; changes in cholesterol, glucose and prolactin; the occurrence of sedation and weight gain. Quetiapine was advantageous in the use of antiparkinson medication (one study, low‐quality evidence; <a href="./references#CD006625-fig-00611" title="">Analysis 6.11</a>) and for prolactin levels (two studies, moderate‐quality evidence; <a href="./references#CD006625-fig-00612" title="">Analysis 6.12</a>; <a href="./references#CD006625-fig-00613" title="">Analysis 6.13</a>), and two studies with moderate‐quality evidence favoured ziprasidone for weight gain (<a href="./references#CD006625-fig-00617" title="">Analysis 6.17</a>; <a href="./references#CD006625-fig-00618" title="">Analysis 6.18</a>) and sedation (<a href="./references#CD006625-fig-00610" title="">Analysis 6.10</a>). </p> </section> <section id="CD006625-sec4-0186"> <h5 class="title">6.4 Quality of life</h5> <p>Quality of life was not measured in these studies.</p> </section> </section> </section> <section id="CD006625-sec2-0012"> <h3 class="title" id="CD006625-sec2-0012">Overall completeness and applicability of evidence</h3> <p>We did not identify a single study for almost half of the possible comparisons of quetiapine with other second‐generation antipsychotic drugs. Evidence, therefore, is incomplete. Only two studies were long term, limiting applicability of the evidence, as, after all, schizophrenia is a chronic, often lifelong, disorder. Furthermore, most of the included studies were efficacy studies; therefore external validity is limited, and further effectiveness (pragmatic/real‐world) studies are needed. </p> </section> <section id="CD006625-sec2-0013"> <h3 class="title" id="CD006625-sec2-0013">Quality of the evidence</h3> <p>All studies were randomised and at least single‐blind, but details were rarely presented. Therefore it is unclear in almost all studies whether randomisation and blinding were really done appropriately. Furthermore, the high numbers of participants leaving the studies early (overall 50.2%) and the small number of long‐term studies (<a href="./references#CD006625-bbs2-0014" title="* Lieberman JA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353(12):1209‐23. ChwastiakLA , RosenheckRA , McEvoyJP , StroupTS , SwartzMS , DavisSM , et al. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry2009;31:1‐9. DaumitGL , GoffDC , MeyerJM , DavisVG , NasrallahHA , McEvoyJP , et al. Antipsychotic effects on estimated 10‐year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105:178‐87. KeefeRSE , BilderRM , DavisSM , HarveyPD , PalmerBW , GoldJM , et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry2007;64:633‐47. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. MeyerJM , DavisVG , McEvoyJP , GoffDC , NasrallahHA , DavisSM , et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research2008;103:104‐9. MeyerJM , McEvoyJP , DavisVG , GoffDC , NasrallahHA , DavisSM , et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry2006;66:1013‐22. MeyerJM , NasrallahHA , McEvoyJP , GoffDC , DavisSM , ChakosM , et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research2005;80:9‐18. MillerDD , CaroffSN , DavisSM , RosenheckRA , McEvoyJP , SaltzBL , et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. The British Journal of Psychiatry2008;193:279‐88. MillerDD , McEvoyJP , DavisSM , CaroffSN , SaltzBL , ChakosMH , et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research2005;80:33‐43. MohamedS , RosenheckR , McEvoyJ , SwartzM , StroupS , LiebermanJA . Cross‐sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin2009;35(2):336‐46. MohamedS , RosenheckR , SwartzM , StroupS , LiebermanJA , KeefeRSE . Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry2008;165:978‐87. NasrallahHA . Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrum2006;11(7 Suppl 7):32‐9. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PennDL , KeefeRSE , DavisSM , MeyerPS , PerkinsDO , LosardoD , et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research2009;115:17‐23. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. PerlickDA , RosenheckRA , KaczynskiR , SwartzMS , CaniveJM , LiebermanJA . Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research2010;116:118‐25. ResnickSG , RosenheckRA , CaniveJM , SouzaCD , StroupTS , McEvoyJ , et al. Employment outcomes in a randomised trial of second‐generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research2008;35(2):215‐25. RosenheckRA , DavisS , CovellN , EssockS , SwartzM , StroupS , et al. Data from the CATIE Trial. Schizophrenia Research2009;107:22‐9. RosenheckRA , DavisVG , DavisSM , StroupS , McEvoyJ , SwartzM , et al. The CATIE schizophrenia trial. Schizophrenia Research2009;113:12‐8. StroupS , AppelbaumP , SwartzM , PatelM , DavisS , JesteD , et al. Decision‐making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research2005;80:1‐8. StroupTS , LiebermanJA , McEvoyJP , DavisSM , SwartzMS , KeefeRSE , et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research2009;107:1‐12. SwansonJW , SwartzMS , vanDornRA , VolavkaJ , MonahanJ , StroupTS , et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry2008;193:37‐43. SwartzMS , PerkinsDO , StroupTS , DavisSM , CapuanoG , RosenheckRA , et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry2007;164:428‐36. SwartzMS , StroupTS , McEvoyJP , DavisSM , RosenheckRA , KeefeRSE , et al. What CATIE found: results from the schizophrenia trial. Psychiatric Services2008;59(5):500‐6. SwartzMS , WagnerHR , SwansonJW , StroupTS , McEvoyJP , ReimherrF , et al. The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study. Schizophrenia Research2008;100:39‐52. ">Lieberman 2005</a>; <a href="./references#CD006625-bbs2-0019" title="KeefeR , GuH , SweeneyJ , PerkinsD , McEvoyJ , HamerR , LiebermanJ . A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first‐episode psychosis. Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11‐15, 2005. KeefeRSE , GuH , SweeneyJA , PerkinsDO , McEvoyJP , HamerRM , LiebermanJA . The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first‐episode psychosis: a double‐blind 52‐week comparison. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. KeefeRSE , SweeneyJA , GuH , HamerRM , PerkinsDO , McEvoyJP , et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1061‐71. LiebermanJ , McEvoyJP , PerkinsD , HamerRH . Comparison of atypicals in first‐episode psychosis: a randomized, 52‐week comparison of olanzapine, quetiapine, and risperidone. Journal of the European College of Neuropsychopharmacology2005;15(Suppl 3):S525. McEvoyJP . Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20‐25, 2006, Toronto, Canada. McEvoyJP , LiebermanJA , PerkinsDO , HamerRM , GuH , LazarusA , et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double‐blind 52‐week comparison. American Journal of Psychiatry2007;164:1050‐60. McEvoyJP , PerkinsDO , GuH , HamerRM , LiebermanJA . Clinical effectiveness and predictors of treatment non‐adherence: comparison of olanzapine, quetiapine, and risperidone in first‐episode psychosis. Schizophrenia Research2006;86(Suppl 1):S130. PatelJK , BuckleyPF , WoolsonS , HamerRM , McEvoyJP , PerkinsDO , et al. Metabolic profiles of second‐generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophrenia Research2009;111:9‐16. PerkinsDO , GuH , WeidenPJ , McEVoyJP , HamerRM , LiebermanJA . Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double‐blind, flexible‐dose, multicenter study. J Clin Psychiatry2008;69(1):106‐13. ">McEvoy 2007</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>) call the validity of the findings into question. Selective reporting was evident in all but five studies, and thirteen studies were sponsored by an industry with considerable pecuniary interest in the results. All these factors limit the quality of the evidence. </p> </section> <section id="CD006625-sec2-0014"> <h3 class="title" id="CD006625-sec2-0014">Potential biases in the review process</h3> <p>We are aware of flaws in our review process. We are unclear whether or not these have add biases to the review. </p> <p> <ul id="CD006625-lst1-0001"> <li> <p>First: The search took place some time ago. This review has been a considerable undertaking, and its expansion and upgrading have taken time. We are aware that more trials are likely to be available, and we do hope to update swiftly. </p> </li> <li> <p>Second: We have excluded studies that are not fully blinded. This excludes many trials. On one hand, by doing this we have attempted to find trials that have taken some precautions against performance bias and detection bias. On the other hand, however, we have not made judgements to suggest that this has really been successful (and from the profile of adverse effects, this seems unlikely). In addition, quetiapine or the control drugs are not given blindly in the real world. The intervention in everyday care is not solely prescription of the drug, it is open giving of the drug with potential biases surrounding that open giving. This review, therefore, attempts to summarise the more explanatory studies (<a href="./references#CD006625-bbs2-0287" title="ThorpeKE , ZwarensteinM , OxmanAD , TreweekS , FurbergCD , AltmanDG , et al. A pragmatic‐explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology2009;62(5):464‐75. [PUBMED: 19348971] ">Thorpe 2009</a>) by providing their advantages, drawbacks and potential biases. </p> </li> </ul> </p> </section> <section id="CD006625-sec2-0015"> <h3 class="title" id="CD006625-sec2-0015">Agreements and disagreements with other studies or reviews</h3> <p>This update substantially expands the earlier version (<a href="./references#CD006625-bbs2-0290" title="KomossaK , Rummel‐KlugeC , SchmidF , HungerH , SchwarzS , SrisurapanontM , KisslingW , LeuchtS . Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: DOI:10.1002/14651858.CD006625.pub2.] ">Komossa 2009</a>). However, generally its findings are consistent with findings from previous versions. </p> <p>A previous Cochrane review compared the effects of quetiapine with those of placebo, first‐generation antipsychotic drugs and second‐generation antipsychotic drugs for schizophrenia (<a href="./references#CD006625-bbs2-0286" title="SrisurapanontM , ManeetonB , ManeetonN . Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 2. [DOI: CD000967] ">Srisurasapont 2004</a>). A single study fell into the last category and compared quetiapine with risperidone. This update with reformatting of the review has identified many new studies, and the data included are far more comprehensive than those provided previously. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006625-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Quetiapine." data-id="CD006625-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Quetiapine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006625-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006625-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD006625-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 1 Leaving the study early." data-id="CD006625-fig-00101" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 1 Leaving the study early.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 2 Mental state: 1. General ‐ average endpoint score (PANSS total, high=poor)." data-id="CD006625-fig-00102" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 2 Mental state: 1. General ‐ average endpoint score (PANSS total, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 3 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor)." data-id="CD006625-fig-00103" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 3 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 4 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor)." data-id="CD006625-fig-00104" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 4 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 5 General functioning: General ‐ average endpoint score ‐ medium term (GAF total score, high=poor." data-id="CD006625-fig-00105" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 5 General functioning: General ‐ average endpoint score ‐ medium term (GAF total score, high=poor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 6 Adverse effects: 1. General ‐ at least one adverse effect." data-id="CD006625-fig-00106" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 6 Adverse effects: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 7 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation." data-id="CD006625-fig-00107" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 7 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 8 Adverse effects: 2b. Cardiac effects ‐ Tachycardia." data-id="CD006625-fig-00108" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 8 Adverse effects: 2b. Cardiac effects ‐ Tachycardia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 9 Adverse effects: 3a. Extrapyramidal effects." data-id="CD006625-fig-00109" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 9 Adverse effects: 3a. Extrapyramidal effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 10 Adverse effects: 4a. Prolactin associated side effects." data-id="CD006625-fig-00110" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 10 Adverse effects: 4a. Prolactin associated side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 11 Adverse effects: 5a. Metabolic ‐ weight gain of 7% or more of total body weight." data-id="CD006625-fig-00111" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 11 Adverse effects: 5a. Metabolic ‐ weight gain of 7% or more of total body weight. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 12 Adverse effects. 5b. Metabolic ‐ weight gain ‐ change from baseline in kg." data-id="CD006625-fig-00112" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 12 Adverse effects. 5b. Metabolic ‐ weight gain ‐ change from baseline in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 13 Adverse effects: 5c. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl." data-id="CD006625-fig-00113" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 13 Adverse effects: 5c. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 14 Adverse effects: 5d. Metabolic ‐ glucose ‐ change from baseline in mg/dl." data-id="CD006625-fig-00114" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 14 Adverse effects: 5d. Metabolic ‐ glucose ‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 15 Adverse effects: 6. Death  ." data-id="CD006625-fig-00115" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 QUETIAPINE versus ARIPIPRAZOLE, Outcome 15 Adverse effects: 6. Death  .</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 1 Leaving the study early." data-id="CD006625-fig-00201" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 1 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 2 Global state: 1a. No clinically significant response (as defined by original studies)." data-id="CD006625-fig-00202" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 2 Global state: 1a. No clinically significant response (as defined by original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 3 Global state: 1b. No clinically important change ‐ short term (as measured by CGI)." data-id="CD006625-fig-00203" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 3 Global state: 1b. No clinically important change ‐ short term (as measured by CGI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 4 Mental state: 1a. General ‐ no clinically important change ‐ short term (less than 50% PANSS total score reduction)." data-id="CD006625-fig-00204" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 4 Mental state: 1a. General ‐ no clinically important change ‐ short term (less than 50% PANSS total score reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 5 Mental state: 1b. General ‐ average endpoint score ‐ short term (PANSS total, high=poor)." data-id="CD006625-fig-00205" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 5 Mental state: 1b. General ‐ average endpoint score ‐ short term (PANSS total, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 6 Mental state: 1c. General ‐ average endpoint score ‐ short term (BPRS total, high=poor)." data-id="CD006625-fig-00206" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 6 Mental state: 1c. General ‐ average endpoint score ‐ short term (BPRS total, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 7 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor)." data-id="CD006625-fig-00207" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 7 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 8 Mental state: 3a. Negative symptoms ‐ average endpoint score ‐ short term (PANSS negative subscore, high=poor)." data-id="CD006625-fig-00208" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 8 Mental state: 3a. Negative symptoms ‐ average endpoint score ‐ short term (PANSS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 9 Mental state: 3b. Negative symptoms ‐ no clinically important change ‐ short term (less than 50% SANS total score reduction)." data-id="CD006625-fig-00209" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 9 Mental state: 3b. Negative symptoms ‐ no clinically important change ‐ short term (less than 50% SANS total score reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 10 Mental state: 3c. Negative symptoms ‐ average endpoint score ‐ short term (SANS total, high=poor)." data-id="CD006625-fig-00210" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 10 Mental state: 3c. Negative symptoms ‐ average endpoint score ‐ short term (SANS total, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 11 Adverse effects: 1. General ‐ at least one adverse effect." data-id="CD006625-fig-00211" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 11 Adverse effects: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 12 Adverse effects: 2. Cardiac effects: ECG abnormalities." data-id="CD006625-fig-00212" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 12 Adverse effects: 2. Cardiac effects: ECG abnormalities. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 13 Adverse effects: 3. Central nervous system ‐ sedation." data-id="CD006625-fig-00213" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 13 Adverse effects: 3. Central nervous system ‐ sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 14 Adverse effects: 4. Extrapyramidal effects." data-id="CD006625-fig-00214" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 14 Adverse effects: 4. Extrapyramidal effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 15 Adverse effects: 5. Haematological: Important decline in white blood cells." data-id="CD006625-fig-00215" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 15 Adverse effects: 5. Haematological: Important decline in white blood cells. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 16 Adverse effects: 6a. Metabolic ‐ weight ‐ gain." data-id="CD006625-fig-00216" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 16 Adverse effects: 6a. Metabolic ‐ weight ‐ gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 17 Adverse effects: 6b. Metabolic ‐ weight ‐ change from baseline (kg)." data-id="CD006625-fig-00217" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 QUETIAPINE versus CLOZAPINE ‐ all data short term, Outcome 17 Adverse effects: 6b. Metabolic ‐ weight ‐ change from baseline (kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 1 Leaving the study early." data-id="CD006625-fig-00301" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 1 Leaving the study early.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 2 Global state: 1a. No clinically significant response (as defined by the original studies)." data-id="CD006625-fig-00302" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 2 Global state: 1a. No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00303"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 3 Global state: 1b. No clinically important change (as measured by CGI)." data-id="CD006625-fig-00303" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 3 Global state: 1b. No clinically important change (as measured by CGI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00303">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00304"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 4 Mental state: 1a. General ‐ no clinically important change ‐ short term (less than 50% PANSS total score reduction)." data-id="CD006625-fig-00304" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 4 Mental state: 1a. General ‐ no clinically important change ‐ short term (less than 50% PANSS total score reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00304">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00305"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 5 Mental state: 1b. General ‐ average endpoint score (PANSS total, high=poor)." data-id="CD006625-fig-00305" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 5 Mental state: 1b. General ‐ average endpoint score (PANSS total, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00305">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00306"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 6 Mental state: 2a. Positive symptoms ‐ no clinically important change ‐ short term (less than 20% SAPS total score reduction)." data-id="CD006625-fig-00306" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 6 Mental state: 2a. Positive symptoms ‐ no clinically important change ‐ short term (less than 20% SAPS total score reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00306">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00307"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 7 Mental state: 2b. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor)." data-id="CD006625-fig-00307" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 7 Mental state: 2b. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00307">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00308"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 8 Mental state: 2c. Positive symptoms ‐ SAPS total score ‐ percent change ‐ short term (high=poor)." data-id="CD006625-fig-00308" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 8 Mental state: 2c. Positive symptoms ‐ SAPS total score ‐ percent change ‐ short term (high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00308">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00309"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 9 Mental state: 3a. Negative symptoms ‐ no clinically important change ‐ short term (less than 20% SANS total score reduction)." data-id="CD006625-fig-00309" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 9 Mental state: 3a. Negative symptoms ‐ no clinically important change ‐ short term (less than 20% SANS total score reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00309">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00310"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 10 Mental state: 3b. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor)." data-id="CD006625-fig-00310" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 10 Mental state: 3b. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00310">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00311"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 11 Mental state: 3c. Negative symptoms ‐ average endpoint score ‐ medium term (SANS, high=poor)." data-id="CD006625-fig-00311" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 11 Mental state: 3c. Negative symptoms ‐ average endpoint score ‐ medium term (SANS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00311">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00312"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 12 Mental state: 3d. Negative symptoms ‐ average change in endpoint score ‐ short term (SANS, high=poor)." data-id="CD006625-fig-00312" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 12 Mental state: 3d. Negative symptoms ‐ average change in endpoint score ‐ short term (SANS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00312">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00313"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 13 General functioning: General ‐ average endpoint score ‐ medium term (GAF total score, low=poor)." data-id="CD006625-fig-00313" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 13 General functioning: General ‐ average endpoint score ‐ medium term (GAF total score, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00313">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00314"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 14 Quality of life: General ‐ average change in endpoint score ‐ medium term (QLS total score, low=poor)." data-id="CD006625-fig-00314" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 14 Quality of life: General ‐ average change in endpoint score ‐ medium term (QLS total score, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00314">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00315"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 15 Service use: 1. Number of participants re‐hospitalised." data-id="CD006625-fig-00315" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 15 Service use: 1. Number of participants re‐hospitalised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00315">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00316"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 16 Adverse effects: 1. General ‐ at least one adverse effect." data-id="CD006625-fig-00316" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 16 Adverse effects: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00316">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00317"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 17 Adverse effects: 2. Death." data-id="CD006625-fig-00317" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 17 Adverse effects: 2. Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00317">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00318"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 18 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation." data-id="CD006625-fig-00318" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 18 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00318">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00319"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 19 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms." data-id="CD006625-fig-00319" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 19 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00319">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00320"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 20 Adverse effects: 4a. Central nervous system ‐ sedation." data-id="CD006625-fig-00320" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 20 Adverse effects: 4a. Central nervous system ‐ sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00320">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00321"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 21 Adverse effects: 4b. Central nervous system ‐ seizures." data-id="CD006625-fig-00321" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 21 Adverse effects: 4b. Central nervous system ‐ seizures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00321">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00322"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 22 Adverse effects: 5a. Extrapyramidal effects." data-id="CD006625-fig-00322" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 22 Adverse effects: 5a. Extrapyramidal effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00322">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00323"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 23 Adverse effects: 5b. Extrapyramidal effects ‐ scale measured." data-id="CD006625-fig-00323" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 23 Adverse effects: 5b. Extrapyramidal effects ‐ scale measured. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00323">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00324"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 24 Adverse effects: 6a. Prolactin associated side effects." data-id="CD006625-fig-00324" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 24 Adverse effects: 6a. Prolactin associated side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00324">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00325"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 25 Adverse effects: 6b. Prolactin ‐ change from baseline in ng/ml." data-id="CD006625-fig-00325" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 25 Adverse effects: 6b. Prolactin ‐ change from baseline in ng/ml. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00325">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00326"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 26 Adverse effects: 7a. Metabolic ‐ cholesterol ‐ significant cholesterol increase." data-id="CD006625-fig-00326" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 26 Adverse effects: 7a. Metabolic ‐ cholesterol ‐ significant cholesterol increase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00326">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00327"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 27 Adverse effects: 7b. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl." data-id="CD006625-fig-00327" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 27 Adverse effects: 7b. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00327">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00328"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 28 Adverse effects: 7c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value." data-id="CD006625-fig-00328" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 28 Adverse effects: 7c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00328">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00329"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 29 Adverse effects: 7d. Metabolic ‐ glucose ‐ change from baseline in mg/dl." data-id="CD006625-fig-00329" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 29 Adverse effects: 7d. Metabolic ‐ glucose ‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00329">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00330"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 30 Adverse effects: 7e. Metabolic ‐ weight ‐ gain." data-id="CD006625-fig-00330" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 30 Adverse effects: 7e. Metabolic ‐ weight ‐ gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00330">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00331"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-003-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-003-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 31 Adverse effects: 7f. Metabolic ‐ weight ‐ change from baseline in kg." data-id="CD006625-fig-00331" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.31</div> <div class="figure-caption"> <p>Comparison 3 QUETIAPINE versus OLANZAPINE, Outcome 31 Adverse effects: 7f. Metabolic ‐ weight ‐ change from baseline in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00331">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-003-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00401"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 1 Leaving the study early." data-id="CD006625-fig-00401" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 1 Leaving the study early.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00401">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00402"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 2 Mental state: 1. General ‐ average endpoint score (PANSS total, high=poor)." data-id="CD006625-fig-00402" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 2 Mental state: 1. General ‐ average endpoint score (PANSS total, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00402">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00403"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 3 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor)." data-id="CD006625-fig-00403" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 3 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00403">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00404"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 4 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor)." data-id="CD006625-fig-00404" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 4 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00404">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00405"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 5 Adverse effects: 1. General ‐ at least one adverse effect." data-id="CD006625-fig-00405" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 5 Adverse effects: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00405">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00406"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 6 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation." data-id="CD006625-fig-00406" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 6 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00406">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00407"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 7 Adverse effects: 2b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms." data-id="CD006625-fig-00407" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 7 Adverse effects: 2b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00407">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00408"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 8 Adverse effects: 3a. Extrapyramidal effects." data-id="CD006625-fig-00408" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 8 Adverse effects: 3a. Extrapyramidal effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00408">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00409"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 9 Adverse effects: 3b. Extrapyramidal effects ‐ scale measured." data-id="CD006625-fig-00409" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 9 Adverse effects: 3b. Extrapyramidal effects ‐ scale measured. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00409">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00410"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 10 Adverse effects: 4a. Prolactin associated effects." data-id="CD006625-fig-00410" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 10 Adverse effects: 4a. Prolactin associated effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00410">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00411"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 11 Adverse effects: 4b. Prolactin ‐ change from baseline in ng/ml." data-id="CD006625-fig-00411" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 11 Adverse effects: 4b. Prolactin ‐ change from baseline in ng/ml. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00411">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00412"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 12 Adverse effects: 5a. Metabolic ‐ weight gain ‐ change from baseline in kg." data-id="CD006625-fig-00412" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 12 Adverse effects: 5a. Metabolic ‐ weight gain ‐ change from baseline in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00412">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00413"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 13 Adverse effects: 5b. Metabolic ‐ weight gain of 7% or more of total body weight." data-id="CD006625-fig-00413" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 QUETIAPINE versus PALIPERIDONE, Outcome 13 Adverse effects: 5b. Metabolic ‐ weight gain of 7% or more of total body weight. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00413">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00501"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 1 Leaving the study early." data-id="CD006625-fig-00501" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 1 Leaving the study early.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00501">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00502"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 2 Global state: 1a. No clinically significant response (as defined by the original studies)." data-id="CD006625-fig-00502" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 2 Global state: 1a. No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00502">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00503"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 3 Global state: 1b. No clinically important change (as measured by CGI)." data-id="CD006625-fig-00503" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 3 Global state: 1b. No clinically important change (as measured by CGI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00503">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00504"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 4 Mental state: 1a General ‐ no clinically important change ‐ short term (less than 30% PANSS total score reduction)." data-id="CD006625-fig-00504" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 4 Mental state: 1a General ‐ no clinically important change ‐ short term (less than 30% PANSS total score reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00504">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00505"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 5 Mental state: 1b. General ‐ no clinically important change ‐ short term (less than 20% BPRS total score reduction)." data-id="CD006625-fig-00505" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 5 Mental state: 1b. General ‐ no clinically important change ‐ short term (less than 20% BPRS total score reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00505">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00506"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 6 Mental state: 1c. General ‐average endpoint score (PANSS total score, high=poor)." data-id="CD006625-fig-00506" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 6 Mental state: 1c. General ‐average endpoint score (PANSS total score, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00506">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00507"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 7 Mental state: 1d. General ‐ average endpoint score ‐ short term (BPRS total score, high=poor)." data-id="CD006625-fig-00507" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 7 Mental state: 1d. General ‐ average endpoint score ‐ short term (BPRS total score, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00507">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00508"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 8 Mental state: 2a. Positive symptoms ‐ no clinically important change ‐ short term (less than 40% PANSS positive reduction)." data-id="CD006625-fig-00508" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 8 Mental state: 2a. Positive symptoms ‐ no clinically important change ‐ short term (less than 40% PANSS positive reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00508">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00509"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 9 Mental state: 2b. Positive symptoms ‐ average endpoint score ‐ (PANSS positive subscore, high=poor)." data-id="CD006625-fig-00509" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 9 Mental state: 2b. Positive symptoms ‐ average endpoint score ‐ (PANSS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00509">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00510"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 10 Mental state: 2c. Positive symptoms ‐ average change in endpoint score ‐ short term (BPRS positive subscore, high=poor)." data-id="CD006625-fig-00510" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 10 Mental state: 2c. Positive symptoms ‐ average change in endpoint score ‐ short term (BPRS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00510">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00511"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 11 Mental state: 3a. Negative symptoms ‐ no clinically important change ‐ short term (less than 40% PANSS negative reduction)." data-id="CD006625-fig-00511" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 11 Mental state: 3a. Negative symptoms ‐ no clinically important change ‐ short term (less than 40% PANSS negative reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00511">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00512"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 12 Mental state: 3b. Negative symptoms ‐average endpoint score ‐ (PANSS negative subscore, high=poor)." data-id="CD006625-fig-00512" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 12 Mental state: 3b. Negative symptoms ‐average endpoint score ‐ (PANSS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00512">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00513"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 13 Mental state: 3c. Negative symptoms ‐ average change in endpoint score ‐ (BPRS negative subscore, high=poor)." data-id="CD006625-fig-00513" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 13 Mental state: 3c. Negative symptoms ‐ average change in endpoint score ‐ (BPRS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00513">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00514"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 14 Quality of life: General ‐ average endpoint score ‐ (QLS total score, low=poor)." data-id="CD006625-fig-00514" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 14 Quality of life: General ‐ average endpoint score ‐ (QLS total score, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00514">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00515"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 15 Service use: number of participants re‐hospitalised." data-id="CD006625-fig-00515" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 15 Service use: number of participants re‐hospitalised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00515">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00516"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 16 Adverse effects: 1. General ‐ at least one adverse effect." data-id="CD006625-fig-00516" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 16 Adverse effects: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00516">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00517"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 17 Adverse effects: 2. Death." data-id="CD006625-fig-00517" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 17 Adverse effects: 2. Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00517">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00518"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 18 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation." data-id="CD006625-fig-00518" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 18 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00518">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00519"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 19 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms." data-id="CD006625-fig-00519" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 19 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00519">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00520"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 20 Adverse effects: 4. Central nervous system ‐ sedation." data-id="CD006625-fig-00520" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 20 Adverse effects: 4. Central nervous system ‐ sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00520">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00521"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 21 Adverse effects: 5a. Extrapyramidal effects." data-id="CD006625-fig-00521" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 21 Adverse effects: 5a. Extrapyramidal effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00521">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00522"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 22 Adverse effects: 5b. Extrapyramidal effects ‐ scale measured ‐ endpoint/ change to endpoint score." data-id="CD006625-fig-00522" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 22 Adverse effects: 5b. Extrapyramidal effects ‐ scale measured ‐ endpoint/ change to endpoint score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00522">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00523"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 23 Adverse effects: 6. Haematological: important decline in white blood cells." data-id="CD006625-fig-00523" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 23 Adverse effects: 6. Haematological: important decline in white blood cells. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00523">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00524"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 24 Adverse effects: 7a. Prolactin associated side effects." data-id="CD006625-fig-00524" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 24 Adverse effects: 7a. Prolactin associated side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00524">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00525"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 25 Adverse effects: 7b. Prolactin ‐ change from baseline in mg/dl." data-id="CD006625-fig-00525" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 25 Adverse effects: 7b. Prolactin ‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00525">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00526"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 26 Adverse effects: 8a. Metabolic ‐ cholesterol ‐ significant cholesterol increase." data-id="CD006625-fig-00526" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.26</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 26 Adverse effects: 8a. Metabolic ‐ cholesterol ‐ significant cholesterol increase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00526">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00527"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 27 Adverse effects: 8b. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl." data-id="CD006625-fig-00527" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.27</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 27 Adverse effects: 8b. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00527">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00528"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 28 Adverse effects: 8c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value." data-id="CD006625-fig-00528" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.28</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 28 Adverse effects: 8c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00528">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00529"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 29 Adverse effects: 8d. Metabolic ‐ glucose ‐ change from baseline in mg/dl." data-id="CD006625-fig-00529" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.29</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 29 Adverse effects: 8d. Metabolic ‐ glucose ‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00529">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00530"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 30 Adverse effects: 8e. Metabolic ‐ weight gain of 7% or more of total body weight." data-id="CD006625-fig-00530" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.30</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 30 Adverse effects: 8e. Metabolic ‐ weight gain of 7% or more of total body weight. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00530">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00531"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-005-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-005-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 31 Adverse effects: 8f. Metabolic ‐ weight gain ‐ change from baseline in kg." data-id="CD006625-fig-00531" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.31</div> <div class="figure-caption"> <p>Comparison 5 QUETIAPINE versus RISPERIDONE, Outcome 31 Adverse effects: 8f. Metabolic ‐ weight gain ‐ change from baseline in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00531">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-005-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00601"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 1 Leaving the study early." data-id="CD006625-fig-00601" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 1 Leaving the study early.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00601">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00602"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 2 Mental state: 1. General ‐ average endpoint score (PANSS total score, high=poor)." data-id="CD006625-fig-00602" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 2 Mental state: 1. General ‐ average endpoint score (PANSS total score, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00602">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00603"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 3 Mental state: 2. Positive symptoms ‐ average endpoint score ‐ medium term (PANSS positive subscore, high=poor)." data-id="CD006625-fig-00603" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 3 Mental state: 2. Positive symptoms ‐ average endpoint score ‐ medium term (PANSS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00603">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00604"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 4 Mental state: 3. Negative symptoms ‐ average endpoint score ‐ medium term (PANSS negative subscore, high=poor)." data-id="CD006625-fig-00604" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 4 Mental state: 3. Negative symptoms ‐ average endpoint score ‐ medium term (PANSS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00604">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00605"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 5 Service use: number of participants re‐hospitalised." data-id="CD006625-fig-00605" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 5 Service use: number of participants re‐hospitalised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00605">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00606"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 6 Adverse effects: 1. General ‐ at least one adverse effect." data-id="CD006625-fig-00606" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 6 Adverse effects: 1. General ‐ at least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00606">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00607"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 7 Adverse effects: 2. Death." data-id="CD006625-fig-00607" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 7 Adverse effects: 2. Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00607">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00608"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 8 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation." data-id="CD006625-fig-00608" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 8 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00608">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00609"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 9 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms." data-id="CD006625-fig-00609" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 9 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00609">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00610"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 10 Adverse effects: 4. Central nervous system ‐ sedation." data-id="CD006625-fig-00610" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 10 Adverse effects: 4. Central nervous system ‐ sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00610">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00611"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 11 Adverse effects: 5. Extrapyramidal effects." data-id="CD006625-fig-00611" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 11 Adverse effects: 5. Extrapyramidal effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00611">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00612"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 12 Adverse effects: 6a. Prolactin associated effects." data-id="CD006625-fig-00612" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 12 Adverse effects: 6a. Prolactin associated effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00612">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00613"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 13 Adverse effects: 6b. Prolactin ‐ change from baseline in ng/ml." data-id="CD006625-fig-00613" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 13 Adverse effects: 6b. Prolactin ‐ change from baseline in ng/ml. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00613">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00614"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 14 Adverse effects: 7a. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl." data-id="CD006625-fig-00614" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 14 Adverse effects: 7a. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00614">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00615"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 15 Adverse effects: 7b. Metabolic ‐ glucose‐ change from baseline in mg/dl." data-id="CD006625-fig-00615" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 15 Adverse effects: 7b. Metabolic ‐ glucose‐ change from baseline in mg/dl. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00615">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00616"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 16 Adverse effects: 7c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value." data-id="CD006625-fig-00616" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 16 Adverse effects: 7c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00616">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00617"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 17 Adverse effects: 7d. Metabolic ‐ weight gain of 7% or more of total body weight." data-id="CD006625-fig-00617" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 17 Adverse effects: 7d. Metabolic ‐ weight gain of 7% or more of total body weight. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00617">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00618"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-006-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-006-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 18 Adverse effects: 7e. Metabolic ‐ weight gain ‐ change from baseline in kg." data-id="CD006625-fig-00618" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6 QUETIAPINE versus ZIPRASIDONE, Outcome 18 Adverse effects: 7e. Metabolic ‐ weight gain ‐ change from baseline in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00618">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-006-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00701"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 QUETIAPINE versus ARIPIPRAZOLE ‐ sensitivity analyses (skewed data excluded), Outcome 1 Mental state: 1. General ‐ average endpoint score ‐ short term (PANSS total, high=poor)." data-id="CD006625-fig-00701" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 QUETIAPINE versus ARIPIPRAZOLE ‐ sensitivity analyses (skewed data excluded), Outcome 1 Mental state: 1. General ‐ average endpoint score ‐ short term (PANSS total, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00701">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00801"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 QUETIAPINE versus CLOZAPINE‐ sensitivity analysis (skewed data excluded), Outcome 1 Mental state: 1. General ‐ average endpoint score ‐ short term (PANSS total, high=poor)." data-id="CD006625-fig-00801" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 QUETIAPINE versus CLOZAPINE‐ sensitivity analysis (skewed data excluded), Outcome 1 Mental state: 1. General ‐ average endpoint score ‐ short term (PANSS total, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00801">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00901"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 QUETIAPINE versus OLANZAPINE‐ sensitivity analysis (skewed data excluded), Outcome 1 Mental state: 1. General ‐ average endpoint score (PANSS total subscore, high=poor)." data-id="CD006625-fig-00901" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 QUETIAPINE versus OLANZAPINE‐ sensitivity analysis (skewed data excluded), Outcome 1 Mental state: 1. General ‐ average endpoint score (PANSS total subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00901">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00902"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 QUETIAPINE versus OLANZAPINE‐ sensitivity analysis (skewed data excluded), Outcome 2 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor)." data-id="CD006625-fig-00902" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 QUETIAPINE versus OLANZAPINE‐ sensitivity analysis (skewed data excluded), Outcome 2 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00902">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-00903"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 QUETIAPINE versus OLANZAPINE‐ sensitivity analysis (skewed data excluded), Outcome 3 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor)." data-id="CD006625-fig-00903" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 QUETIAPINE versus OLANZAPINE‐ sensitivity analysis (skewed data excluded), Outcome 3 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-00903">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-01001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 1 Global state: 1a. No clinically significant response (as defined by the original studies)." data-id="CD006625-fig-01001" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 1 Global state: 1a. No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-01001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-01002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 2 Mental state: 1. General ‐ average endpoint score ‐ (PANSS total score, high=poor)." data-id="CD006625-fig-01002" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 2 Mental state: 1. General ‐ average endpoint score ‐ (PANSS total score, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-01002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-01003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 3 Mental state: 6. Positive symptoms ‐ average endpoint score ‐ (PANSS positive subscore, high=poor)." data-id="CD006625-fig-01003" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 3 Mental state: 6. Positive symptoms ‐ average endpoint score ‐ (PANSS positive subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-01003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-01004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 4 Mental state: 6. Negative symptoms ‐ average endpoint score ‐ (PANSS negative subscore, high=poor)." data-id="CD006625-fig-01004" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 4 Mental state: 6. Negative symptoms ‐ average endpoint score ‐ (PANSS negative subscore, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-01004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006625-fig-01005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/urn:x-wiley:14651858:media:CD006625:CD006625-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_t/tCD006625-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 5 Adverse effects: 1. Extrapyramidal effects ‐ Simpson‐Angus Scale (high=poor)." data-id="CD006625-fig-01005" src="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded), Outcome 5 Adverse effects: 1. Extrapyramidal effects ‐ Simpson‐Angus Scale (high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-fig-01005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/media/CDSR/CD006625/image_n/nCD006625-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD006625-tbl-0017"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies possible to include but not fully blinded</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study tag</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0036" title="AnBF , LiuXQ , ChenJX . A comparative study between quetiapine and clozapine in the treatment of schizophrenia and the relation with the plasman levels of IL‐2, SIL‐2R. Schuan Mental Health2003;16(3):152‐4. ">An 2003</a>;<a href="./references#CD006625-bbs2-0037" title="AnBF , ZhangML , QiSG . Comparitive study between the effect olanzapine and quetiapine in first‐episode schizophrenia. Journal of Clinical Psychological Medicine2006;16(2):84‐5. ">An 2006</a>;<a href="./references#CD006625-bbs2-0040" title="ArangoC , RoblesO , ParelladaM , FraguasD , Sancho‐RuizA , MedinaO , et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry2009;18:418‐28. ">Arango 2009</a>; <a href="./references#CD006625-bbs2-0043" title="BanN , CuiJB . Analysis of the efficacy of aripiprazole and quetiapine in the treatment of schizophrenia. Occupation and Health2008;24(3):292‐3. ">Ban 2008</a>; <a href="./references#CD006625-bbs2-0044" title="BeuzenJ‐N , PansM , ModellS , HagensP , McQuadeR , IwamotoT , et al. Naturalistic study of aripiprazole treatment. Proceedings of the XIII World Congress of Psychiatry, Cairo, Egypt, September 10‐15, 2005. ">Beuzen 2005</a>; <a href="./references#CD006625-bbs2-0045" title="BoterH , PeuskensJ , LibigerJ , FleischhackerWW , DavidsonM , GalderisiS , KahnRS . Effectiveness of antipsychotics in first‐episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research2009;115:97‐103. GalderisiS , DavidsonM , KahnRS , MucciA , BoterH , GheorgheMD , et al. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophrenia Research2009;115:104‐14. KahnRS , FleischhackerWW , BoterH , DavidsonM , VergouweY , KeetIPM , et al. Effectiveness of antipsychotic drugs in first‐episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet2008;371:1085–97. ">Boter 2005</a>; <a href="./references#CD006625-bbs2-0046" title="BrecherM , NewcomerJW , RatnerRE , ErikssonJW , EmsleyR , MeulienD , et al. Differential effects of quetiapine, olanzapine and risperidone on glucose metabolism: a 24‐week study in schizophrenia. International Congress on Schizophrenia Research. 2007. ">Brecher 2007</a>; <a href="./references#CD006625-bbs2-0049" title="CaiQQ , WangZW , LinYC , WangXY . A control study of quetiapine and clozapine in the treatment of schizophrenia. The Medicine Magazine of China2005;3(8):465‐6. ">Cai 2005</a>; <a href="./references#CD006625-bbs2-0051" title="CaoD , XieS‐P , ChenQ‐B , YuanY‐G , FangQ . Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation2005;9(36):63‐8. ">Cao 2005</a>; <a href="./references#CD006625-bbs2-0051" title="CaoD , XieS‐P , ChenQ‐B , YuanY‐G , FangQ . Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation2005;9(36):63‐8. ">Cao 2005</a>a; <a href="./references#CD006625-bbs2-0053" title="CaoD , XieSP , ChenQB , YuanYG , FangQ . Effects of antipsychotic on pituitary‐gonadal axis in male patients with schizophrenia. Journal of Clinical Psychological Medicine2006;16(4):209‐11. ">Cao 2006a</a>;<a href="./references#CD006625-bbs2-0055" title="ChangGS , LiJ . A control study of quetiapine and risperidone in the treatment of schizophrenia. China Practice Medicine2007;2(34):52‐3. ">Chang 2007</a>; <a href="./references#CD006625-bbs2-0056" title="ChangYS , GuYS . A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health2008;20(17):2010‐1. ">Chang 2008</a>; <a href="./references#CD006625-bbs2-0057" title="ChaudhryHR , NiazS , ArshadN , PerachaF , AyubA , MuftiKA . Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels. Journal of the European College of Neuropsychopharmacology2006;16(Suppl 4):S241. ">Chaudhry 2006</a>; <a href="./references#CD006625-bbs2-0058" title="ChenZE , LiuHR , WuSQ . A control study of quetiapine and risperidone in the treatment of female schizophrenia. Herald of Medicine2006;25(6):548‐50. ">Chen 2006a</a>; <a href="./references#CD006625-bbs2-0060" title="ChenJG . Control study on management of first‐episode schizophrenia with risperidone and quetiapine. China Pharmaceuticals2007;16(9):43‐4. ">Chen 2007a</a>; <a href="./references#CD006625-bbs2-0061" title="ChenFX . A control study of quetiapine vs risperidone in first‐episode schizophrenia. Jiangxi Medicine2007;42(10):917‐8. ">Chen 2007b</a>; <a href="./references#CD006625-bbs2-0062" title="ChenF , WangHY , LiDY , ZhouBW , ChenFY . A control study of quetiapine and aripiprazole in the treatment of female first‐episode schizophrenia. Journal of Psychiatry2007;20(6):381‐3. ">Chen 2007c</a>; <a href="./references#CD006625-bbs2-0063" title="ChenHB , FuF , YangQJ . A control study of quetiapine and risperidone in the treatment of schizophrenia. Medical Information2008;21(3):389‐90. ">Chen 2008</a>; <a href="./references#CD006625-bbs2-0065" title="CorteseL , CaligiuriMP , WilliamsR , SchieldropP , ManchandaR , MallaA , HarricharanR . Reduction in neuroleptic‐induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol2008;28:69‐73. ">Cortese 2008</a>; <a href="./references#CD006625-bbs2-0066" title="DaiJ‐P , ZhaoZ‐H , MaiG‐Y . Comparative study on the effect of olanzapine and seroquel of schizophrenia. Chinese Journal of Behavioral Medical Science2004;13(3):291‐3. ">Dai 2004</a>; <a href="./references#CD006625-bbs2-0067" title="DaiJ‐P , ZhaoZ‐H , LiuG‐X . Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Sience2005;14(8):712‐14. ">Dai 2005</a>; <a href="./references#CD006625-bbs2-0070" title="DingY , AnB , LiG , LiY . A comparative study of risperidone and quetiapine in the treatment of schizophrenia and relationship between efficacy and the serum levels of il‐2?sil‐2r. Shandong Archives of Psychiatry2004;17(2):76‐8. ">Ding 2004</a>; <a href="./references#CD006625-bbs2-0073" title="FengD‐J , ZhouT , XiongL‐H , ThianD‐F . A study of quetiapine and clozapine in treatment of chronic schizophrenia. Journal of Luzhou Medical College2003;26(6):511‐12. ">Du 2003</a>; <a href="./references#CD006625-bbs2-0075" title="FanJ‐H , LiW‐J . A study of quetiapine in treatment of negative symptoms dominant schizophrenia. Sichuan Mental Health2005;18:178. ">Fan 2005</a>; <a href="./references#CD006625-bbs2-0077" title="FleischhackerWW , KeetIPM , KahnRS . The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophrenia Research2005;78(2‐3):147‐56. ">Fleischhacker 2005</a>; <a href="./references#CD006625-bbs2-0078" title="FuH , YuH , HuoJ . A comparative study of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2005;11(4):313‐4. ">Fu 2005</a>; <a href="./references#CD006625-bbs2-0079" title="FuH , YuH , HuoJ . A comparative study of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2005;11(4):313‐4. ">Fu 2005a</a>; <a href="./references#CD006625-bbs2-0080" title="GaoCZ , GaoZ . A study of quetiapine in the treatment of first‐onset schizophrenia. Journal of Clinical Psychological Medicine2003;13(4):221‐2. ">Gao 2003</a>; <a href="./references#CD006625-bbs2-0084" title="HarriganEP , MiceliJJ , AnzianoR , WatskyE , ReevesKR , CutlerNR , et al. A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology2004;24(1):62‐9. ">Harrigan 2004</a>; <a href="./references#CD006625-bbs2-0085" title="HeJ , ChenYX . A controlled study on quetiapine and clozapine in the treatment of schizophrenic patients. Medical Journal of Chinese Civil Administration2003;15(6):335‐6. ">He 2003</a>; <a href="./references#CD006625-bbs2-0086" title="HoracekJ , SeifertovaD , JanuL , PetranovaT . The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia. Proceedings of the Biennial Winter Workshop on Schizophrenia, February 7‐13, 2004. ">Horacek 2004</a>; <a href="./references#CD006625-bbs2-0087" title="HuangS‐P , MaZ‐W , GuoB‐Y . Effectiveness of quetiapine vs clozapine in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2003;9(4):206‐7. ">Huang 2003</a>; <a href="./references#CD006625-bbs2-0090" title="JiangZX , HeXY , HeXC , LiLW , PengZE . A control study of quetiapine and aripiprozole in the treatment of schizophrenia. Journal of Clinical Research2006;23(8):1327‐8. ">Jiang 2006</a>; <a href="./references#CD006625-bbs2-0092" title="KeksNA , TonsoM , TaboneK , McHughM , ThomasR , TuneP , GelmanM . Clinical experience with atypical antipsychotics in acute inpatient unit: focus on quetiapine. International Journal of Psychiatry in Clinical Practice2006;10(2):1‐4. ">Keks 2006</a>; <a href="./references#CD006625-bbs2-0095" title="KnegteringR , CasteleinS , BousH , Van DerLindeJ , BruggemanR , KluiterH , et al. A randomized open‐label study of the impact of quetiapine versus risperidone on sexual functioning. Journal of Clinical Psychopharmacology2004;24(1):56‐61. ">Knegtering 2004</a>; <a href="./references#CD006625-bbs2-0096" title="KolotkinRL , Corey‐LislePK , CrosbyRD , KanHJ , McQuadeRD . Changes in weight and weight‐related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. European Psychiatry2008;23:561‐6. ">Kolotkin 2008</a>; <a href="./references#CD006625-bbs2-0097" title="Koponen . Study in Schizophrenic In‐Patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose. Clinical Trial Registration Data2008. ">Koponen 2008</a>; <a href="./references#CD006625-bbs2-0101" title="LiHF , GuNF , XieB , LiM , ZhangL , ChengY , WangMJ . Quetiapine in treatment of schizophrenia: a randomized, controlled, multicentre study. Chinese Journal of New Drugs and Clinical Remedies2001;20(4):260‐3. ">Li 2001</a>; <a href="./references#CD006625-bbs2-0103" title="LiCM . A comparison of cognitive function in the first‐onset schizophrenia treated with quetiapine and clozapine. Medical Journal of Chinese People Health2003;15(12):718‐21. ">Li 2003a</a>; <a href="./references#CD006625-bbs2-0104" title="LiX , LaoG , CaoL . Comparison of efficacy and safety of seroquel and resperidone in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science2003;12(1):45‐6. ">Li 2003b</a>; <a href="./references#CD006625-bbs2-0105" title="LiH . A controlled study of schizophrenia treated with quetiapine and clozapine. Chinese Modern Medical and Clinical2005;3(7):33‐4. ">Li 2005a</a>; <a href="./references#CD006625-bbs2-0106" title="LiG , ChenQ‐G , ZhangQ‐H . A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia. Chinese Journal of Behavioral Medical Science2005;14(11):1007‐8, 1036. ">Li 2005b</a>; <a href="./references#CD006625-bbs2-0107" title="LiM , LvW , XingX . A control study of quetiapine and aripiprazole in the treatment of schizophrenia. Chinese Journal of Postgraduate Medicine2007;30(11):49‐50. ">Li 2007a</a>; <a href="./references#CD006625-bbs2-0108" title="LiQ , WangW , ChenC , LiYM . Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia. Huaxi Pharmacy2007;22(3):354‐5. ">Li 2007h</a>; <a href="./references#CD006625-bbs2-0109" title="LiG , ZuoJ , ChenQ , ZhouH . A comparison analysis on the efficacy of quetiapine and risperidone in the treatment of schizophrenia. Tianjin Pharmacy2008;20(1):42‐4. ">Li 2008a</a>; <a href="./references#CD006625-bbs2-0111" title="LiW . Influence on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine. Medical Information2008;21(12):2253‐5. ">Li 2008c</a>; <a href="./references#CD006625-bbs2-0112" title="LiDM . The cross‐check analysis of risperdal and quetiapine alleviating negative symptoms of schizophrenia. Laboratory Medicine and Clinic2008;5(19):1162‐3. ">Li 2008d</a>; <a href="./references#CD006625-bbs2-0114" title="LinZ . Analysis of therapeutic effect of quetiapine on schizophrenia patient. China Tropical Medicine2005;5(6):1299. ">Lin 2005</a>; <a href="./references#CD006625-bbs2-0115" title="LinH , WangJ . A study of quetiapine in the treatment of elderly schizophrenia. Qinghai Pharmacy2007;37(4):67‐8. ">Lin 2007</a>; <a href="./references#CD006625-bbs2-0099" title="L’ItalienG , HanssensL , KanHJ , BakerRA , MarcusRN , McQuadeRD , et al. Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the Star trial). Proceedings of the 11th International Congress on Schizophrenia Research, Colorado Springs, Colorado, USA, March 28‐April 1, 2007. ">L'Italien 2007</a>; <a href="./references#CD006625-bbs2-0116" title="LiuX , LinL , FanY , DongX . A comparative study of new anti‐psychopathic drugs lead to gain weight. Medical Journal of Chinese People's Health2003;15(4):230‐1. ">Liu 2003</a>; <a href="./references#CD006625-bbs2-0117" title="LiuK , WangX , JiangL , GengH , CngX , ShiL , ZhaoH . A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Hebei Mental Health2003;16(1):37‐9. ">Liu 2003a</a>; <a href="./references#CD006625-bbs2-0118" title="LiuY , XuM , ChenX . A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry2004;17(1):6‐8. ">Liu 2004a</a>; <a href="./references#CD006625-bbs2-0119" title="LiuY , XuM , ChenX . A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms. Shandong Archires of Psychiatry2004;17(1):6‐8. ">Liu 2004b</a>; <a href="./references#CD006625-bbs2-0120" title="LiuCX , LiuSH , TuZM , LiuB . A study of quetiapine with small doze of clozapine in treatment of resistant schizophrenia. Medical Journal of Chinese People´s Health2005;17:748‐9. ">Liu 2005</a>; <a href="./references#CD006625-bbs2-0121" title="LiuH , ShiY , LiuZ . A comparative study between quetiapine and risperidone in the treatment of schizophrenia. Journal of Heze Medical College2005;17(1):15‐6. ">Liu 2005a</a>; <a href="./references#CD006625-bbs2-0122" title="LiuZ , HanJ , ChengY , YanM , ZhouH . Study on quetiapine fumarate and risperidone in the treatment of schizophrenia. Journal of Hebei Medical College for Continuing Education2006;23(2):14‐6. ">Liu 2006</a>; <a href="./references#CD006625-bbs2-0125" title="LuS , ZhangS‐A , RenY . Comparative study on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine. Journal of Nursing Science2005;20(3):57‐9. ">Lu 2005</a>; <a href="./references#CD006625-bbs2-0126" title="LuoY , ZhangS‐W , WangA‐Q . The comparative study of quetiapine and clozapine in the treatment of female schizophrene. Medical Journal of Chinese People Health2005;17(6):269‐70. ">Luo 2005</a>; <a href="./references#CD006625-bbs2-0127" title="LvB , WangJ , LinY . A control study of quetiapine and risperidone in the treatment of eldly schizophrenia. Shandong Pharmacy2008;48(16):91‐2. ">Lv 2008</a>; <a href="./references#CD006625-bbs2-0129" title="MintzerJE , MullenJA , SweitzerDE . A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Current Medical Research and Opinion2004;20(9):1483‐91. ">Mintzer 2004</a>; <a href="./references#CD006625-bbs2-0130" title="MullenJ , JibsonMD , SweitzerD . A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clinical Therapeutics2001;23(11):1839‐54. ">Mullen 2001</a>; <a href="./references#CD006625-bbs2-0133" title="PanM , WangH , ZhangS . A controlled study of domestic quetiapine and risperidone in the treatment of first‐episode schizophrenia. Journal of Clinical Psychosomatic Diseases2004;10(4):244‐6. ">Pan 2004</a>; <a href="./references#CD006625-bbs2-0134" title="PanM , ZhangS‐Q , ZhaoZ . A comparative study of domestic quetiapine and risperidone in the treatment of schizophrenia. Medical Journal of Chinese Peoples Health2004;16(10):597‐8, 637. ">Pan 2004a</a>; <a href="./references#CD006625-bbs2-0135" title="PanM , ZhangS , ZhaoZ . Influence of three antipsychotic drugs on electrocardiogram in patients with schizophrenia. Journal of XinXiang Medical College2004;21:403‐4. ">Pan 2004b</a>; <a href="./references#CD006625-bbs2-0137" title="PangD , WangC , CuiA . Effect of quetiapine fumarate and clozapine on clinical rehabilitation of schizophrenia:a controlled study. Chinese Journal of Clinical Rehabilitation2002;6(7):1007. ">Pang 2002</a>; <a href="./references#CD006625-bbs2-0139" title="PettyF . Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia. Clinical Trial Registration Data2006. ">Petty 2005</a>; <a href="./references#CD006625-bbs2-0140" title="Pfizer . Effect and Safety of Ziprasidone Compared to Other Atypical Antipsychotic Drug in Schizophrenic Patients. Clinical Trial Registration Data2005. ">Pfizer 2005</a>; <a href="./references#CD006625-bbs2-0141" title="QiF , WangL , ZhenY . Comparison of efficacy and safety of quetiapine and risperidone in the treatment of schizophrenia. Shanghai Archives of Psychiatry2004;16(2):78‐9, 119. ">Qi 2004</a>; <a href="./references#CD006625-bbs2-0142" title="QianD , PanB , YangG . Cost‐effectiveness analysis of 3 kinds of therapeutic schemes for schizophrenia. Evaluation and Analysis of Drug Use in Hospital of China2004;4(2):110‐1. ">Qian 2004</a>; <a href="./references#CD006625-bbs2-0143" title='ReznikI , SlavkinL , ShabashE , ShakedG , KertzmanS , SpivakB , et al. Quetiapine ("Seroquel") and olanzapine for acute treatment of patients with schizophrenia: an open‐label, comparative study. Proceedings of the XXIV Collegium Internationale Neuro‐Psychopharmacologicum; Paris, France, June 20‐24, 2004. 1‐4. '>Reznik 2004</a>; <a href="./references#CD006625-bbs2-0144" title="RieraL , TandonR , StockEG , KujawaMJ , TorbeynsAF , BorianFE . Broad effectiveness trial with aripiprazole. Proceedings of the Twelfth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February 7‐13, 2004. ">Riera 2004</a>; <a href="./references#CD006625-bbs2-0145" title="RuanJ , HuangG . A control study of quetiapine and clozapine in the treatment of difficult‐to‐treat schizophrenia. Medical Journal of Chinese People's Health2005;17(12):747‐8. ">Ruan 2005</a>; <a href="./references#CD006625-bbs2-0147" title="SajatovicM , MullenJA , SweitzerD . Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychotic disorders. Proceedings of the 155th Annual Meeting of the American Psychiatric Association, Philadelphia, Pennsylvania, USA, May 18‐23, 2002. ">Sajatovic 2002</a>; <a href="./references#CD006625-bbs2-0150" title="SongF . A control study of quetiapine and clozapine in the treatment of schizophrenia. Health Horizon·Medical Science Fascicule2006;(7):91. ">Song 2006</a>; <a href="./references#CD006625-bbs2-0160" title="SwansonJW , SwartzMS , VanDornRA . Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20‐25, 2006. ">Swanson 2006</a>; <a href="./references#CD006625-bbs2-0161" title="TangY . A controlled study of schizophrenia treated with quetiapine and clozapine. Shanghai Archives of Psychiatry2003;15(1):27‐9. ">Tang 2003</a>; <a href="./references#CD006625-bbs2-0162" title="TangZ‐K , XuC‐M , ChenD . A comparative study of quetiapine and clozapine in the treatment of recurrent schizophrenia. Shandong Archives of Psychiatry2005;18(3):167‐8. ">Tang 2005</a>; <a href="./references#CD006625-bbs2-0164" title="TianB , LiJ , JingH , ZhangW , LiuY . A comparative study between seroquel and risperidone in the treatment of schizophrenia. Shandong Archives of Psychiatry2006;19(1):25‐6. ">Tian 2006</a>; <a href="./references#CD006625-bbs2-0167" title="WangM , LiuM , LuL . A controlled study on seroquel and risperidone in the treatment of schizophrenic patients. Journal of Clinical Psychological Medicine2000;10(4):200‐1. ">Wang 2000</a>; <a href="./references#CD006625-bbs2-0168" title="WangX . Comparative study of effects of quetiapine and clozapine on quality of life of schizophrenics. Journal of Clinical Psychosomatic Diseases2004;10(3):167‐8. ">Wang 2004</a>; <a href="./references#CD006625-bbs2-0170" title="WangC‐H , LiY , LiuX . Cognitive function and p300 potentials in first‐episode schizophrenia treated with quetiapine and risperidone. Chinese Mental Health Journal2005;19(5):333‐6. ">Wang 2005</a>; <a href="./references#CD006625-bbs2-0171" title="WangC‐H , LiY , WangL‐H , PanM , ZHaoZ , MuJ‐L . Comparison of cognitive function and event related potentials in first episode schizophrenic treated with antipsychotic drugs. Journal of Clinical Psychological Medicine2005;15(3):168‐70. ">Wang 2005a</a>; <a href="./references#CD006625-bbs2-0172" title="WangX , YangJ , GuoH . Clinical study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2005;11(2):118‐9. ">Wang 2005b</a>; <a href="./references#CD006625-bbs2-0173" title="WangX‐F , WangW‐H , WangJ‐C . Analysis of quetiapine in treatment of first‐episode schizophrenia. Sichuan Mental Health2005;18:235‐6. ">Wang 2005c</a>; <a href="./references#CD006625-bbs2-0174" title="WangY , SunM , ShaoX . A comparative study between quetiapine and clozapine in the treatment of schizophrenia. Heath Psychology Journal2005;13(4):271‐2. ">Wang 2005d</a>; <a href="./references#CD006625-bbs2-0176" title="WangJ , RanR . Effects of quetiapine vs clozapine on the quality of life in first‐episode schizophrenics. Journal of Clinical Psychosomatic Disorders2006;12(6):416‐7. ">Wang 2006b</a>; <a href="./references#CD006625-bbs2-0184" title="WeiS . A randomized, double blind double dummy parallel controlled study in the female first‐onset schizophrenia treated with aripiprazole and quetiapine. Nervous Diseases and Mental Health2006;6(3):194‐7. ">Wei 2006</a>; <a href="./references#CD006625-bbs2-0187" title="WenS , ChenF . A control study of quetiapine and risperidone in the treatment of schizophrenia. Modern Medicine Health2005;21(22):3089‐90. ">Wen 2005</a>; <a href="./references#CD006625-bbs2-0188" title="WuY , WangX . A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychological Medicine2005;15(2):106‐7. ">Wu 2005</a>; <a href="./references#CD006625-bbs2-0189" title="XiangDF , LiuXL . Treatment of 31 cases of schizophrenia with quetiapine. Herald of Medicine2005;24(1):40‐2. ">Xiang 2005</a>; <a href="./references#CD006625-bbs2-0190" title="XuMQ , PengMY . A study of Quetiapine in treatment of schizophrenia. Journal of Clinical Psychology Medicine2002;12:227‐8. ">Xu 2002</a>; <a href="./references#CD006625-bbs2-0191" title="XuLZ , OuyangJL , GaoSZ . Effects of domestic quetiapine vs clozapine in treatment of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2003;7477(9):542‐5. ">Xu 2003</a>; <a href="./references#CD006625-bbs2-0192" title="XuXF , ZhangXB , ZhouCY , DaiXG . Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia. Journal of Jiangsu Clinical Medicine2005;9(1):20‐2. ">Xu 2005</a>; <a href="./references#CD006625-bbs2-0195" title="YangFS , YangYL , ZhangZH . Control study on quetiapine and clozapine in treatment of refractory schizophrenia. Medical Journal of Chinese People Health2004;16(1):12‐3. ">Yang 2004</a>; <a href="./references#CD006625-bbs2-0196" title="YangQ‐P , HuangY‐P , YangB‐X . The effect of quetiapine and risperidone on the EEG of first‐episode schizophrenic patients. Shandong Archives of Psychiatry2005;18(3):159‐60. ">Yang 2005</a>; <a href="./references#CD006625-bbs2-0197" title="YangQ‐P , HuangY‐P , YangB‐X . The effect of quetiapine and risperidone on the EEG of first‐episode schizophrenic patients. Shandong Archives of Psychiatry2005;18(3):159‐60. ">Yang 2005a</a>; <a href="./references#CD006625-bbs2-0198" title="YangY . Control study of quetiapine and clozapine in the treatment of refractory schizophrenia. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2006;14(4):276‐7. ">Yang 2006</a>; <a href="./references#CD006625-bbs2-0203" title="YuG , LiangS , HeZ‐G . Comparison of quetiapine and clozapine in treatment of schizophrenia. Journal of Clinical Psychiatry Medicine2003;25:4‐5. ">Yu 2003</a>; <a href="./references#CD006625-bbs2-0204" title="YuH , KongH . A control study of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychological Medicine2005;15(6):362. ">Yu 2005</a>; <a href="./references#CD006625-bbs2-0205" title="YuW , LiuH , PanS . A control study of quetiapine and loxapine in the treatment of schizophrenia. Journal of Clinical Psychological Medicine2006;16(5):298. ">Yu 2006</a>; <a href="./references#CD006625-bbs2-0206" title="YuanF‐J , GaoM‐Z , LiuX . A contrast observation of quetiapine and clozapine in affecting electroencephalogram. Journal of Practical Medical Techniques2005;12(2B):482‐4. ">Yuan 2005</a>; <a href="./references#CD006625-bbs2-0208" title="ZhangL , WuY , GuoC . A comparative study between quetiapine and risperidone in the treatment of schizophrenia. Health Psychology Journal2003;11(4):262‐3. ">Zhang 2003</a>; <a href="./references#CD006625-bbs2-0209" title="ZhangM , ZhangH‐F , GuW . A comparative study of quetiapine and clozapine in the treatment of schizophrenia. Shandong Archives of Psychiatry2005;18(2):86‐8. ">Zhang 2005</a>; <a href="./references#CD006625-bbs2-0210" title="ZhangH , ZhangM , GuW . A comparative study of social function in schizophrenia patients treated with seroquel (quetiapine) or clozapine. Sichuan Mental Health2005;18(2):91‐3. ">Zhang 2005a</a>; <a href="./references#CD006625-bbs2-0211" title="ZhangR‐X , CaoY‐F . A comparative study of EKG changed by quetiapine and clozapine in the treatment of schizophrenia. Medical Journal of Chinese People Health2005;17(6):290‐1. ">Zhang 2005b</a>; <a href="./references#CD006625-bbs2-0212" title="ZhangY , JiangY , ZhaoS . A comparative study of quetiapine combined with clomipramine in treatment of schizophrenia with obsessive‐compulsive symptoms. Chinese Journal of Health Psychology2005;13(4):260‐2. ">Zhang 2005c</a>; <a href="./references#CD006625-bbs2-0213" title="ZhangW , MaJ , MaL . A control study of quetiapine and risperidone in the treatment of first‐episode schizophrenia. Chinese Journal of Current Traditional and Western Medicine2005;3(12):1088‐9. ">Zhang 2005d</a>; <a href="./references#CD006625-bbs2-0215" title="ZhangY , ZhouB . A control study of quetiapine and clozapine in the treatment of schizophrenia. Journal of Clinical Psychological Medicine2006;16(5):300. ">Zhang 2006a</a>; <a href="./references#CD006625-bbs2-0219" title="ZhaoF , ZhangZ , LiH . Control studies of quetiapine and risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases2004;10(1):25‐6. ">Zhao 2004</a>; <a href="./references#CD006625-bbs2-0220" title="ZhaoL , LiY , QiF . Control study of quetiapine and risperidone in treatment of schizophrenics. Heath Psychology Journal2005;13(1):56, 79‐80. ">Zhao 2005</a>; <a href="./references#CD006625-bbs2-0221" title="ZhaoYH , FangJH , WangSH , AnCG , MaX , LiHX . A study of quetiapine and clozapine in treatment of schizophrenia. Journal of Clinical Psychology Medicine2005;15:231‐2. ">Zhao 2005a</a>; <a href="./references#CD006625-bbs2-0224" title="ZhongZ‐Y , TaoJ , WangX‐L , WuX‐L , ZhangJ‐B . Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia. Zhongguo Linchuang Kangfu2006;10(2):30‐2. ">Zhong 2006a</a>; <a href="./references#CD006625-bbs2-0225" title="ZhouP , GongF , FanC . A control of treating chronic schizophrenia with seroquel or clozapine. Jiangxi Medical Journal2003;38(6):395‐6. ">Zhou 2003</a>; <a href="./references#CD006625-bbs2-0226" title="ZhouR , DaiX . A comparative study of quetiapine and clozapine in the treatment of patients with schizophrenia. Shanghai Archives of Psychiatry2003;15(4):215‐7. ">Zhou 2003a</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies possible to include but not fully blinded</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006625-tbl-0018"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies relevant to other quetiapine comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0223" title="ZhengJ , WangB , FuA , LiP . A control study of quetiapine and clozapine in the treatment of schizophrenia. Medical Recapitulate2007;13(23):1878‐9. ">Zheng 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus quetiapine + clozapine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0054" title="CaoCA , GuoJH , GaoH . Comparison of curative effect and safety of quetiapine and risperidone in the treatment of female schizophrenia. Medical Journal of Chinese People's Health2006;18(6):433‐4. ">Cao 2006d</a>; <a href="./references#CD006625-bbs2-0082" title="GuoZY , LiuJM , YangJZ , GuoH , WangAQ . Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life. China Journal of Health Psychology2008;16(5):544‐6. ">Guo 2008</a>; <a href="./references#CD006625-bbs2-0132" title="NaiX , HuX , QiuW , LiuN , WeiH . Effect of quetiapine on cognitive function of patients with first episode schizophrenia. Journal of Medical Forum2007;28(2):38‐9. ">Nai 2007</a>; <a href="./references#CD006625-bbs2-0214" title="Zhangw , MaJ , XuF . Comparison study on treatment of primary schizophrenia with quetiapine and chlorpromazine. Heilongjiang Medical Journal2006;30(2):81‐2. ">Zhang 2006</a>; <a href="./references#CD006625-bbs2-0154" title="SunX , ZouS , LiZ , HanZ . Effect of cognitive function in first‐episode schizophrenia treated with quetiapine. Journal of Clinical Psychological Medicine2006;16(2):94‐5. ">Sun 2006e</a>; <a href="./references#CD006625-bbs2-0193" title="XuB . Comparative observation on the efect of quetiapine fumarate on chronic schizoprenia patients. China Tropical Medicine2006;6(6):1032. ">Xu 2006</a>; <a href="./references#CD006625-bbs2-0217" title="ZhangL . A comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Modern Medicine Journal of China2007;9(2):97‐8. ">Zhang 2007a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus chlorpramazine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0199" title="YangM , MuX , ZhaoA . A clinical study of quetiapine associated with clonazepam in the treatment of schizophrenia. Journal of Qiqihar Medical College2006;27(9):1034‐5. ">Yang 2006a</a>; <a href="./references#CD006625-bbs2-0200" title="YangC , GuoP , GuoH . Control study on using quetiapine to treat schizophrenic patients. China Practical Medicine2006;1(1):24‐6. ">Yang 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus haloperidol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0059" title="ChenRY , LuoRQ , WangAQ , MeiHB . A study of quetiapine on the quality of life of elderly schizophrenia. Medical Journal of Chinese People's Health2006;18(6):447‐8. ">Chen 2006k</a>; <a href="./references#CD006625-bbs2-0156" title="SunM , LiangF , MengY . A control study on quetiapine in gerontic first‐episode schizophrenia. Journal of Chinese Psychosomatic Disorders2007;13(5):407‐8. ">Sun 2007b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus perphenazine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0222" title="ZhaoL , GongGQ . A study of low‐dos equetiapine with sulpiride in the treatment of schizophrenia. Journal of Clinical Research2007;24(7):1181‐2. ">Zhao 2007</a>; <a href="./references#CD006625-bbs2-0227" title="ZhouM . A study of quetiapine with sulpiride in the treatment of chronic schizophrenia. Journal of Clinical Psychological Medicine2006;16(6):368. ">Zhou 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine versus sulpiride</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006625-bbs2-0083" title="HaoH . A control study of quetiapine and seroquel in the treatment of schizophrenia. Journal of Medical Forum2007;28(15):60‐1. ">Hao 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>quetiapine from non‐domestic source vs domestic quetiapine</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies relevant to other quetiapine comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006625-tbl-0019"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blindness: double ‐ described and tested.<br/> Duration: 6 months minimum. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia (operational criteria).<br/> N = 3000*.<br/> Age: any.<br/> Gender: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Quetiapine: dose ˜300‐800 mg/day. N=300.</p> <p>2. Amisulpride: dose ˜ 400‐800 mg/day. N=300.</p> <p>3. Aripiprazole: dose ˜ 10‐30 mg/day. N=300.</p> <p>4. Clozapine: dose ˜ 300‐800 mg/day. N=300.</p> <p>5. Olanzapine: dose ˜ 10‐20 mg/day. N=300.</p> <p>6. Ziprasidone: dose ˜ 120‐160 mg/day. N=300.</p> <p>7. Risperidone: dose ˜ 4‐8 mg/day. N=300.</p> <p>8. Sertindole: dose ˜ 12‐24 mg/day. N=300.</p> <p>9. Zotepine: dose ˜ 100‐300 mg/day. N=300.</p> <p>10. Paliperidone: dose˜ 6‐12 mg/day. N=300.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global state: CGI**, relapse.</p> <p>Leaving study early (any reason, adverse events, inefficacy).<br/> Mental state: PANSS.<br/> Service outcomes: hospitalised, time in hospital, attending out patient clinics.<br/> Adverse events: UKU.<br/> Employment, family satisfaction, patient satisfaction. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>*Power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<br/> <br/> **Primary outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggested design of future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006625-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">QUETIAPINE versus ARIPIPRAZOLE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus ARIPIPRAZOLE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus ARIPIPRAZOLE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus ARIPIPRAZOLE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score</b> <br/> PANSS total </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 1. General ‐ average endpoint score in the intervention groups was<br/> <b>1.62 higher</b> <br/> (0.89 lower to 4.14 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 2. Positive symptoms ‐ average endpoint score in the intervention groups was<br/> <b>0.62 higher</b> <br/> (1.13 lower to 2.38 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high = poor)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high = poor) in the intervention groups was<br/> <b>1 higher</b> <br/> (0.25 lower to 2.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: substantial improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.67</b> <br/> (0.12 to 3.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> <br/> (6 to 178) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b> <br/> (18 to 535) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> <br/> (30 to 892) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic ‐ weight gain</b> ≥<b>7% of total body weight</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.52</b> <br/> (0.1 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>155<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (1 to 27) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (5 to 137) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> <br/> (10 to 274) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated serious ‐ only one study adequately described appropriate allocation concealment methods (but not sequence generation). All other studies did not adequately describe sequence generation and allocation concealment.<br/> <sup>2</sup> Inconsistency: rated 'no' the P value for heterogeneity not statistically significant and I<sup>2</sup> &lt; 50%.<br/> <sup>3</sup> Imprecise data: rated serious ‐ only a few studies contributed to this outcome and confidence interval was wide.<br/> <sup>4</sup> Moderate risk equates to that found within study.<br/> <sup>5</sup> Risk of bias: rated serious ‐ the one study that contributed to this outcome adequately described appropriate allocation concealment methods but not sequence generation.<br/> <sup>6</sup> Imprecise data: rated serious ‐ only one study with a wide confidence interval reported this outcome.<br/> <sup>7</sup> Publication bias: rated no ‐ only one study reported this outcome making publication bias difficult to assess<br/> <sup>8</sup> Risk of bias: rated serious ‐ neither of the two studies reporting this outcome adequately described appropriate allocation concealment and sequence generation methods.<br/> <sup>9</sup> Imprecise data: rated serious ‐ only two studies reported this outcome, both with wide confidence intervals crossing the line of no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">QUETIAPINE versus ARIPIPRAZOLE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006625-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">QUETIAPINE versus CLOZAPINE ‐ all data short term for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus CLOZAPINE all data short term for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus CLOZAPINE all data short term </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus CLOZAPINE all data short term</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score short term (PANSS total, high = poor)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score short term (PANSS total, high = poor) in the intervention groups was<br/> <b>0.5 lower</b> <br/> (2.85 lower to 1.86 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 2. Positive symptoms ‐ average endpoint score in the intervention groups was<br/> <b>0.7 lower</b> <br/> (2.07 lower to 0.68 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score short term</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 3. Negative symptoms ‐ average endpoint score short term in the intervention groups was<br/> <b>2.23 lower</b> <br/> (3.48 to 0.99 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: substantial improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>5</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.22</b> <br/> (0.11 to 0.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>135<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> <br/> (22 to 94) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>5</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (55 to 235) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>5</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> <br/> (88 to 376) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risks were calculated from pooled risk differences. No events in either group (RD 0.0 CI ‐0.13 to 0.13) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic ‐ weight gain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>5</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.53</b> <br/> (0.25 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>135<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> <br/> (25 to 111) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>5</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (62 to 278) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>5</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> <br/> (100 to 444) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated serious none of the studies adequately described sequence generation and allocation concealment.<br/> <sup>2</sup>Inconsistency: rated 'no' the P value for heterogeneity not statistically significant and I<sup>2</sup> &lt; 50%.<br/> <sup>3</sup>Imprecise data: rated serious wide confidence intervals for all individual studies, all crossing the line of no effect.<br/> <sup>4</sup>Imprecise data: rated serious only two studies, both with wide confidence intervals.<br/> <sup>5</sup>Moderate risk equates to that within trials.<br/> <sup>6</sup>Imprecise data: rated serious one small study. No events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">QUETIAPINE versus CLOZAPINE ‐ all data short term for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006625-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">QUETIAPINE versus OLANZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus OLANZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus OLANZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus OLANZAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score (PANSS total, high = poor)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score (PANSS total, high = poor) in the intervention groups was<br/> <b>3.67 higher</b> <br/> (1.95 to 5.39 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1486<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 2. Positive symptoms ‐ average endpoint score in the intervention groups was<br/> <b>1.02 higher</b> <br/> (0.81 lower to 2.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ endpoint score</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 3. Negative symptoms ‐ average endpoint score in the intervention groups was<br/> <b>0.86 higher</b> <br/> (0.32 lower to 2.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: general ‐ average change in endpoint score medium term</b> <br/> QLS total score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life: general ‐ average change in endpoint score medium term in the intervention groups was<br/> <b>1.8 higher</b> <br/> (2.42 lower to 6.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>7</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.98</b> <br/> (0.84 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1615<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>98 per 1000</b> <br/> (84 to 113) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b> <br/> (252 to 339) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> <br/> (420 to 565) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>7</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1127<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Risks were calculated from pooled risk differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (10 to 44) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> <br/> (21 to 89) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b> <br/> (31 to 133) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic ‐ weight significant gain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>7</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.69</b> <br/> (0.51 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1321<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> <br/> (102 to 190) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b> <br/> (204 to 380) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>7</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> <br/> (306 to 570) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated serious no studies adequately described sequence generation and allocation concealment.<br/> <sup>2</sup>Imprecision: rated ’very serious’ only few studies contribute data to this event and the CI was quite wide.<br/> <sup>3</sup>Risk of bias: rated serious one study adequately described appropriate allocation concealment methods but not sequence generation, and another study adequately described sequence generation but not allocation concealment. All other studies did not adequately describe sequence generation and allocation concealment.<br/> <sup>4</sup>Inconsistency: rated ’no’ although the P value for heterogeneity was statistically significant and the I<sup>2</sup> &gt; 50%, the direction of the effect of almost all studies was the same. Exclusion of one outlier (<a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>) rendered the heterogeneity not statistically significant and I<sup>2</sup> &lt; 50%. Therefore, this inconsistency does not challenge the overall results.<br/> <sup>5</sup>Imprecision: rated 'no' exclusion of potentially skewed data (<a href="./references#CD006625-bbs2-0020" title="MoriK , NagaoM , YamashitaH , MorinobuS , YamawakiS . Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2004;28(4):659‐65. ">Mori 2004</a>; <a href="./references#CD006625-bbs2-0031" title="VorugantiLP , AwadAG , ParkerG , ForrestC , UsmaniY , FernandoMLD , et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophrenia Research2007; Vol. 96, issue 1:146‐55. ">Voruganti 2007</a>) revealed an overall significant difference in favour of olanzapine.<br/> <sup>6</sup>Risk of bias: rated serious no studies adequately described sequence generation and allocation concealment.<br/> <sup>7</sup>Moderate risk equates to that of studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">QUETIAPINE versus OLANZAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006625-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">QUETIAPINE versus PALIPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus PALIPERIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus PALIPERIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus PALIPERIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score</b> <br/> PANSS total </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score in the intervention groups was<br/> <b>6.3 higher</b> <br/> (2.77 to 9.83 higher)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 2. Positive symptoms average endpoint score in the intervention groups was<br/> <b>1.60 higher</b> <br/> (0.42 to 2.78 higher)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 3. Negative symptoms ‐ average endpoint score in the intervention groups was<br/> <b>1.3 higher</b> <br/> (0.52 to 2.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: substantial improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.64</b> <br/> (0.45 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>128 per 1000</b> <br/> (90 to 182) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> <br/> (180 to 364) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>384 per 1000</b> <br/> (270 to 546) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 3. Metabolic weight gain</b> ≥<b>7% of total body weight</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.52</b> <br/> (0.5 to 12.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>319<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (5 to 128) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>252 per 1000</b> <br/> (50 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Calculated using generic inverse variance.<br/> <sup>2</sup>Imprecision: rated ’serious’ only one study contributes data to outcome and the CI was quite wide.<br/> <sup>3</sup>Moderate risk equates to that within the trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">QUETIAPINE versus PALIPERIDONE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006625-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">QUETIAPINE versus RISPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus RISPERIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus RISPERIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus RISPERIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score</b> <br/> PANSS total score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score in the intervention groups was<br/> <b>1.74 higher</b> <br/> (0.19 to 3.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2155<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 2. Positive symptoms ‐ average endpoint score in the intervention groups was<br/> <b>1.38 higher</b> <br/> (0.51 to 2.24 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1492<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean mental state: 3. Negative symptoms ‐ average endpoint score in the intervention groups was<br/> <b>0.69 higher</b> <br/> (0.02 lower to 1.41 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1367<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: general average endpoint score</b> <br/> QLS total score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life: general average endpoint score in the intervention groups was<br/> <b>3.44 lower</b> <br/> (4.46 to 2.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.21</b> <br/> (1.06 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2226<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>298 per 1000</b> <br/> (261 to 340) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>289 per 1000</b> <br/> (253 to 330) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>6</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.5</b> <br/> (0.36 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2163<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (18 to 34) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> <br/> (54 to 103) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> <br/> (90 to 172) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic weight gain</b> ≥<b>7% of total body weight</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>6</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.96</b> <br/> (0.82 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2070<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> <br/> (82 to 114) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> <br/> (164 to 228) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> <br/> (246 to 342) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. Only two studies adequately described sequence generation.<br/> <sup>2</sup>Inconsistency: rated ’no’ although the P value for heterogeneity was statistically significant and the I<sup>2</sup> &gt; 50%, the direction of the effect of almost all studies was the same. Therefore, this inconsistency does not challenge the overall results.<br/> <sup>3</sup>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. One study adequately described sequence generation and one study sequence generation.<br/> <sup>4</sup>Imprecision: rated serious most studies comprised small samples sizes with wide confidence intervals.<br/> <sup>5</sup>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. One study adequately described sequence generation and two studies sequence generation.<br/> <sup>6</sup>Moderate risk equates to that within trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">QUETIAPINE versus RISPERIDONE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006625-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">QUETIAPINE versus ZIPRASIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>QUETIAPINE versus ZIPRASIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> QUETIAPINE versus ZIPRASIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> QUETIAPINE versus ZIPRASIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1. General ‐ average endpoint score</b> <br/> PANSS total score </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 1. General ‐ average endpoint score in the intervention groups was<br/> <b>3.7 higher</b> <br/> (2.97 lower to 10.37 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2. Positive symptoms ‐ average endpoint score medium term</b> <br/> PANSS positive subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 2. Positive symptoms ‐ average endpoint score medium term in the intervention groups was<br/> <b>0 higher</b> <br/> (2.18 lower to 2.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 3. Negative symptoms ‐ average endpoint score medium term</b> <br/> PANSS negative subscore </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mental state: 3. Negative symptoms ‐ average endpoint score medium term in the intervention groups was<br/> <b>1.6 higher</b> <br/> (0.34 lower to 3.54 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: substantial improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported this outcome in any form</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 1. Sedation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.36</b> <br/> (1.03 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>754<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> <br/> (103 to 181) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>272 per 1000</b> <br/> (206 to 362) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>408 per 1000</b> <br/> (309 to 543) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.43</b> <br/> (0.2 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>522<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (10 to 47) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> <br/> (20 to 93) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b> <br/> (30 to 140) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: 3. Metabolic weight gain</b> ≥<b>7% of total body weight</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 2.22</b> <br/> (1.35 to 3.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>754<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> <br/> (14 to 36) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> <br/> (68 to 182) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> <br/> (135 to 363) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: rated serious ‐ inadequately described sequence generation and allocation concealment.<br/> <sup>2</sup>Imprecision: rated serious ‐ only one study contributed to this important outcome and the confidence interval was large.<br/> <sup>3</sup>Moderate risk equates to that within trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">QUETIAPINE versus ZIPRASIDONE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/full#CD006625-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">QUETIAPINE versus ARIPIPRAZOLE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.59, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.59, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. General ‐ average endpoint score (PANSS total, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [‐0.89, 4.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [‐0.89, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [‐1.13, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [‐1.13, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.25, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.25, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 General functioning: General ‐ average endpoint score ‐ medium term (GAF total score, high=poor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐14.43, 12.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.13, 76.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2b. Cardiac effects ‐ Tachycardia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.50 [0.40, 140.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 3a. Extrapyramidal effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.45, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.08, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [0.14, 72.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.10, 20.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.28, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.08, 35.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 4a. Prolactin associated side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.13, 76.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 galactorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.13, 76.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 5a. Metabolic ‐ weight gain of 7% or more of total body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects. 5b. Metabolic ‐ weight gain ‐ change from baseline in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.7 [‐0.14, 3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 5c. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.2 [‐12.24, 28.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 5d. Metabolic ‐ glucose ‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.4 [‐17.90, ‐0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 6. Death   <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 natural causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 suicide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">QUETIAPINE versus ARIPIPRAZOLE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">QUETIAPINE versus CLOZAPINE ‐ all data short term</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.18, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 due to inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1a. No clinically significant response (as defined by original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 1b. No clinically important change ‐ short term (as measured by CGI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1a. General ‐ no clinically important change ‐ short term (less than 50% PANSS total score reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.53, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1b. General ‐ average endpoint score ‐ short term (PANSS total, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.85, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1c. General ‐ average endpoint score ‐ short term (BPRS total, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐3.20, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐2.07, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 3a. Negative symptoms ‐ average endpoint score ‐ short term (PANSS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.23 [‐3.48, ‐0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 3b. Negative symptoms ‐ no clinically important change ‐ short term (less than 50% SANS total score reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 3c. Negative symptoms ‐ average endpoint score ‐ short term (SANS total, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.64 [‐8.17, 4.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.26, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 2. Cardiac effects: ECG abnormalities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 3. Central nervous system ‐ sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.11, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 4. Extrapyramidal effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 rigor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.18, 20.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.29, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 5. Haematological: Important decline in white blood cells <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 6a. Metabolic ‐ weight ‐ gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.25, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 6b. Metabolic ‐ weight ‐ change from baseline (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.11 [‐4.30, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">QUETIAPINE versus CLOZAPINE ‐ all data short term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">QUETIAPINE versus OLANZAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1821</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.12, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.69, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 due to inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.42, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1a. No clinically significant response (as defined by the original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.86, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 1b. No clinically important change (as measured by CGI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.89, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.59, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.86, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1a. General ‐ no clinically important change ‐ short term (less than 50% PANSS total score reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.54, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1b. General ‐ average endpoint score (PANSS total, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.67 [1.95, 5.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [‐1.30, 5.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.57 [1.97, 9.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [0.91, 5.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2a. Positive symptoms ‐ no clinically important change ‐ short term (less than 20% SAPS total score reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.0 [0.93, 241.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2b. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [‐0.81, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [‐0.48, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.90, 3.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.25 [‐7.28, 4.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 2c. Positive symptoms ‐ SAPS total score ‐ percent change ‐ short term (high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>40.84 [23.97, 57.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 3a. Negative symptoms ‐ no clinically important change ‐ short term (less than 20% SANS total score reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.53, 4.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 3b. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [‐0.32, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐1.70, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.67, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [‐1.29, 6.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 3c. Negative symptoms ‐ average endpoint score ‐ medium term (SANS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐0.48, 7.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state: 3d. Negative symptoms ‐ average change in endpoint score ‐ short term (SANS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [‐31.90, 36.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 General functioning: General ‐ average endpoint score ‐ medium term (GAF total score, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [0.33, 4.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Quality of life: General ‐ average change in endpoint score ‐ medium term (QLS total score, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐2.42, 6.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Service use: 1. Number of participants re‐hospitalised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.33, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.05, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.24, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 2. Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.13, 4.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.05, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 suicide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.96 [0.24, 102.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.96 [0.73, 229.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.81 [0.34, 9.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 4a. Central nervous system ‐ sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.78, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 4b. Central nervous system ‐ seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.3 [0.14, 76.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 5a. Extrapyramidal effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.68, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 akinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.11, 59.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.21, 6.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5 extrapyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.72, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.6 parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.34, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.12, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.8 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.32, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 5b. Extrapyramidal effects ‐ scale measured <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 akathisia: Barnes Akathisia Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.10, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 extrapyramidal symptoms: ESRS total score (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐2.68, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 extrapyramidal symptoms: Simpson‐Angus Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.57, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 extrapyramidal symptoms: Abnormal Involuntary Movement Scale (AIMS, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.38, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse effects: 6a. Prolactin associated side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 abnormally high prolactin value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 amenorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.36, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 galactorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.25, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4 gynecomastia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.5 sexual dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse effects: 6b. Prolactin ‐ change from baseline in ng/ml <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.89 [‐11.62, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse effects: 7a. Metabolic ‐ cholesterol ‐ significant cholesterol increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.59, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse effects: 7b. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.73 [‐8.05, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse effects: 7c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.21, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse effects: 7d. Metabolic ‐ glucose ‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.67 [‐9.41, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse effects: 7e. Metabolic ‐ weight ‐ gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.51, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 significant weight gain (as defined by the original studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 as "weight gain" reported adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.04, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse effects: 7f. Metabolic ‐ weight ‐ change from baseline in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.54 [‐3.82, ‐1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">QUETIAPINE versus OLANZAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">QUETIAPINE versus PALIPERIDONE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.70, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.61, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.37, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 due to inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.97 [0.59, 42.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. General ‐ average endpoint score (PANSS total, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.3 [2.77, 9.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.3 [2.77, 9.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.42, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.42, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.52, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.52, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.06, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.01, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 2b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.3 [‐2.50, 7.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 3a. Extrapyramidal effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.42, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.55, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.15, 6.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.17, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.45, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 3b. Extrapyramidal effects ‐ scale measured <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [‐0.43, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 abnormal involuntary movement: AIMS (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.39, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 extrapyramidal symptoms: Simpson‐Angus Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.9 [0.51, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 4a. Prolactin associated effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 sexual dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 4b. Prolactin ‐ change from baseline in ng/ml <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.3 [‐57.80, ‐40.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 5a. Metabolic ‐ weight gain ‐ change from baseline in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.20, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 5b. Metabolic ‐ weight gain of 7% or more of total body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.50, 12.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">QUETIAPINE versus PALIPERIDONE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">QUETIAPINE versus RISPERIDONE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [1.00, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.80, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 due to inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.02, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1a. No clinically significant response (as defined by the original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.95, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 1b. No clinically important change (as measured by CGI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.98, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.95, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.87, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1a General ‐ no clinically important change ‐ short term (less than 30% PANSS total score reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.87, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1b. General ‐ no clinically important change ‐ short term (less than 20% BPRS total score reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.63, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1c. General ‐average endpoint score (PANSS total score, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.39, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [‐0.28, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [‐1.56, 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.40, 5.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 1d. General ‐ average endpoint score ‐ short term (BPRS total score, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [‐8.33, 11.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 2a. Positive symptoms ‐ no clinically important change ‐ short term (less than 40% PANSS positive reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.90, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 2b. Positive symptoms ‐ average endpoint score ‐ (PANSS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.51, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.28, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [‐0.21, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐0.13, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 2c. Positive symptoms ‐ average change in endpoint score ‐ short term (BPRS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.1 [0.18, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 3a. Negative symptoms ‐ no clinically important change ‐ short term (less than 40% PANSS negative reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state: 3b. Negative symptoms ‐average endpoint score ‐ (PANSS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.13, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [‐0.25, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [‐0.24, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.64, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mental state: 3c. Negative symptoms ‐ average change in endpoint score ‐ (BPRS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.17, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Quality of life: General ‐ average endpoint score ‐ (QLS total score, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.44 [‐4.46, ‐2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐13.87, 12.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.46 [‐4.48, ‐2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Service use: number of participants re‐hospitalised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.00, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.3 [0.71, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.97, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.91, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 2. Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.17, 3.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 natural causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.06, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 suicide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.11, 18.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.36, 5.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [‐5.05, 9.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 4. Central nervous system ‐ sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.06, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 5a. Extrapyramidal effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.32, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 akinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.61, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.04, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5 extrapyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.43, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6 parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.19, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7 rigor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.16, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.8 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.04, 27.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.36, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 5b. Extrapyramidal effects ‐ scale measured ‐ endpoint/ change to endpoint score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 abnormal involuntary movement: AIMS (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.76, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 akathisia: Barnes Akathisia Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐2.00, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 extrapyramidal symptoms: Simpson‐Angus Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.16, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 6. Haematological: important decline in white blood cells <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [0.12, 72.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse effects: 7a. Prolactin associated side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 amenorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.32, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 dysmenorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.08, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 galactorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.16, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4 gynecomastia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.07, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.5 sexual dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.48, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse effects: 7b. Prolactin ‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐35.25 [‐43.59, ‐26.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse effects: 8a. Metabolic ‐ cholesterol ‐ significant cholesterol increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.72, 2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse effects: 8b. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.57 [4.85, 12.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse effects: 8c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.47, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse effects: 8d. Metabolic ‐ glucose ‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐2.45, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse effects: 8e. Metabolic ‐ weight gain of 7% or more of total body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse effects: 8f. Metabolic ‐ weight gain ‐ change from baseline in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [‐0.59, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">QUETIAPINE versus RISPERIDONE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">QUETIAPINE versus ZIPRASIDONE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.97, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.72, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.89, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. General ‐ average endpoint score (PANSS total score, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐6.36, 6.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐2.97, 10.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.78 [‐6.81, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 2. Positive symptoms ‐ average endpoint score ‐ medium term (PANSS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐2.18, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 3. Negative symptoms ‐ average endpoint score ‐ medium term (PANSS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐0.34, 3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Service use: number of participants re‐hospitalised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.85, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.71, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.78, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 1. General ‐ at least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.91, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 2. Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.05, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.03, 8.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 suicide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 3a. Cardiac effects ‐ QTc prolongation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.34, 8.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 3b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.41 [‐1.37, 8.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 4. Central nervous system ‐ sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.03, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 5. Extrapyramidal effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.42, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 extrapyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.66, 6.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.20, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 6a. Prolactin associated effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 amenorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.15, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 galactorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.18, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 sexual dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.64, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 6b. Prolactin ‐ change from baseline in ng/ml <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.77 [‐8.16, ‐1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 7a. Metabolic ‐ cholesterol ‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.01 [8.57, 23.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 7b. Metabolic ‐ glucose‐ change from baseline in mg/dl <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [‐3.99, 10.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 7c. Metabolic ‐ glucose ‐ abnormally high fasting glucose value <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.30, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 7d. Metabolic ‐ weight gain of 7% or more of total body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.35, 3.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 7e. Metabolic ‐ weight gain ‐ change from baseline in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [‐0.05, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">QUETIAPINE versus ZIPRASIDONE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">QUETIAPINE versus ARIPIPRAZOLE ‐ sensitivity analyses (skewed data excluded)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1. General ‐ average endpoint score ‐ short term (PANSS total, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [‐1.91, 4.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">QUETIAPINE versus ARIPIPRAZOLE ‐ sensitivity analyses (skewed data excluded)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">QUETIAPINE versus CLOZAPINE‐ sensitivity analysis (skewed data excluded)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1. General ‐ average endpoint score ‐ short term (PANSS total, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐4.11, 4.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐4.11, 4.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">QUETIAPINE versus CLOZAPINE‐ sensitivity analysis (skewed data excluded)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">QUETIAPINE versus OLANZAPINE‐ sensitivity analysis (skewed data excluded)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1. General ‐ average endpoint score (PANSS total subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [2.25, 5.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [‐1.30, 5.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.57 [1.97, 9.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.31 [1.60, 7.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 2. Positive symptoms ‐ average endpoint score (PANSS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.02, 2.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [‐1.87, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.90, 3.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.39, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐0.37, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐1.70, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.67, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐0.73, 2.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">QUETIAPINE versus OLANZAPINE‐ sensitivity analysis (skewed data excluded)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006625-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1a. No clinically significant response (as defined by the original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.93, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. General ‐ average endpoint score ‐ (PANSS total score, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [1.49, 4.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [0.50, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.27 [‐3.94, 16.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.40, 5.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 6. Positive symptoms ‐ average endpoint score ‐ (PANSS positive subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.04, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.60, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [‐0.01, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐0.13, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 6. Negative symptoms ‐ average endpoint score ‐ (PANSS negative subscore, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.04, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [‐0.82, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐0.75, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.64, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 1. Extrapyramidal effects ‐ Simpson‐Angus Scale (high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐1.95, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">QUETIAPINE versus RISPERIDONE‐ sensitivity analysis (skewed data excluded)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006625.pub3/references#CD006625-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006625.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006625-note-1206">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD006625-note-1205">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006625-note-1204">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006625\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006625\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006625\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006625\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006625\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006625.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006625.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006625.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006625.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006625.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717280508"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006625.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717280512"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006625.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db4110ae39365',t:'MTc0MDcxNzI4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 